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Covalent histone modifications constitute a complex network of transcriptional 
regulation involved in diverse biological processes ranging from stem cell 
differentiation to immune response. The advent of modern sequencing technologies 
enables one to query the locations of histone modifications across the genome in an 
efficient manner. However, inherent biases in the technology and diverse enrichment 
patterns complicate data analysis. Marek’s disease (MD) is an acute, lymphoma-
inducing disease of chickens with disease outcomes affected by multiple host and 
environmental factors. Inbred chicken lines 63 and 72 share the same major 
  
histocompatibility complex haplotype, but have contrasting responses to MD. This 
dissertation presents novel methods for analysis of genome-wide histone modification 
data and application of new and existing methods to the investigation of epigenetic 
effects of MD on these lines. First, we present WaveSeq, a novel algorithm for 
detection of significant enrichments in ChIP-Seq data. WaveSeq implements a 
distribution-free approach by combining the continuous wavelet transform with 
Monte Carlo sampling techniques for effective peak detection. WaveSeq 
outperformed existing tools particularly for diffuse histone modification peaks 
demonstrating that restrictive distributional assumptions are not necessary for 
accurate ChIP-Seq peak detection. Second, we investigated latent MD in thymus 
tissues by profiling H3K4me3 and H3K27me3 in infected and control birds from 
lines 63 and 72. Several genes associated with MD, e.g. MX1 and CTLA-4, along with 
those linked with human cancers, showed line-specific and condition-specific 
enrichments. One of the first studies of histone modifications in chickens, our work 
demonstrated that MD induced widespread epigenetic variations. Finally, we 
analyzed the temporal evolution of histone modifications at distinct phases of MD 
progression in the bursa of Fabricius. Genes involved in several important pathways, 
e.g. apoptosis and MAPK signaling, and various immune-related miRNAs showed 
differential histone modifications in the promoter region. Our results indicated 
heightened inflammation in the susceptible line during early cytolytic MD, while 
resistant birds showed recuperative symptoms during early MD and epigenetic 
silencing during latent infection. Thus, although further elucidation of underlying 
  
mechanisms is necessary, this work provided the first definitive evidence of the 
epigenetic effects of MD.  
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1. Literature Review 
Introduction 
The term ‘epigenetics’ can be loosely defined as the study of changes in the 
phenotype of an individual caused by mechanisms other than underlying DNA 
sequence. One of the first indications that there was more to gene regulation than 
DNA sequence was the discovery of histone modifications and their possible effects 
on transcriptional regulation [1]. The involvement of DNA methylation in various 
regulatory functions [2, 3] further confirmed the presence of significant epigenetic 
mechanisms in transcriptional control. Subsequent studies have shown that epigenetic 
mechanisms are associated with a multitude of critical biological processes, such as, 
X chromosome inactivation, stem cell differentiation and immune response. The 
advent of next-generation sequencing technology has revolutionized the field, making 
it possible to investigate histone modification profiles in a genome-wide manner. 
However, the enormity of associated data sets has posed new challenges in data 
analysis and interpretation that are far from being solved. 
Epigenetic processes play major roles in various human diseases. Cancer cells 
demonstrate major variations in DNA methylation, e.g. large-scale demethylation in 
tumor cells is concurrent with hypermethylation at specific promoters [2, 3]. Histone 
modification changes are observed in conjunction with aberrant DNA methylation in 
various cancers [4, 5]. However, further study has suggested that variations in histone 
modifications are important prognostic markers for cancer [6-8]. Recent studies have 




[9]. Herpesviruses, in particular, appear to be affected by cellular chromatin 
machinery. For instance, a transcriptional activator HCF-1 (host cell factor 1), which 
is associated with several chromatin-modifying enzymes [10], controls the early 
transcriptional program of the herpes simplex virus [11]. Kaposi’s sarcoma-associated 
herpesvirus (KSHV) exhibits increased activating and repressive histone marks 
during latent infection [12]. Thus, histone modifications are epigenetic indicators of 
the adverse effect of various diseases, and further study is necessary to delineate their 
particular roles in the process. 
Histone Modifications 
DNA is packaged in the form of chromatin, with the DNA double helix wound 
around an octamer of four core histone proteins (H3, H4, H2A and H2B). A 147 
nucleotide-long fragment of DNA, together with the histone proteins it is wrapped 
around, constitutes the nucleosome, the fundamental unit of chromatin. Eukaryotic 
nucleosomes also contain lower levels of histone variants with specialized functions, 
e.g. the histone variant H2A.Z, which occurs within nucleosomes adjacent to the 
transcription start site (TSS) of genes [13]. Chromatin can be structurally and 
functionally separated into two forms: euchromatin and heterochromatin. 
Euchromatin is conformationally open, relatively rich in genes, and conducive to 
active transcription, while the highly-condensed heterochromatin is relatively 
inaccessible to transcription factors and hence, constitutively silent [14]. 
DNA exists primarily in the form of heterochromatin during certain cellular processes 
such as mitosis and meiosis which lack DNA regulatory activity [15]. On the other 




transcription, with various activating and silencing mechanisms at play. However, in 
spite of the relatively low density of euchromatin, it is still refractory to essential 
cellular processes and must be relaxed for easier access by the transcriptional 
machinery. This need has resulted in the evolution of a wide array of chromatin-
modifying mechanisms, including chromatin remodeling, an ATP-dependent process 
which alters the structure, composition and position of nucleosomes, and covalent 
post-translational modification of histones by particular enzymes. 
Histone modifications occur primarily on the unstructured N-terminal tails of histone 
proteins, which contain several residues that are subject to various modifications, 
such as, methylation, acetylation and phosphorylation. Eight classes of histone 
modifications occurring on over 60 different residues have been discovered, with 
histone methylation and acetylation the two most common and well-studied 
modifications. Several histone marks have been associated with regulatory roles such 
as transcription, replication and DNA repair [16]. For instance, the trimethylation of 
the lysine residue at the fourth position of the histone H3 (H3K4me3) is associated 
with the TSS of active genes [17], while the trimethylation of lysine 36 (H3K36me3) 
is found on exons and introns of actively transcribing genes [18]. On the other hand, 
certain modifications are associated with gene silencing. These changes include 
H3K9 trimethylation, which is highly associated with heterochromatin, and 
H3K27me3, which is associated with the chromatin-modifying Polycomb repressive 
complexes (PRCs) [19]. Multiple histone modifications with seemingly contrasting 
functions have been observed on the same gene. For example, certain key 




marks in embryonic stem cells (ESCs) suggesting a possible ‘bivalence’ depending 
upon lineage-determination [20]. In some cases, different modifications of the same 
histone residue perform contrasting functions. For instance, in T helper cells, H3K9 
trimethylation and acetylation mark the promoters of repressed and active genes, 
respectively [21]. Certain lysine and arginine residues can also display varying levels 
of methylation (mono-, di- or tri- in the case of lysines and mono- or di- in the case of 
arginines), which, in turn, could be associated with different functions. For example, 
H3K4me3, as mentioned above, is associated with the promoters of active genes 
while H3K4me1 is highly enriched on promoter-distal enhancers [22]. Thus, histone 
modifications encode tremendous diversity into the genome and their dynamic nature 
plays major roles in a wide range of biological processes ranging from development 
to disease response. Also, owing to the diversity of function encompassed by histone 
methylation (activation, repression, transcription elongation and enhancers), we 
discuss this class of modifications in greater detail throughout this review. 
Mechanisms of Formation 
The majority of histone modifications are dynamic. A class of enzymes, called the 
histone-modifying enzymes, catalyzes the addition or removal of specific 
modifications from histone proteins. A host of such enzymes have been identified 
recently [23-31]. For instance, histone methylation can occur on lysines and arginines 
and is carried out by three classes of enzymes:  
1) Histone methyltransferases (HMTs), which contain the lysine-specific SET 




methylate lysines 4, 9, 27 and 36 of histone H3 and lysine 20 of histone H4 
[23, 24]. 
2) Non-SET domain-containing HMTs methylate the lysine 79 of histone H3 and 
consist of the evolutionarily conserved protein Dot1 (disrupter of telomeric 
silencing, also known as Kmt4) [25]. 
3) Protein arginine methyltransferases (PRMTs) methylate arginines 2, 17 and 26 
of histone H3 and also arginine 3 of histone H4 [26]. 
Similarly, enzymes that remove methyl groups from lysine residues of histone 
proteins have also been the subjects of great interest. An amine oxidase, lysine-
specific histone demethylase 1 (LSD1), was the first protein found to possess histone 
demethylase activity. LSD1 primarily demethylates H3K4 [27], but can also target 
H3K9 when complexed with the androgen receptor [28]. However, the enzymatic 
action of LSD1 requires the presence of a protonated methyl-ammonium group, and 
therefore, it can only demethylate mono- and dimethylated lysines. Two years after 
the discovery of LSD1, a class of proteins containing the Jumonji C (JmjC) catalytic 
domain was discovered and shown to demethylate trimethylated lysines [29]. Indeed, 
the demethyase activity of JmjC-containing enzymes is amenable to mono-, di- and 
trimethylated lysines but appears to favour trimethylated residues [30]. Moreover, 
JmjC proteins have also been shown to demethylate arginine residues [31]. Out of 27 
known members of the Jumonji family about 15 possess demethylase activity, further 
emphasizing the importance of this family of chromatin-modifying enzymes. 
Other major histone-modifying enzymes include the activating histone 




HMTs, HATs and HDACs have been the subject of intense study leading to the 
discovery of a large number of members of each class. The addition of the ubiquitin 
moiety (ubiquitylation) is carried out by members of an enzymatic pathway including 
ubiquitin activating (E1), conjugating (E2) and ligase (E3) enzymes [32]. E2 and E3 
enzymes largely determine the specificity of the modification [33]. SUMOylation 
consists of the addition of a small ubiquitin-related modifier (SUMO) protein by the 
E1-E2-E3 enzymes which can also be removed by specific proteases [34]. 
Biological Functions 
Covalent histone modifications can function in two major ways. First, they can affect 
the high-level interaction between neighboring nucleosomes or between the DNA and 
chromatin, leading to the ‘unraveling’ of nucleosomes. For instance, histone 
acetylation has a strong activating effect as it neutralizes the basic charge on the 
lysine residues producing electrostatic repulsive forces between the histone protein 
and the negatively charged DNA. The second and better characterized mode of 
function for histone modifications is the recruitment of non-histone proteins in what 
is believed to be a highly ordered and coordinated manner. For example, the addition 
of a methyl group does not affect the charge on the histone protein and hence, has no 
effect on chromatin-DNA interactions. However, methylation of specific residues 
exhibits affinity towards particular proteins (which can act as either activators or 
repressors), thereby influencing the transcriptional regulation of underlying DNA. 
Ubiquitylation and SUMOylation involve the addition of large covalent groups to the 
chromatin, which can affect chromatin structure via steric effects. SUMOylation is 




recruitment of HDACs [35]. However, histone ubiquitylation, like methylation, can 
have diverse outcomes. For example, addition of multiple ubiquitin groups marks a 
protein for proteasomal degradation, while monoubiquitylation alters protein 
function. However, the latter modification can produce different effects on histones, 
e.g. lysine residues in the C-termini of H2A and H2B correlate with activation and 
repression, respectively. 
 
Figure 1.1 Chromatin model of transcriptional regulation (from [36]). 
(a) Silenced state: Repressor factors (REP) bound at an upstream repressor site (URS) 
recruit negative modifiers like histone deacetylase (HDAC) which removes the acetyl 
group from histone H3/H4. (b) Active state: Activating transcription factors (ACT) 
bound at an upstream activation site (UAS), induces H3/H4 acetylation by HATs in 
the promoter region, while RNA polymerase (POL) induces methylation at lysine 4 
by SET1 (part of the COMPASS complex) and lysine 79 by DOT1. Later, the POL 





Non-histone proteins bind to specific histone residues with the help of particular 
protein domains, e.g. methylation is bound by proteins containing domains of the 
Royal family similar to chromo-domains, and distinct PHD domains, while 
acetylation is bound by bromodomains. A schematic model of chromatin regulation 
of transcriptional is shown in Figure 1.1 [24]. Briefly, activating histone marks appear 
on gene promoters and transcription start sites in response to cellular stimulus, 
through recruitment of enzymes by activating transcription factors and RNA 
polymerase. In contrast, repressive marks are established through the action of DNA-
bound repressors or heterochromatic regions. Since a major focus of our studies has 
been histone methylations, in particular trimethylations of H3K4 and H3K27, it is 
worthwhile to examine their mechanisms of action in some detail. 
H3K4 and H3K27 Methylation 
The positive correlation between H3K4 methylation and active genes suggested that 
this histone modification attracts activating factors for binding. This was proved to be 
true by the discovery of several such proteins including chromatin-remodeling 
enzyme CHD1 [37], nucleosome remodeling factor (NURF) [38] and PHD domain-
containing Yng1 protein in the NuA3 (nucleosomal acetyltransferase of histone H3) 
[39]. The latter two are specific to H3K4me3, while CHD1 recognizes either di- or 
trimethylated H3K4. Surprisingly, H3K4 methylation also associates with repressive 
protein complexes. The Sin3-Hdac1 complex, which functions as a deacetylase, binds 
to H3K4me3, thereby stabilizing its recruitment to target genes and leading to the 




H3K4me3 is believed to recruit the lysine demethylase JMJD2A, which demethylates 
H3K9me3 and H3K36me3 and causes gene repression [41]. Thus, H3K4 methylation 
is apparently context-specific and can lead to varying outcomes in terms of 
transcriptional control. 
The methylation of H3K27, however, is undoubtedly repressive in nature, and was 
found to be associated with Polycomb-group (PcG) silencing [19]. Polycomb group 
proteins, discovered in Drosophila melanogaster, are repressors of homeobox (Hox) 
genes, transcription factors crucial to the determination of cell fate during embryonic 
development. These proteins are essential for maintenance of the transcriptional 
status of Hox genes after initial developmental cues, and bind to regulatory elements 
called Polycomb repressive elements (PREs) [42]. Subsequent studies identified the 
roles of PcG proteins in diverse biological contexts, such as, X chromosome 
inactivation [43], cell proliferation [44] and cancer [45], in vertebrates, plants and 
mammals. One of the Polycomb repressive complexes, PRC2, methylates H3K27, 
and subsequently, this histone mark is recognized by PRC1, which results in gene 
silencing. However, the mechanism of H3K27me3 and PRC1-mediated silencing is 
still unclear, as PRC1 is not found in several organisms, such as plants [46]. 
H3K27me3 is also found on broad swathes of the genome, which is believed to be the 
key to epigenetic inheritance of PcG silencing. 
Another intriguing subplot to the functional consequences of H3K4 and H3K27 
methylation is the interplay of the respective methylating protein complexes. H3K4 
methylation is carried out by proteins belonging to the Trithorax group (TxG), which 




the determination of transcriptional fate [47, 48]. In summary, these two histone 
marks encompass a remarkable diversity of function in a variety of biological 
contexts, but further study is necessary for a clearer understanding of the associated 
regulatory mechanisms. 
Detection using Chromatin Immunoprecipitation (ChIP) 
The functional importance of histone modifications made it important to develop 
assays that could pinpoint the genomic locations of particular histone marks. 
Chromatin immunoprecipitation (ChIP) is a robust technique of studying DNA-
protein interactions [49]. Originally developed to study the association of RNA 
polymerase and active genes in bacteria [50], this method has been subsequently used 
across a wide range of organisms, including Drosophila [51] and humans [52]. In 
brief, ChIP involves the use of a crosslinking agent, to preserve protein-DNA 
interactions, either irreversibly by ultraviolet radiation [53] or reversibly by 
formaldehyde [54]. Shearing via sonication or restriction enzyme digestion follows 
crosslinking and subsequently, antibodies specific to the protein of interest, e.g. 
modified histones, are used to immunoprecipitate the cross-linked protein-DNA 
complexes. The precipitated products are purified, the crosslinks reversed and DNA 
fragments analyzed using Southern blot or polymerase chain reaction (PCR). If so 
desired, the ChIP experiment could also be performed without a crosslinking step 
(native ChIP) to assay stable DNA-protein interactions. While highly specific and 
robust, this technique is only suitable for analyzing known regions of interest at a 





The development of microarray technology provided a significant advance [55]. 
Microarrays consist of several thousand oligonucleotide sequences or ‘probes’, 
chosen to complement specific genomic regions, attached to a solid surface 
(Affymetrix or Agilent) or microscopic beads (Illumina). The test sample is 
fluorescently labeled before hybridization to the microarray and laser scanning. The 
fluorescent intensity at each spot of the microarray is assumed to be proportional to 
the number of molecules hybridizing to the probe specific to the spot, and provides a 
measure of the representation of the associated genomic region in the test sample. 
Thus, microarrays simultaneously query several thousand loci across the genome and, 
when combined with ChIP (ChIP-on-chip), vastly increases throughput [52]. 
However, this technique suffers from certain drawbacks. Microarrays and other 
fluorescence-based detection systems have a fixed dynamic range, with reduced 
sensitivity at upper and lower extremes of detectable signal amplitudes [56]. ChIP-on-
chip depends on the availability of a suitable microarray for performing the 
experiment, e.g. a high-density tiling array, which consists of overlapping probes 
placed at a fixed distance from each other. While the possible resolution is high, so is 
the cost, due to the necessity of biological replicates and multiple arrays for large 
genome sizes. The design of the tiling array depends on a high-quality genome 
assembly and hence, has reduced accuracy and limited applicability for non-
traditional model organisms. Also, repetitive regions are usually not represented on 





Combination with Next-Generation Sequencing 
The advent of modern sequencing technologies was the next big step forward. Next-
generation sequencing (NGS) enables one to obtain the DNA sequence of millions of 
short fragments or reads from across the genome in a massively parallel manner. 
There are multiple such sequencers currently available, but since we used the 
Illumina sequencers for our experiments, I will discuss their experimental workflow 
in some detail (Figure 1.2). 
 
Figure 1.2 Overview of Illumina Sequencing protocol (modified from [57]).  
The major steps include fragmentation, size-selection, library construction, bridge 














The Illumina sequencing protocol utilizes reversible DNA terminators in a 
sequencing-by-synthesis procedure. Initial library preparation involves the repair of 
DNA fragment-pairs, attachment of an Adenine overhang and ligation of Illumina 
adaptors. The DNA sample is amplified using PCR to ensure enough starting material 
and fragments of suitable size are selected from the amplified sample. The next step, 
called cluster generation, involves use of a ‘flowcell’, a glass surface with eight 
channels, each containing adhered adaptors, complementary to those attached to the 
DNA fragments during library preparation. The size-selected DNA fragments are 
hybridized to the flowcell and extended by polymerases. Subsequently, the double-
stranded DNA is denatured and the original template washed away. The free ends of 
the DNA molecules randomly attach to neighboring complementary adaptors, 
forming a ‘bridge’, and the extension procedure is repeated. This so-called ‘bridge-
PCR’ step, thus, effectively amplifies several million DNA fragments in parallel, and 
the iteration of hybridization and bridge-PCR results in ‘clusters’ containing forward 
and reverse DNA fragments. The reverse strands are cleaved and washed away, 
leaving several million clusters spread across the surface of the flowcell, each 
containing approximately 1000 identical DNA fragments. In the final step, 
sequencing primers are attached to the free ends of the clustered DNA strands, and 
four fluorescently-labeled NTP terminators and polymerases are added to the reaction 
mixture. Each cluster incorporates a fluorescent NTP terminator, which represents the 
corresponding complementary nucleotide of its constituent DNA strands on the 
detected image. The terminator and fluorescent groups are subsequently cleaved and 




The above process is highly efficient, dramatically reducing the overall cost of 
sequencing experiments, leading to a wide array of applications including whole-
genome sequencing [58], transcriptomics [59, 60], structural variant detection [61], 
epigenomics [62-64] and metagenomics [65, 66]. The combination of ChIP and next-
generation sequencing, called ChIP-Seq, resulted in a powerful new experimental 
technique of detecting genome-wide histone modification profiles [67-70]. ChIP-Seq 
offers several advantages over the microarray-based ChIP-on-chip. ChIP-Seq 
protocols typically require lower amounts of starting DNA (~ng range) and 
amplification. Several repetitive regions can be assayed, particularly with longer 
reads and paired-end sequencing. ChIP-Seq does not suffer from a fixed dynamic 
range and has single nucleotide resolution. Moreover, with the improvement of 
associated technologies, sequencing yield has dramatically increased, allowing the 
use of multiplexing, a technique whereby multiple ‘bar-coded’ samples can be 
sequenced simultaneously. For instance, the Illumina Genome Analyzer II.x yields a 
maximum of 40 million reads per lane, while the newer HiSeq 2000 can generate up 
to 187 million reads per lane at a comparable cost. Thus, four lanes of the earlier 






Figure 1.3. Overview of a ChIP-Seq experiment [71]. Using this technique, DNA 
associated with histones displaying covalent modifications or non-histone proteins, 
e.g. transcription factors, are obtained using specific antibodies. After subsequent 
purification the enriched DNA fragments are subjected to next-generation sequencing 
using one of various platforms, such as, Illumina. The short reads are further analyzed 




ChIP Followed by Next-Generation Sequencing (ChIP-Seq) 
At the time of the writing of this introduction, a major limitation of NGS technology 
is the prohibitive cost of sequencing. However, recent improvements, such as, 
increases in sequencing yield and development of multiplexing protocols, have 
resulted in significantly reduced costs. The bigger issue at present is data analysis, as 
improvements in computing power cannot keep pace with the exponential increase in 
sequence data. Therefore, a growing need exists for efficient analysis strategies. 
ChIP-Seq experiments generate millions of short DNA sequence reads representing 
the locations of proteins of interest, such as, histone modifications or transcription 
factors, distributed across the genome. The key steps of ChIP-Seq data analysis are 
outlined here. 
First, the reads are mapped to a reference genome of the organism in question. Once 
considered a bottleneck in NGS analysis, recent advances have led to the 
development of several efficient and accurate mapping tools that have greatly sped up 
this process. The initial mapping step is followed by the detection of peaks signifying 
enrichments of histone modifications, a process known as ‘peak-calling’. To 
investigate the biological function of observed peaks, the flanking regions of called 
peaks are often searched for coding or non-coding transcripts. The resulting lists of 
genes analyzed for evidence of enriched functional terms or pathways using various 
databases, such as, gene ontology (GO) or Kyoto Encyclopedia for Genes and 
Genomes (KEGG). Genes associated with biologically relevant pathways can be 
further examined, e.g. ChIP-Seq profiles in the promoter region can be compared 




factors of such analyses include large sample size – each ChIP-Seq profile may have 
several thousand loci of interest; incomplete genome annotation that may require the 
integration of information from several existing databases, and relative lack of 
existing statistical literature. Before examining the various steps of ChIP-Seq analysis 
in detail, let us first look at some of the accompanying issues. 
Challenges Associated with Analysis 
NGS technology is subject to biases dependent on technical aspects of the 
experiments and varied genomic context [71-73]. For instance, the ‘mappability’ of a 
genomic region measures the likelihood of sequences from this region being uniquely 
mapped. Mappability depends on read length, because longer reads have a greater 
likelihood of mapping uniquely to most regions of the genome. A highly mappable 
genomic region could, therefore, have higher read counts purely as a result of the 
sequencing process. Nucleotide composition could be another source of sequencing 
bias, because Illumina sequencers, for example, favor guanine-cytosine (GC)-rich 
regions [74]. Copy-number variations can lead to fluctuations in the expected 
numbers of reads from a genomic region that may not be observed in the ChIP 
sample. These sources of variation contribute to the ‘background’ signal that is non-
stochastic [75, 76] and present significant modeling difficulties. The ChIP-Seq assay 
is also prone to amplification bias; PCR amplification is a part of the standard ChIP-
Seq protocol to ensure enough starting material, but can lead to preferential 
amplification of abundant species. The more serious problem, however, is the 
variation in sampling rates due to differences in chromatin accessibility. In other 




restriction enzyme or micrococcal nuclease digestion, compared to regions having 
compact chromatin. While the former scales with fragment abundance, the latter 
depends on the particular library and is unpredictable. It is impossible to distinguish 
between the two at a sequence level and thus, it is considered prudent to discard 
redundant reads as a pre-processing step. 
Negative controls can be used to partially account for the above factors. Examples 
include input DNA (normal sample preparation but no ChIP), non-specific antibodies, 
such as, immunoglobulin G (IgG), or ChIP without antibodies (mock IP). The 
suitability of such controls is a topic of continuing debate. Of the above three, input 
DNA is used most often and can correct biases in shearing and amplification. 
However, since input DNA fragments are spread across the genome, increased depth 
of sequencing may be necessary for improved coverage. A region of non-specific IgG 
binding can be a true binding site for a particular transcription factor and the rejection 
of such a site constitutes a false negative. Mock IP results in very low pull down and 
corresponding results are difficult to replicate [71]. Thus, there are obvious 
drawbacks of each method, which underlines the importance of accurate estimation of 
background variation. 
A major difficulty of ChIP-Seq analysis is the diversity of patterns observed in 
enrichment regions. The detection of such enrichments, termed peak-calling, is not a 
trivial problem, as ChIP-Seq profiles demonstrate remarkable diversity, ranging from 
the sharp, punctate peaks of transcription factor data to broad, diffuse enrichments 
characteristic of certain histone modifications (Figure 1.4). This variability in the 




still no undisputed numero uno when it comes to peak-calling algorithms, in spite of 
much recent interest. A favored approach is to model ChIP-Seq data using a fitted 
discrete distribution (see below), but such approaches have their shortcomings [77]. 
Thus, there is a need for accurate methods of ChIP-Seq peak-calling free of limiting 
assumptions that is robust to diversity in binding profiles. 
 
Figure 1.4. Diverse histone modification profiles observed on FoxP1 in murine 
embryonic stem cells (ESCs) and embryonic fibroblasts (MEFs) (from [69]). 
H3K4me3 exhibits punctate peaks at TSS regions while H3K36me3 enrichment is 
broad and diffuse. FoxP1 has one high CpG (HCP) and one low CpG promoter 
(LCP). An additional promoter 500 kb upstream of the HCP appears to be bivalent as 
it shows peaks of H3K4me3 and H3K27me3. 
Genomic Mapping of Sequence Reads 
As mentioned above, one of the first steps of NGS analysis is the mapping of 
sequence reads to the reference genome. A hot topic of research in the past few years, 
read mapping tools have made great strides in recent years, and as a result, a large 
number of mapping softwares are currently available, e.g. MAQ [78], RMAP [79], 





profusion of sequence aligners, a majority of available tools can be broadly divided 
into two groups based on underlying principles – hash tables and suffix arrays 
(reviewed in [84]). In both cases, the key to computational efficiency is the creation 
of an index either for the sequence reads or the reference genome, to enable fast 
matching.  
Methods Based on Hash Tables 
Hash tables are computational data structures that utilize index-key pairs to enable 
fast searching of lists. In other words, given a list of sequences, a hash table can be 
used to store the location (index) of each unique sequence (key) in the list. This idea 
can be easily extended to the genomic mapping of short sequence reads where the 
reference genome or sequence reads represent a searchable list, while unique k-mers 
of nucleotides and their locations represent key-index pairs. The iconic BLAST [85, 
86] tool utilizes this approach; the query is first hashed into its constituent k-mers 
(keys), following which database lookup for matches is performed for each key. 
Exact matches (seeds) are joined before being refined and extended to produce the 
final alignment result, in an approach termed seed-and-extend. 
BLAST requires k consecutive exact matches (default = 11) which represents a seed 
of ‘11111111111’. However, allowing for mismatches in the seed was found to 
increase sensitivity [87], thus lending credence to the use of spaced seeds. For 
example, a seed of ‘110110111101101’, which looks for matches of length 15 while 
allowing for 4 mismatches, will find alignments with up to three mismatches in the 




MAQ [78], which stands for mapping and alignment with quality, was one of the first 
widely-used short-read alignment programs that employed spaced seeds. The 
mapping algorithm is applicable for k mismatches, but to avoid prohibitive memory 
requirements the default policy of MAQ ensures maximum sensitivity for up to two 
mismatches in the first 28 bp of Illumina reads. Two mismatches can be divided 
between four sections of a read in 
4
C2 ways; thus, full sensitivity for at most two 
mismatches is achieved using six spaced seeds, MAQ provided various other 
advances such as the concept of mapping quality, an estimate of the error probability 
of an alignment based on sequencing qualities at mismatched bases, and also output a 
consensus sequence which could be used for variant detection and genotyping. 
Moreover, the gapped alignment used by MAQ is robust to indels (insertion-
deletions). However, the memory requirements of holding a hash table in memory are 
large. Also, increasing sequencing yields and read lengths are likely to impact 
processing time as MAQ hashes the sequence reads. 
Methods Based on Suffix Arrays 
A suffix array is a data structure that consists of a sorted list of all suffixes of a string. 
A close relative of the suffix tree, the suffix array has lower space constraints and is 
easier to construct and implement [88]. Moreover, when combined with additional 
enhancements, such as, the full-text minute-space (FM) index [89], which enables 
efficient string matching in an array compressed using the Burrows-Wheeler 
Transform (BWT), the suffix array provides a significant improvement in speed. 




regions need only be performed once, while in the case of hash table-based methods, 
explicit matching would be necessary for each occurrence.  
The most commonly used tool in this category is Bowtie [80]. Default parameters of 
this program are similar to MAQ, with at most two mismatches allowed in an 
acceptable alignment. However, in contrast to MAQ, Bowtie indexes the reference 
genome and has a low memory footprint. Also, multiple CPU cores are utilized, if 
available, to further accelerate the alignment. At the time of its release, Bowtie was 
several orders of magnitude faster than MAQ or SOAP under similar conditions and, 
thus, represented a sizeable step forward. Other implementations of BWT and FM-
index, such as, BWA [81] and SOAP2 [90], have since been released. However, 
despite obvious speed advantages, the sensitivity of this approach is reduced in the 
presence of indels. Recent tools, such as, Bowtie 2 [91] seeks to overcome this 
weakness by combining the efficiency of suffix arrays with the sensitivity of spaced 
seeds. 
Peak Detection in ChIP-Seq Data 
Following the accurate mapping of sequence reads to the reference genome, there 
needs to be a quantification step to determine regions that exhibit marked enrichment 
of reads or peaks. The challenges associated with peak calling, as mentioned above, 
have led to great interest in recent years to develop efficient, accurate and sensitive 
peak callers. As a result, a large number of peak-calling algorithms encompassing a 
great variety of techniques are currently available [92-103]. Although efforts to 
benchmark these algorithms have been carried out, there are no clear winners [104-




tested on a limited number of qPCR-validated sites, although a great deal of variation 
in the number of called peaks was observed. However, comparisons of peak sites 
revealed significant overlap – smaller peak sets called by more conservative 
algorithms were usually contained within larger sets output by less stringent methods 
[105]. Often, the default parameters of a program are tuned to specific training data 
sets and therefore, results from different methods diverge considerably in general 
usage. Peak lengths for different methods on the same data set also display marked 
differences. 
Despite major differences in algorithm design and performance, the primary 
workflow of most ChIP-Seq peak callers involves an initial modeling or training step, 
followed by peak detection either in the presence or absence of negative control data. 
Each peak is, then, assigned a significance score or p-value, an estimate of the 
likelihood of it being a ‘true’ enrichment versus an artifact. 
Data Preprocessing 
Raw sequence data needs to be preprocessed before being subjected to peak calling. 
As sequencing occurs in the 5’-3’ direction, sequence reads represent the 5’ end of 
the sequenced DNA fragment. For a more representative view, reads can be ‘shifted’ 
towards the 3’ end to represent the middle of the fragment [92, 98, 101, 102], or 
extended to the length of the entire fragment [93, 95]. Some methods model the 
fragment length empirically. For instance, as sequencing of a DNA fragment is 
independent of the original strand, clusters (peaks) of sense and anti-sense reads 
usually flank bona fide transcription factor-binding sites (TFBSs). The distance 




length [92, 93], which can also be determined experimentally. However, sequenced 
fragment lengths usually consist of a spread of values and a point estimate is only a 
rough approximation. 
After adjusting for fragment length, most algorithms produce an estimate of the read 
density across the genome, which is then analyzed for peak detection. Some tools 
partition the genome into bins or windows and calculate the distribution of reads. For 
instance, the number of ‘shifted’ reads falling within each window can be used to 
produce a read count histogram. This mode ensures the unambiguous representation 
of each read, but can suffer from edge effects depending on the size of the window. 
Counting the number of overlaps between extended reads or reads within a 
predetermined distance (sliding window) produces a smoother profile. The latter 
approach, while less susceptible to edge effects, contains some redundancy as a read 
can overlap more than one window. Smoothing techniques, such as, kernel density 
estimation (see below), can be used to produce a continuous probabilistic estimate of 
read density after one of the above steps. However, the degree of smoothing needs to 
be monitored closely to avoid removal of low intensity peaks.  
Background Correction 
As discussed above, NGS data is subject to multiple sources of background variation 
and bias, and accurate discrimination of ChIP-Seq peaks against the background is 
one of the foremost challenges of analysis. Negative controls have been used for the 
purposes of background correction, but, it is difficult to decide the appropriate control 
for a particular study, each of which has its own weaknesses. For instance, the 




have a matching input library for each sample in a large sequencing experiment. 
Thus, even though it is recommended, many studies do not include negative controls. 
Consequently, accurate modeling of the background from the ChIP-Seq data is 
extremely important. A common assumption for this step is that genomic regions with 
lower read counts are likely to be part of the background signal. Thus, several 
methods approximate the background as a random variable that follows a discrete 
distribution, such as, Poisson [64, 101, 107] or negative binomial (NB) [96, 103], 
fitted to genomic regions with low read densities. The Poisson distribution can be 
used to model the probability of observing counts y, and has a probability density 
function (pdf) defined as follows: 
 
where, is both the mean and variance of the distribution. This assumption is 
inadequate for NGS data as the observed variance (also called dispersion) can be 
much higher than the mean [108]. A variation of the Poisson model to allow for 




The mean of the generalized Poisson distribution is  and variance is . The 
parameter α controls dispersion with α > 0 modeling overdispersion and α = 0 




































distribution which includes a dispersion parameter  and can be represented as a 
mixture of the Poisson and Gamma distributions [110]. If observed counts are 
distributed as y ~ Poisson(), but  is itself a random variable with a Gamma 
distribution, 
               
 
where,  is called the shape parameter and  represents the scale parameter. The 
mean of the above distribution is  and variance is 

. Then, the probability mass 
function of y is negative binomial as, 
 
The mean of the above distribution is  and variance is 

. For statistical 
modeling, an alternate parameterization is used: y ~ NB(, where  and 
, so that the mean of the distribution is  and variance is 

. This model 
also reduces to the Poisson model when . The dispersion parameter can be 
estimated from the data using maximum likelihood and allows greater dispersion than 
allowed by the Poisson model.  
However, given that the background signal has been shown to be non-random the 
above models are often inadequate [77] and as a result the associated methods tend to 
call more false positives [111]. Thus, it is clear that the existing approaches for 
















































Methods of Peak Detection 
Peak-calling algorithms, as mentioned above, are extremely diverse. A majority of 
methods are aimed at detecting TFBSs [64, 92, 93, 98], while a relative few focus on 
histone modification data [100-102]. However, underlying modeling philosophies 
share some similarities and can be loosely grouped under the following headings: 
1. Simple threshold 
2. Local measures of enrichment 
3. Kernel density estimation 
4. Hidden Markov models 
5. Incorporation of additional covariates 
I will now discuss the characteristics of each category and give a brief overview of 
some tools within each class.  
Methods Based on a Simple Threshold 
The number of reads within a putative enrichment region is often used as an estimate 
of significance and thus, early peak calling methods utilized a simple read-height 
threshold T to call peaks [68]. However, this simplistic approach can be difficult to 
apply as peak heights observed in a ChIP-Seq sample are subject to sequencing depth, 
antibody quality and data characteristics. ChIP-Seq profiles for transcription factor 
binding are usually sharp and well defined, and thus, the choice of a suitable 
threshold may be evident from the data. However, the same cannot be said of most 
histone modifications and even certain proteins, such as, growth-associated binding 
protein (GABP), which produce more diffuse peaks. Secondly, an antibody that 




affinity binding sites can be mistaken for background, although, in this case, a 
majority of peak callers would have difficulty in distinguishing these peaks from true 
peaks. Finally, the sequencing depth varies from one sample to another and thus, 
appropriate thresholds have to be different for different samples in a single 
sequencing experiment. 
FindPeaks [93], a widely used tool, is based on this approach. Briefly, sequence reads 
are extended to represent their estimated fragment length and the peaks of overlapped 
read profiles are used for peak detection. This initial step can be followed by peak 
refinement via ‘trimming’ and segmentation into sub-peaks. An empirical estimate of 
false discovery rate (FDR) is obtained using Monte Carlo simulations. FindPeaks 
boasts a modular design with various user options to tweak performance. However, 
the lack of a user guide to choose a suitable threshold is a major drawback. 
Another method that utilizes a height threshold in peak detection is cisGenome [96], a 
tool capable of analyzing both ChIP-on-chip and ChIP-Seq data. CisGenome 
implements a two-pass peak detection procedure. In the first pass, genome-wide read 
counts are obtained using a sliding window and those above a user-defined threshold 
are called as putative peaks. High confidence peaks obtained from the first pass are 
used to estimate DNA fragment size; subsequently, sequence reads are shifted to 
represent the center of the fragment and the peak detection process is repeated. In the 
absence of negative control data, cisGenome estimates FDR by fitting a NB 
distribution to low read-count windows in the ChIP sample. If a negative control is 
present, cisGenome calculates binomial p-values as a measure of significant 




proportion of successes p = T/(C+T). Then the binomial probability of observing at 
least T successes in t = C + T trials under the null hypothesis H0: p = 0.5, is, 
                                 ∑(
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In contrast to FindPeaks, the user-defined cutoff used in cisGenome is associated with 
an FDR level making it easier for the user to choose a suitable value. Other 
innovations include the application of the NB distribution, shown to be a better fit to 
the background than the Poisson distribution, and a graphical user interface (GUI) for 
clickable data analysis and visualization. 
Local Measures of Enrichment 
The gradual increase in sophistication of peak calling algorithms saw tools utilizing 
local features of the data to detect peaks. The so-called ‘directional methods’ 
leveraged the distance between nearby peaks of sense and anti-sense reads to serve as 
an indication of the existence of a TFBS. Kharchenko et al.’s spp package [111], 
contains a collection of measures most of which depend on the strand-specific read 
density. For instance, window tag density (WTD) scores each window based on sense 
and anti-sense read counts within a user-specified distance. Peaks are called based on 
local maxima of score profiles and FDR calculated as a ratio of the number of peaks 
detected in the test sample versus that in a negative control. SiSSRs (Site 
Identification from Short Sequence Reads) [64, 94], uses a similar idea. First, strand 
specific read count profiles are calculated with a sliding window approach. Sense and 
anti-sense read counts are assigned positive and negative scores, respectively, and a 
composite count is calculated for each window. Putative binding sites are predicted at 




TFBS predictions are further filtered for total read counts and FDR estimated as a 
ratio of the number of peaks with the same number of reads in the background 
(Poisson distribution or negative control), to that observed in the ChIP sample. 
Directional models are simple and thus, efficient and easy to implement. However, 
the assumption of proximal sense and anti-sense peaks flanking a binding site is less 
applicable to broad enrichment regions and results in lower sensitivity. 
The widely used tool, MACS [92], also uses local modeling of the data to detect 
peaks. Similar to cisGenome, MACS uses a two-pass approach to peak calling. 
Sequence reads are shifted to represent the center of the fragment and read count 
profiles are calculated based on a sliding window scan. In the first pass, MACS fits a 
global Poisson model (global) to the ChIP data and calls putative peaks based on a 
specified p-value cutoff. The second pass is used to capture local biases by fitting 
Poisson models to regions of varying length (k, 5k, 10k) flanking the putative 
peaks. For each peak, a dynamic Poisson parameter local is defined as, 
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and used to assign a p-value. The latter process is designed to model the background 
and is performed in a control data set or in the ChIP data in the absence of a control.  
Note that 1k is not used in the absence of control data ensuring that local variations 
in the ChIP sample In the presence of a control data set, MACS also calculates the 
FDR as follows: the peak calling procedure is performed in the ChIP sample versus 
control, and again in control vs ChIP. The FDR is then estimated as the ratio of 




ChIP-Seq data sets and has thus, been widely adopted, particularly for TFBS 
prediction [112].  
Kernel Density Estimation 
Kernel density estimation (KDE) is a non-parametric procedure to estimate the pdf of 
a data set. Widely used for data smoothing, KDE involves sampling a set of points 
within a specified distance that are weighted based on a predefined function referred 
to as the ‘kernel’. If y represents the observed counts, a kernel density estimator of the 
‘true’ ChIP-Seq profile F at i could be represented by, 
 
where, n points on either side of i are sampled to produce the estimate, K is the kernel 
function and h is the bandwidth. The kernel defines the shape of the smoothed data, 
while the ‘bandwidth’ determines the degree of smoothing, with larger values 
resulting in greater smoothing. Since the shearing of DNA is a random process, the 
shape of ChIP-Seq peaks resembles a Gaussian distribution, making a Gaussian 
kernel suitable for ChIP-Seq data analysis.  
 
KDE produces a continuous smoothed estimate of the data, and enables easier 
visualization of various genomic patterns. However, it is important to choose a 
suitable bandwidth, since too much smoothing could markedly reduce the signal from 
smaller peaks, thus reducing sensitivity. 
Several methods employed the above statistical framework to detect peaks in NGS 





























ChIP-Seq data was QuEST (Quantitative Enrichment of Short Tags) [98]. This tool 
first generates a KDE profile for each strand, before combining them into a single 
profile for detecting local maxima. QuEST enforces a fold-change requirement for 
peak calls, i.e. ChIP reads have to be at least a certain fold (specified by the user) 
greater than a control sample. Peaks satisfying the above criteria are marked as 
putative enrichments and an FDR estimate is calculated based on the negative control. 
Briefly, the control sample is randomly divided into two parts, and the peak-calling 
procedure is performed on one part of the control sample with the other serving as the 
background. The ratio between the number of control and ChIP peaks serves as an 
estimate of FDR. QuEST implements some stringent restrictions, which limit its 
applicability. The FDR estimation step is only performed if the control sample 
contains at least twice as many reads as the ChIP sample. Also, experiments without a 
negative control are not supported. 
Another method that employs KDE is SICER (Spatial clustering approach for the 
Identification of ChIP-Enriched Regions) [101], although at a different stage of peak 
calling. First, shifted reads are partitioned into non-overlapping windows and a 
Poisson model is used to mark windows with significantly elevated read counts 
(eligible). Windows containing non-significant read counts are called ‘gaps’ and the 
maximum number of allowable gaps in a peak (g) can be set by the user. Putative 
peaks are scored with the negative logarithm of the product of window p-values with 
gaps contributing 0. The likelihood of observing the score distribution is modeled 






where, the fitting coefficient α is modeled from the data. The expected number of 
peaks in a random background model (E-value) is used to control for false positives. 
In the presence of negative control data, the number of reads within each peak is 
compared to that in the control sample using a binomial test. SICER was one of the 
first peak callers aimed at histone modifications and the ‘gap’ parameter allowed the 
detection of broader enrichment regions. 
KDE is the most commonly used technique for ChIP-Seq peak detection due in part 
to its flexibility and statistical properties. However, the choice of bandwidth is critical 
and should match the DNA fragment length from the sequencing experiment. 
Hidden Markov Models 
A random process is said to have the Markov property if the state of the process at 
any time t only depends on its state at the immediately preceding time point t – 1. A 
hidden Markov model (HMM) is a probabilistic statistical framework used for 
modeling a random Markov process with unobserved (hidden) states. The most 
important parameters associated with an HMM are the number of states of the process 
N, state transition probabilities A and emission probabilities E (the probability of 
observing an output value given a specific state). The HMM framework has seen 
wide application in pattern recognition across a variety of fields [114].  
Given its properties some methods have applied HMMs to ChIP-Seq data by likening 
the analysis to a classification problem: by observing a sequence of counts we want to 
infer the (hidden) state of the system, whether enriched or not. BayesPeak [103], uses 
the above framework, employing an HMM that can assume one of two states: a true 




sense strands using the 5’ ends of sequence reads. The emission probabilities are 
modeled using the NB distribution and parameters are estimated in a fully Bayesian 
manner using Markov chain Monte Carlo (MCMC) sampling techniques. HPeak [99] 
also models the data with a two-state HMM, but emission probabilities are based on 
generalized Poisson (enrichment) or zero-inflated Poisson distributions (background). 
Parameters for the HMM are estimated using the Viterbi algorithm [115] and the read 
counts in predicted peaks are compared with that in a control sample using a 
2
 test. 
A more recent method, RSEG [100], uses HMMs to detect broad enrichment regions 
characteristic of several histone modifications, such as, H3K27me3 and H3K36me3. 
Although RSEG also applies a two-state HMM to the problem of ChIP-Seq peak 
detection, it focuses on the detection of boundaries between regions of significant 
enrichment and background. Like BayesPeak, the emission probabilities of the two 
states are modeled using the NB distribution. The empirical distribution of transition 
probabilities is used to find windows with a high likelihood of being points of 
transition from an enrichment region to background and vice-versa. Other innovations 
include the development of a novel distribution for the difference between two 
independent random variables that follow the NB distribution (NBDiff), which is 
used for comparisons with a control. In the latter case, the HMM has three states 
corresponding to no difference between ChIP and control, greater enrichment and 
lower enrichment in the ChIP sample, respectively. 
The greater algorithmic complexity of HMMs makes the implementation of the above 
methods more difficult. BayesPeak, owing to its generalized design, requires 




high computational demands [116]. HPeak is simpler in comparison and hence more 
efficient, although the Poisson models implemented in the algorithm might not 
provide a very good fit for the background. RSEG, by design, is well suited to the 
detection of broad peaks, but this may limit its applicability to TFBS prediction. 
Methods Incorporating Additional Covariates 
As mentioned above, accounting for sources of technical variation in NGS data is 
necessary for the accurate discrimination of peaks from background. Therefore, it is 
reasonable to expect that the incorporation of additional covariates, e.g. mappability 
and G/C content, into the peak-calling procedure can improve accuracy. PeakSeq [95] 
was one of the first methods to adopt this approach by accounting for mappability in 
its peak-calling procedure. First, read density maps are created by calculating 
overlaps between reads extended to their fragment length. Each chromosome is 
divided into segments and a random distribution of reads mapping to these segments 
is generated using the Poisson distribution, taking into account the number of 
mappable bases in the segment. This procedure is similar to the dynamic Poisson 
model used in MACS, although the recommended segment is much larger (1 Mb) and 
the effective segment size accounts for mappability. In the first pass, a set of putative 
peaks are generated using a read count threshold, which is calculated separately for 
individual segments using the fitted Poisson model. This threshold when applied to 
negative control data also provides an estimate of the FDR and can be adjusted to 
user specifications. Linear regression is used to normalize the ChIP sample to a 




A recent method, ZINBA (Zero-Inflated Negative Binomial Algorithm), further 
generalizes the process of including covariates in the peak detection procedure [102]. 
ZINBA uses a mixture regression approach to classify windowed read-counts into 
one of three components – enrichment, background and zero. The third component is 
introduced due to the presence of large numbers of zero-count windows in sparse 
ChIP-Seq data sets, either due to inherent characteristics of the data or low 
sequencing depth. ZINBA employs an expectation-maximization (EM) algorithm to 
estimate the probability of component membership of each window, with enrichment 
and background read counts modeled using the NB distribution. Moreover, the 
relative contributions of covariates (including interactions) can be estimated and the 
important factors chosen using a model selection procedure based on the Bayesian 
information criterion (BIC). Windows having probability of enrichment greater than a 
specified threshold (default 0.95) are marked as putative peaks and adjacent enriched 
windows are merged. A further setting enables the concatenation of peaks within a 
fixed distance for broad enrichment regions. ZINBA provides an important advance 
in the field of ChIP-Seq peak-calling by jointly modeling ChIP-Seq data with 
genomic covariates. However, increased complexity, e.g. in the computationally 
intensive model-selection step, results in high computational demands. 
Detection of Differential Binding 
The accurate detection of enrichment regions in ChIP-Seq data may be sufficient for 
most exploratory analyses. However, at times it may be informative to compare ChIP-
Seq profiles across different experimental conditions. Possible questions include, for 




dynamics of histone modifications during stem cell differentiation. The prohibitive 
cost of next generation sequencing at the time of its introduction, served as a deterrent 
for such extensive epigenetic studies. However, with the gradual reduction of 
sequencing cost, the use of intricate experimental designs for epigenetics assays has 
become more prevalent, with the detection of ‘differential’ binding or enrichment a 
topic of interest. 
ChipDiff [117] was an early attempt at the detection of differential histone 
modification enrichments. This method uses a three-state HMM to compare two 
sequencing libraries L1 and L2 using fold-changes of normalized read counts. Similar 
to the two-sample analysis in RSEG, the three states correspond to no difference 
between the two samples, higher enrichment in L1 and higher enrichment in L2, 
respectively. Windows with a high probability of being in one of the latter two states 
are marked as putative points of differential histone marks with adjacent sites being 
merged. The fold-change approach used by ChipDiff can be prone to large variations 
particularly at low signal strength while a fixed window size of 1 kb causes lowered 
resolution. Moreover, ChipDiff only supports two ChIP-Seq libraries and thus, has 
limited applicability to more complex experimental designs. 
Rapid advances in the field of mRNA sequencing (RNA-Seq) analysis saw the 
development of suitable statistical methodology and the development of two popular 
tools, edgeR [118] and DESeq [119]. Both these methods utilize the NB distribution 
to model read counts although the respective implementations are somewhat 
different. EdgeR adopts the classical NB distribution wherein the mean  and 
variance 





each gene using conditional maximum likelihood, while an empirical Bayes 
procedure is employed to enable the shrinkage of dispersions. Since  is the only 
parameter to be estimated per gene, edgeR can be applied to experiments with smaller 
numbers of replicates, as is often the case in sequence-based assays. 
DESeq extends the model used by edgeR with a more flexible data-driven approach. 
The ‘true’ fragment count for each gene is assumed to be proportional to the observed 
count scaled by a normalization factor dependent on the library size. The raw 
variance of each gene is assumed to be a smooth function of the read count of each 
gene, which is estimated using local regression. The local regression approach uses 
genes of similar expression level to predict gene-wise variances and as a result 
DESeq is applicable to experiments having small numbers of replicates.  
Although both edgeR and DESeq were developed for gene expression assays, they 
can be extended to other NGS applications, such as, ChIP-Seq. However, due to 
major differences in the applied protocols, relevant results may need to be treated 
with some caution. For instance, the RNA-Seq is less susceptible to amplification bias 
and thus, raw reads can be used directly with the above tools for differential 
expression analysis, while redundant reads need to be removed from ChIP-Seq data. 
In summary, ChIP-Seq analysis is a complicated process comprising several 
important steps. The maturation of next-generation sequencing technologies and 
development of efficient software has meant that the computationally intensive read-
mapping step is no longer the bottleneck of the analysis. Also, statistical methodology 
suited to analysis of count data has made it easier to perform differential analyses. 




makes distributional assumptions for computational efficiency that have been shown 
to be inadequate. The added complexity of diverse enrichment patterns observed in 
ChIP-Seq data means that there is a continuing need for accurate peak-calling 
algorithms, robust to background variations and sensitive to diverse binding patterns. 
Marek’s Disease 
Marek’s disease (MD) is a highly contagious, lymphoproliferative disease of chickens 
caused by an herpesvirus, Marek’s disease virus (MDV). MD was initially 
described and characterized in 1907 by eminent Polish veterinarian, József Marek, as 
a ‘polyneuritis’, but was later found to also cause lymphomas. The discovery of the 
causative agent, MDV, in the 1960s proved to be the next major step forward, 
occurring soon after the economic boom of the poultry industry [120]. The ubiquitous 
nature of MDV results in exposure for virtually all chickens from birth, and the acute 
forms of the disease became a particular cause for concern to the industry during 
expansion and increased production of that decade. The introduction of a successful 
vaccine in 1969 [121] temporarily allayed fears, but also led to increased virulence of 
the virus. Further development of vaccines followed [122], but resulted in even 
greater levels of virulence [123], as it became clear that alternative sustainable 
methods were necessary for controlling MD in the long term. 
Genetic resistance to MD provides such an alternative. Natural resistance to MD was 
observed in commercial flocks of chicken as early as 1932 [124] and the breeding of 
chicken lines selected for resistance or susceptibility to MD had been shown to be 
possible in 1947 [125], even before the discovery of MDV as its causative agent. 




susceptible lines – lines N and P selected by the above researchers at Cornell 
University and lines 6 and 7 selected by Stone at East Lansing. The above two 
unrelated groups of inbred lines have since been the center of extensive study and are 
the primary source of the current understanding of MD-resistance and susceptibility. 
Marek’s disease has several interesting features. It is the only known lymphomatous 
disease that has been successfully controlled by a vaccine. Three closely related 
serotypes of MDV exist – MDV-1, MDV-2 and herpesvirus of turkeys (HVT). MDV-
2 and HVT are usually non-pathogenic, but MDV-1 causes acute lymphomas in 
susceptible birds. Neoplastically transformed cells in MD tumors have been found to 
overexpress CD30 antigen [126] and thus, MD is a natural model for Hodgkin’s 
lymphoma in humans [127]. Also, the outcome of MDV infection depends on various 
host, viral and environmental factors; non-oncogenic strains of MDV can become 
oncogenic under certain conditions, such as, stress. Thus, it is a great animal model 
for the study of host-pathogen interactions, in general, and virus-induced lymphoma 
formation, in particular. Also, the populations of inbred lines can help understand the 
genetic basis of resistance and susceptibility to a cancer-causing agent. 
Marek’s Disease Pathogenesis 
MDV exhibits a complex life cycle in host cells involving an initial cytolytic phase, a 
latent phase, a late cytolytic phase and transformation. Initial infection is believed to 
occur when the birds inhale the virus particles. Once in the respiratory tract, the virus 
is phagocytosed by macrophages or dendritic cells (DCs) that, as a result, become 
infected. The phagocytosis might occur directly or after replication in epithelial cells. 




major lymphatic organs of the bird, and within 24 hours of infection the virus is 
detectable in the spleen, thymus and bursa of Fabricius.  
During the early cytolytic infection that follows, the virus first targets B lymphocytes 
which likely surround infected ellipsoid-associated reticular cells (EARCs) in the 
spleen [128]. This phenomenon is also the reason why B lymphocytes are the primary 
targets of MDV at the cytolytic stage of infection. Subsequently, the infection spreads 
to other lymphoid tissues, such as, bursa and thymus, that lag behind the spleen by a 
day. In each of these organs, B lymphocytes form the largest proportion of infected 
cells, along with smaller numbers of CD4+ and CD8+ T lymphocytes [129]. 
Cytolytic infection can cause major atrophy of bursa and thymus, accompanied by 
immunosuppression, in contrast to the spleen which shows slightly increased weight 
and greater virus load. Interestingly, T lymphocytes activated as a consequence of 
MDV infection of B cells renders them susceptible to infection, while naïve T 
lymphocytes are relatively immune [130]. This has led to the suggestion of an MDV 
receptor expressed on the surface of CD4+ T lymphocytes, but in the absence of 
further evidence this remains a matter of conjecture. 
At 6-7 days post infection (dpi), the infection enters latency during which the viral 
genome is present in host cells but no viral antigens are expressed in lymphoid tissue 
and no viral replication observed. By this time, most cytolytically infected B cells are 
dead and CD4+ T lymphocytes form the bulk of the infected cell population. Latently 
infected T lymphocytes may be transformed in latter stages of the disease and go on 
to form lymphomas, and the relationship between these two stages is poorly 




cytolytic to latent infection is believed to be influenced by host factors. The time of 
incidence of latency coincides with the establishment of the host immune response. 
Also, the reemergence of cytolytic infection in susceptible genotypes is likely 
concurrent with immunosuppression in the host. Various host cytokines such as 
interleukin (IL)-6, IL-18 and interferon (IFN)- and other cell signaling molecules 
such as nitric oxide (NO) are believed to play major roles in the establishment and 
maintenance of latency [131]. Certain virus genes such as a group of latency 
associated transcripts (LATs) and Meq are important players in latency. MDV LATs 
include three RNAs that interfere with MDV immediate-early gene ICP4 and inhibit 
translation of the ICP4 protein resulting in abrogation of lytic infection and onset of 
latency [132]. Meq blocks apoptosis of latently infected CD4+ T lymphocytes and 
transactivates latent gene expression [133], thereby helping maintain latency. In 
resistant chickens, latent infection persists at low levels in circulating lymphocytes 
without reactivation, while inflammatory changes in lymphoid tissues gradually 
recede. 
In susceptible chickens, latency is followed by a second phase of cytolytic infection 
2-3 weeks after initial infection [134]. This late phase of infection affects immune 
organs of thymus and bursa, along with epithelial tissues, such as, kidney. It appears 
that latently infected lymphocytes circulate the virus to different parts of the body 
such as, brain, nerves and skin before reactivating as a result of immunosuppression 
[134]. Following reactivation of the virus there is heightened inflammation, necrosis 
of infected lymphocytes, infiltration of mononuclear cells into infected tissue and 




infection of the feather follicle epithelium, which is fully productive, i.e. there is 
widespread release of infectious, cell-free virus particles and apoptosis of infected 
follicular cells. The feather follicle epithelium is the site of continued expression of 
MDV antigens and persistence of virus particles in resistant and susceptible birds 
alike. 
The final stage of MDV infection is the transformation and proliferation of latently 
infected cells into lymphomas. The major site of proliferation appears to be the 
spleen, although it is not believed to be essential for the formation of lymphomas 
[135]. About 21 dpi, large increases in T cells that are possible precursors of 
transformed cells, are observed in the spleen [136]. Cells expressing high levels of 
CD30 antigen are detected in blood and spleen of both resistant and susceptible birds 
at the end of the early cytolytic infection [129]. This marker, encoded by the host and 
expressed in MD tumors and cell lines, is found only on a small population of MDV-
free lymphocytes [126] and not expressed on naïve CD4+ T lymphocytes. Thus, it is 
likely that the CD30+ T lymphocytes in spleen are precursors of the transforming cell 
population. Soon after, infected T lymphocytes migrate to visceral organs and 
peripheral nerves where they proliferate into tumors. Approximately three-quarters of 
cells found in MD tumors are CD4+ T lymphocytes with the rest being B 
lymphocytes. However, almost all cells showing non-productive infection are CD4+ 
T lymphocytes [137], indicating that these cells form the bulk of the neoplastic cell 
population in lymphomas. In susceptible genotypes, the above CD4+ T lymphocytes 




resistant chickens, cytotoxic CD8+ T lymphocytes appear to keep proliferation in 
check, resulting in apoptosis and regression of MD lesions [138]. 
Immunity to Marek’s Disease 
Host responses to Marek’s disease are determined by innate and acquired immune 
responses. The two major components of innate immunity are macrophages and NK 
cells. Macrophages play an important role in innate immune response and adaptive 
immunity by functioning as antigen-presenting cells (APCs). As mentioned above, 
macrophages engulf virus particles in the respiratory tract and transport them to 
lymphoid tissue where cytolytic infection is initiated. Initial studies in vitro suggested 
that macrophages were resistant to MDV infection [139], but subsequent studies 
showed that splenic macrophages express MDV antigens, consistent with virus 
replication [140]. Macrophages also recognize antigens via pattern recognition 
receptors, release cytokines and soluble factors (e.g. NO) that aid in defense against 
infections. Recent reports have suggested that NO produced by inducible nitric oxide 
synthetase (iNOS) can inhibit MDV replication in early cytolytic and latent phases of 
infection [131]. Higher levels of NO are observed in MD-resistant chickens at early 
stages, and possibly contribute to lowered viral load in these genotypes. Further 
support for the above was obtained when studies found increased tumor incidence and 
viral load after treatments to reduce macrophage numbers [141] and vice-versa [142]. 
Thus, macrophages play an important role in reducing viral load during early 
cytolytic infection possibly via the secretion of NO. 
NK cells constitute another important component of innate defense mechanisms 




property of NK cells is shared with T lymphocytes even though they are non-
phagocytic and do not express antigen receptors. In normal individuals, NK cells are 
found only in peripheral blood, spleen and bone marrow, but can move quickly to 
sites of inflammation upon induction by various chemotactic molecules. Various 
reports have suggested the possible involvement of NK cells in MDV infection. NK 
cells isolated from spleen of normal chickens lysed cells from a MD tumor cell line 
[143]. NK cell activity increased 7 days after MDV infection in both resistant and 
susceptible chickens [144]. MD-resistant line N chickens exhibited higher and more 
sustained NK cell activity than susceptible line P chickens [145]. Also, a genomic 
region strongly associated with MD-resistance was found to be syntenic to human and 
murine NK cell clusters [146]. All in all, NK cells appear to be involved in protective 
immunity against MDV and are possibly most active during the early cytolytic phase 
of infection. However, their mechanism of action remains unclear as the 
characterization of NK cells is hindered by the lack of available markers [147]. 
The major components of the acquired immune response are CD8+ cytotoxic T 
lymphocytes (CTLs) and CD4+ T helper cells that secrete cytokines. CTLs are 
associated with MD-resistance in line N chickens as they interact with and 
subsequently remove MDV ICP4 through the action of specific receptors [148].  
CTLs help in reducing MDV replication, transmission and persistence. The role of 
cytokines in MD has been the subject of intense study in the past few years. As 
mentioned above, several cytokines such as IFN-IL-1and iNOS were 
preferentially upregulated in spleen from line N chickens from early stages of 




upregulation of IFN-  in all infected chickensconsistent with the previous study, 
along with inflammatory cytokines IL-6 and IL-18, in susceptible birds during early 
cytolytic infection. In addition to the above host factors, a virus-encoded IL-8 
homolog (vIL-8) has also been found [149]. Since IL-8 acts as a chemoattractant for 
T lymphocytes, the above finding has led to speculation that the viral homolog 
attracts T cells to sites of infection. However, vIL-8 shares greater homology with a B 
lymphocyte chemoattractant and can be better categorized as a CXC chemokine. The 
precise role of vIL-8, therefore, remains unclear. 
Marek’s Disease Resistance and Susceptibility 
The first major step towards understanding the mechanisms behind MD resistance 
was provided by the observed association between MD resistance and inheritance of 
the B blood group locus [150]. Since this locus was a known marker for the chicken 
major histocompatibility complex (MHC), the above observation gave rise to the 
possibility that genes found within the chicken MHC could be responsible. Several 
subsequent studies confirmed this finding, although it did not preclude the possibility 
that other genes might also be involved. Based on this and further experiments, 
genetic resistance to MD can be subdivided into two categories – MHC-associated 
and non-MHC associated resistance. 
Several known haplotypes of the B locus provide varying levels of resistance, such 
as, B
21
 confers high resistance irrespective of genetic background, and B
19
 is 
associated with susceptibility. However, certain other haplotypes, e.g. B
2
, can have 
widely varying effects on MD-resistance depending on other factors. It was shown 




correlated with their B haplotype [151]. Line N possesses the B
21
 haplotype 
associated with high resistance while line P contains the B
19
 haplotype which confers 
high susceptibility. The mechanism behind MHC-associated MD resistance has been 
elucidated to some degree. MDV infection is believed to induce low levels of CTLs 
that are specific for certain proteins encoded by MDV. For instance, CTL specific to 
the viral immediate-early protein ICP4 were found in MD-resistant line N chickens 
carrying the B
21
 haplotype, but not in line P [152]. It was suggested recently that 
natural killer (NK) cells may be involved in the process [145]. Also, class I MHC 
molecules had varying levels of expression on the cell surface of uninfected cells, 
with B
19
 having the highest expression and B
21
 the lowest [153]. This raised the 
possibility that NK cells are major effectors in MD, as in mammals they can detect 
differences in cell surface expression. Alternatively, CTLs and NK cells can both 
confer some level of protection from infection. 
In contrast to lines N and P, lines 6 and 7 both carry the B
2
 haplotype and thus, 
differences in MD resistance observed in these lines depend on factors outside the 
chicken MHC. This situation is also true of several outbred and commercial flocks of 
chickens whose resistance or susceptibility to MD cannot be fully explained on the 
basis of their B haplotypes alone. Many other genes could possibly be involved in this 
form of MD resistance and several different approaches have been used to investigate 
the underlying mechanisms. 
Early studies reported differences in viral replication between the two lines, with the 
susceptible line 7 showing higher rates of viral replication and subsequent viral load. 




from the early stages of infection which was maintained throughout their lifetime. 
Resistant line 6 chickens, on the other hand, showed a gradual increase in viral load 
which peaked around 10 dpi before falling to low levels. The early differences 
between the two lines suggested differences in innate rather than adaptive immune 
response. The clearance of infection observed in line 6 at later stages of MD suggests 
an adaptive response, although the inability of line 7 to mount a successful defense 
could either be due to greater injury to the immune system during early cytolytic 
infection [136] or inherent differences in immune response [154]. 
Lymphocyte surface markers were believed to be partly responsible for the 
differential disease in the two lines. Investigations led to the discovery of three 
alloantigens designated as Ly-4 [155], Bu-1 and Th-1 [156], each of which showed a 
certain degree of association with MD resistance. Genomic mapping revealed 14 
genomic regions associated with disease resistance [157, 158]. Further attempts to 
map resistance loci using a backcross population [146] resulted in the discovery of a 
region on chromosome 1 with a strong association with MD-resistance. This region 
appeared to control viremia and shared homology with human and mouse NK cell 
clusters. One putative resistance gene present in this region was identified and 
designated MDV1. Subsequent studies using microarrays [159] identified several 
immune-related genes, such as, IFN- that showed significant differences in 
expression in the two lines, located in genomic regions associated with MD 
resistance. Recent studies of host responses to MDV infection have further expanded 




the focus has gradually shifted to systems analyses to uncover pathways associated 
with MD [162, 163].  
Thus, non-MHC associated MD resistance is influenced by many genetic and 
environmental factors. Studies attempting to map the MD-resistance observed in 
these lines to specific genomic regions have met with moderate success, while the 
investigation of the transcriptional effects of MDV have revealed differential 
expression of certain important host cytokines and viral genes. However, none of 
these loci can completely explain the mechanism of MD-resistance and susceptibility. 
Also, environmental factors can have a major impact on the outcome of infection, 
which suggests that epigenetic processes play an important role in MD progression. 
Therefore, this is a great animal model to study epigenetic effects of a lymphomatous 
virus and the epigenetics of disease resistance. We propose to investigate one aspect 
of this by studying histone modifications induced by MDV in line 63 and line 72 
chickens at various time points of the disease. Our results could have potentially far-
reaching consequences on our understanding of the epigenetics of disease resistance. 
Rationale and Significance 
ChIP-Seq combines traditional ChIP with next-generation sequencing to form a 
powerful experimental framework that targets specific histone modifications across 
the genome. This technique is highly efficient and suited to the study of complex 
biological phenomena, such as, MD. Methods of ChIP-Seq analysis often make 
assumptions about the distribution of ChIP-Seq data for computational efficiency. 
These assumptions have been shown to be inadequate, which limit their sensitivity to 




advanced method or strategy to overcome the unreasonable distribution inference. 
Thus, the first goal of this project is to develop an efficient and sensitive method of 
ChIP-Seq analysis that does not make any distributional assumptions. This goal can 
be achieved with the help of spectral analysis techniques, such as, the wavelet 
transform and Monte Carlo sampling procedures. Further, our experimental model of 
MD resistant and susceptible inbred chicken lines provides a unique data set that we 
can use to validate this method. 
Highly inbred chicken lines with drastically different responses to MDV infection, 
originating from the lines 6 and 7 described above, have been developed in the Avian 
Disease and Oncology Laboratory (ADOL), USDA, Michigan – Line 63 shows high 
MD-resistance with very few birds (0-3%) developing tumors; Line 72 exhibits MD-
susceptibility with virtually all individuals (99-100%) developing tumors. The 
investigation of histone modification profiles in this unique population of chickens 
can provide an insight into the epigenetic effects of MDV infection and factors 
influencing disease predisposition. Thus, the second goal of this work is to investigate 
genome-wide chromatin signatures induced by MDV infection in this population, 
with a view to a greater understanding of associated epigenetic factors. This goal can 
be achieved by the application of existing and novel methods to the analysis of 
histone modification data generated from the population of inbred chicken lines. 
The outcomes of this project will further our understanding of histone modifications 
in poultry, in general, and the effect of MDV infection on host chromatin signatures, 




Seq analysis will greatly benefit the scientific community and be useful for many 
future applications. Hence this project consists of the following 3 parts: 
1. To develop a novel method of detecting significant peaks in ChIP-Seq data  
2. To investigate the epigenetic differences induced by MDV infection in the thymus 
3. To apply existing and novel methods to conduct a temporal analysis of chromatin 









2. WaveSeq: A Novel Data-driven Method of Detecting Histone 
Modification Enrichments using Wavelets  
Abstract 
Chromatin immunoprecipitation followed by next-generation sequencing is a 
genome-wide analysis technique that can be used to detect various epigenetic 
phenomena such as, transcription factor binding sites and histone modifications. 
Histone modification profiles can be either punctate or diffuse which makes it 
difficult to distinguish regions of enrichment from background noise. With the 
discovery of histone marks having a wide variety of enrichment patterns, there is an 
urgent need for analysis methods that are robust to various data characteristics and 
capable of detecting a broad range of enrichment patterns. 
To address these challenges we propose WaveSeq, a novel data-driven method of 
detecting regions of significant enrichment in ChIP-Seq data. Our approach utilizes 
the wavelet transform, is free of distributional assumptions and robust to diverse data 
characteristics such as low signal-to-noise ratios and broad enrichment patterns. 
Using publicly available datasets we showed that WaveSeq compares favorably with 
other published methods, exhibiting high sensitivity and precision for both punctate 
and diffuse enrichment regions even in the absence of a control data set. The 
application of our algorithm to a complex histone modification data set helped make 





WaveSeq is a highly sensitive method capable of accurate identification of enriched 
regions in a broad range of data sets. WaveSeq can detect both narrow and broad 
peaks with a high degree of accuracy even in low signal-to-noise ratio data sets. 
WaveSeq is also suited for application in complex experimental scenarios, helping 
make biologically relevant functional discoveries. 
Introduction  
Chromatin immunoprecipitation followed by massively parallel sequencing (ChIP-
Seq) is a powerful experimental framework that enables genome-wide detection of 
epigenetic phenomena such as histone modifications. Histone modification profiles 
have diverse characteristics ranging from sharp well-defined peaks surrounding 
transcription start sites of genes to broad diffuse marks on large genomic regions. 
This inherent variability makes it difficult to distinguish regions of true enrichment 
from background noise.  
There have been several attempts at solving the problem of finding statistically 
enriched peaks in ChIP-Seq data. One class of methods focuses on transcription 
factor ChIP-Seq experiments and uses various features of the data to predict binding 
regions. For instance, FindPeaks [93] adopts a height threshold together with a 
simulated random background to find significant peaks, while MACS [92] uses a 
local Poisson p-value to detect chromatin enrichments. Most of these methods have 
comparable sensitivity in detecting transcription factor binding sites (TFBSs) and are 




While the success of the above set of methods in finding transcription factor binding 
patterns from ChIP-Seq data is undeniable, histone modification data pose new 
challenges. Utilization of local features to detect histone modification peaks is 
difficult due to the relative diffuseness of enrichment patterns. Also, common 
assumptions of such analyses may not hold in this case. For instance, TFBSs cover a 
small proportion of the genome, but certain histone marks can be present on much 
larger genomic fractions. Strong TFBSs are flanked by clusters of sense and anti-
sense reads and this information can be leveraged to predict the location of the 
binding site. However, the diffuse nature of most histone modifications renders this 
impossible. A combination of such factors has led to a relative paucity of methods to 
analyze histone modification data. A commonly used tool, SICER [101], fits a 
Poisson distribution before employing kernel density estimation to predict enriched 
regions, while a recent study employed a negative binomial regression framework and 
incorporated genomic covariates to improve ChIP-Seq peak detection [102]. 
However, with the discovery of an ever-increasing number of histone marks that 
encompass a wide variety of enrichment patterns, there is a continuing need for 
improved methods robust to a range of data characteristics. 
Wavelets belong to a class of spectral analysis techniques that can extract meaningful 
information from data by decomposing it into its underlying patterns. The versatility 
of wavelets has seen them being used in a wide variety of disciplines ranging from 
image processing to medical diagnostics. Recently, we applied this technique to the 
analysis of comparative genomics hybridization data [164], utilizing the wavelet 




copy-number profiles in human and bovine populations. However, wavelets also have 
excellent spatial resolution and comparing data sets one can not only find differences 
in frequencies of global patterns but also the precise locations of such variations. This 
property is highly desirable for genome-wide analyses and is the primary motivation 
for this work. 
We present WaveSeq, a novel data-driven method of ChIP-Seq analysis that utilizes 
the wavelet power spectrum to detect statistically significant peaks in ChIP-Seq data 
having punctate or broad enrichment patterns. WaveSeq employs Monte Carlo 
sampling in the wavelet space to predict regions of true enrichment in ChIP-Seq data. 
In the absence of a control, a randomized algorithm constrained by the length 
distribution of putative peaks is used to estimate the background read distribution and 
predict regions of significant enrichment. The non-parametric modeling approach 
ensures that WaveSeq is robust to variations in data characteristics (e.g. genome 
coverage) and produces accurate peak calls for a wide variety of data types.  
WaveSeq was applied to ChIP-Seq data of Growth-associated binding protein 
(GABP), Neuron restrictive silencing factor (NRSF) and trimethylations of histone 
H3 at lysine 4 (H3K4me3), lysine 27 (H3K27me3) and lysine 36 (H3K36me3), which 
were chosen to capture significant diversity of enrichment patterns and signal-to-
noise ratios (SNRs). We demonstrated that WaveSeq peak calls have high sensitivity 
and precision for narrow and broad regions over a range of SNRs even in the absence 
of a control data set. We further exhibited the utility of our approach in a complex 
experimental setting by analyzing H3K4me3 data from genetically similar chicken 




regions detected by WaveSeq revealed functional differences between the lines that 
could contribute to differences in disease prognosis. Thus, we conclude that WaveSeq 
is a highly sensitive algorithm for ChIP-Seq analysis, with applicability for a diverse 
range of enrichment patterns. 
Materials and Methods 
H3K4me3 data from chicken bursa 
Two specific-pathogen-free inbred lines of White Leghorn chickens either resistant 
(63) or susceptible (72) to MD were hatched, reared and maintained in the Avian 
Disease and Oncology Laboratory (ADOL, Michigan, USDA). The chickens were 
injected intra-abdominally with a partially attenuated very virulent plus strain of 
MDV (648A passage 40) at 5 days after hatch with a viral dosage of 500 plaque-
forming units (PFU). Chickens were terminated at 5dpi to collect bursa tissues. All 
procedures followed the standard animal ethics and use guidelines of ADOL. 
Chromatin immunoprecipitation (ChIP) was carried out using bursa from MDV 
infected and controls birds. About 30 mg bursa samples were collected from three 
individuals, cut into small pieces (1 mm
3
) and digested with MNase to obtain 
mononucleosomes. PNK and Klenow enzymes (NBE, Ipswich, MA, USA) were used 
to repair the ChIP DNA ends pulled down by the antibody. A 3′ adenine was added 
using Taq polymerase and Illumina adaptors ligated to the repaired ends. Seventeen 
cycles of PCR was performed on ChIP DNA using the adaptor primers and fragments 
with a length of about 190 bp (mononucleosome + adaptors) were isolated from 




was performed on the Illumina Genome Analyzer IIx following manufacturer 
protocols. Sequence reads of length 25 bp were aligned to the May 2006 version of 
the chicken genome (galGal3) using bowtie version 0.12.7 [80]. Default alignment 
policies of bowtie were enforced. The antibodies used and the total number of reads 
obtained for all samples are listed in Appendix I. 
Published datasets used in this study 
We used five ChIP-Seq data sets for benchmarking purposes [69, 98]. The GABP and 
NRSF (monoclonal) ChIP-Seq data sets were produced from the human Jurkat cell 
line while a negative control data set was obtained by reverse crosslinking extracted 
DNA without the subsequent immunoprecipitation step (RX-NoIP). The H3K4me3, 
H3K27me3 and H3K36me3 data sets were obtained from murine embryonic 
fibroblast (MEF) cells. We also utilized a previously published synthetic spike-in data 
set for testing precision and recall [107]. For two-sample ChIP-Seq analyses of 
GABP and NRSF, we used the RX-NoIP data set as control. The spike-in data 
consisted of a human input control data set which was randomly divided into three 
subsets; reads corresponding to the spikes were added to one of the subsets which 
constituted the mock ChIP sample while a second subset (without the spike-in reads) 
served as the control. For the MEF histone modification data no control data sets 
were used to assess algorithm performance in the absence of control. 
The GABP and NRSF data from human Jurkat cells were downloaded from: 
 http://mendel.stanford.edu/SidowLab/downloads/quest/  






The list of qPCR validated sites for GABP and NRSF were obtained from [105]. The 
synthetic spike-in data were downloaded from: 
 http://bioserver.hci.utah.edu/SupplementalPaperInfo/2008/Nix_EmpiricalMethods/ 
The “JohnsonSpikeDataHg17Low” data set used for specificity benchmarks was 
generated using human input control data from [68]. All data was downloaded in 
aligned format with read lengths of 25 bp for the GABP and NRSF data and 
approximately 32 bp for the H3K4me3 and H3K27me3 data. All analyses were 
performed on a 2.66 GHz dual core desktop computer running Windows Vista with 3 
GB of RAM, a licensed copy of Matlab v7.4 (R2007a) with the Wavelet Toolbox and 
R version 2.13.0 [165]. 
Analysis parameters 
Downloaded data consisting of aligned sequence reads were converted to the browser 
extensible data (BED) format. Redundancies were removed before subsequent 
analysis. Sequence reads were shifted by 95 bp from the 5’ end to represent the center 
of the DNA fragments obtained from the nucleosome and the linker DNA (≈ 190 bp). 
Summary read counts were calculated using non-overlapping windows of 200 bp for 
visualization and normalized to per million mapped reads in each sample. 
Five methods were chosen for benchmarking: MACS [92] version 1.3.7.1, FindPeaks 
[93] version 4.0.15, SiSSRs [64] version 1.4, SICER [101] version 1.1 and RSEG 




1) FindPeaks v 4.0.15 was downloaded as part of the Vancouver Short Read Analysis 
Toolkit (VSRAT) from http://vancouvershortr.sourceforge.net. The reads in BED 
format were first separated into chromosomes using SeparateReads.jar. The following 
parameters were then used for FindPeaks.jar: 
-aligner bed 
-dist_type 0 190 
2) MACS v 1.3.7.1 was downloaded from http://liulab.dfci.harvard.edu/MACS/. The 
following parameters were used: 
--shiftsize=95 
--nomodel True 
For applying MACS to histone modification data sets, we used the additional 
parameter --nolambda as recommended by [166].  
3) SiSSRs v 1.4 was downloaded from http://sissrs.rajajothi.com/. The following 
parameters were used: 
-F 190 
4) SICER v 1.1 was downloaded from http://home.gwu.edu/~wpeng/Software.htm. 
The following parameters were used: 
Gap size = 2 (H3K4me3), 5 (H3K36me3) and 10 (H3K27me3) 
E-value = 100 
Window size = 200 
5) RSEG was downloaded from http://smithlab.usc.edu/histone/rseg/. The following 





For the transcription factor binding site detection all methods were configured to have 
p-value < 0.001 in single sample experiments and p < 0.01 in the presence of matched 
controls. For uniformity, we set genome size = 3,107,000,000 bp for the GABP and 
NRSF (hg18) data sets and 2,725,000,000 bp for murine embryonic fibroblast (mm8) 
histone modification data. Recommended values were used for all other parameters. 
Gene annotation and functional analysis of differentially marked 
regions (DMRs) 
RefSeq and Ensembl gene annotations for the chicken genome (galGal3) were 
downloaded from the UCSC genome browser [167]. Gene promoters were searched 
for overlaps with DMRs and all gene names were converted to their Ensembl IDs 
using the biomart data retrieval system from Ensembl [168, 169]. This unified list of 
gene IDs was then analyzed for functional annotation enrichment with DAVID [170]. 
Default parameters were used for DAVID analyses. 
Software implementation 
Data pre-processing, Monte Carlo estimation of wavelet coefficient thresholds and 
peak-calling modules of WaveSeq were implemented in Matlab. FDR estimation in 
the presence and absence of control was performed in R. We are currently working on 
a unified R implementation of the software for public release. WaveSeq can be run on 
a standard desktop computer with at least 3 GB of RAM and a 2 GHz processor. The 
software can be used on any species with a sequenced genome. WaveSeq has been 





Wavelets for ChIP-Seq analysis 
The wavelet transform has great utility in data compression and pattern finding, the 
latter involving the choice of a suitable ‘mother’ wavelet ψ to best capture underlying 
patterns in the data. An example of a mother wavelet is the Morlet wavelet, defined as 
the product of a Gaussian envelope and a cosine wave: 
tet t 0
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where, t is the genomic location and 0  is the non-dimensional frequency (Figure 
2.1A). The wavelet transform may be either continuous or discrete – the continuous 
wavelet transform (CWT) is highly redundant and resistant to data loss while the 
discrete transform is less computationally intensive but more prone to information 
loss. The peaks observed in ChIP-Seq data are relatively smooth, making it better 
suited to the application of the CWT.  
The CWT consists of the convolution of a translated and scaled mother wavelet 
























where, (*) indicates the complex conjugate, s is the wavelet scale and t’ denotes 
translation along the genome. The wavelet scale s is representative of the size of the 
scaled wavelet and the mathematical formulation of the transform implies an inverse 
relationship, i.e. the higher the scale, the smaller the scaled wavelet. The wavelet 




the correlation between the mother wavelet and the data, which may be either positive 
or negative. This is also a multi-scale decomposition, i.e. the coefficients at different 
scales represent the correlation of scaled versions of the wavelet to the signal. 
Therefore, smaller localized patterns are likely to be captured by higher scales of the 
transform and vice-versa. 
A natural way of quantifying the wavelet decomposition is the wavelet power 
spectrum, defined as the square of the wavelet coefficients, and synonymous with the 
‘energy density’. A contour plot of the wavelet power spectrum for ChIP-Seq data 
revealed hot-spots that correlated with peaks (Figures 2.1 B, C). This suggested that 
wavelets could be used to detect enrichment regions in this type of data and inspired 
us to use this approach for ChIP-Seq analysis. 
WaveSeq overview 
We introduce WaveSeq, a novel method of ChIP-Seq peak detection that utilizes the 
wavelet power spectrum (Figure 2.1 D). Sequence reads are first ‘shifted’ to represent 
the center of DNA fragments obtained from the ChIP experiment. The genome is 
divided into non-overlapping windows and read counts for each window calculated. 
The summary read counts are the primary input data format used by WaveSeq. 
Typical analyses can be of two types: (i) single sample experiment – without control, 





Figure 2.1. WaveSeq utilizes the continuous wavelet power spectrum to detect 
peaks in ChIP-Seq data.  
(a)  A scaled representation of the morlet wavelet. (b & c) H3K4me3 data and a 
contour plot of the associated wavelet power spectrum shows hot spots that correlate 
with ChIP enrichments. The ChIP-Seq data represents the 15,756,800 – 15,758,200 
bp region of the mouse chromosome 1 from the MEF H3K4me3 data set.  (d) A 
schematic of the WaveSeq analysis pipeline. The workflow consists of two major 
modules: (i) the Monte Carlo background estimation step and (ii) significance 
estimation from randomized algorithm using the peak length distribution (one-sample 
experiment) or an exact binomial test (two-sample experiment). 
For both analyses, we first employ a Monte Carlo sampling technique for modeling 
the data [171]. N random samples are drawn from the ChIP-Seq data and the wavelet 
power calculated for each instance. A slice of the power spectrum at a fixed point of 
each random sample is used to generate an empirical distribution of wavelet powers 
for each scale. This distribution enables us to obtain a suitable significance threshold, 




having significant enrichment. Our thresholding procedure is, therefore, dependent on 
the wavelet fit to the data at a particular position and distinct from a simple read-count 
cutoff.
 
Figure 2.2. Peak length distributions of tested methods when applied to histone 
modification data.  
A comparison of peak length distributions for the top 15000 peaks called from the (a) 
H3K4me3, (b) H3K36me3 and (c) H3K27me3 data. (a) SICER and MACS have 
similar peak lengths in the H3K4me3 data, followed by WaveSeq. RSEG peak 
lengths are almost uniformly distributed between 0 and 20 kb. (b) MACS and RSEG 
called relatively short peaks for H3K36me3 while SICER and WaveSeq detected 
greater peak lengths. (c) WaveSeq called the longest peaks when applied to 
H3K27me3 data followed by SICER and RSEG. 
To further account for broad peaks seen in histone modification data, our algorithm 
implements a ‘gap’ parameter, g. We define a ‘gap’ as a window having a non-
significant wavelet power (non-significant window); for example, if g is set to two, 
peaks separated by at most two non-significant windows are aggregated together. 
This parameter is necessary for two reasons: (i) chromatin enrichments, especially 
broad marks, such as, H3K36me3 and H3K27me3, can be discontinuous and (ii) 
wavelets are very sensitive to boundary events and local fluctuations. A strong 
enrichment region interspersed with areas of low read counts could, therefore, result 
in multiple peak calls and the gap parameter of WaveSeq helps to reduce the effect of 




one major distinction. SICER also imposes an upper limit on allowable non-
significant windows within a significant peak. While this results in an elegant closed 
form expression for estimating statistical significance from the score distribution, in 
practice, this results in smaller peak lengths for the same value of g (Figure 2.2). 
One-sample experiment 
The estimation of statistical significance is crucial to ChIP-Seq analysis approaches to 
filter the results of genome-wide studies, particularly in the absence of a control. For 
a single-sample experiment, WaveSeq utilizes the length distribution of putative 
peaks to estimate the likelihood of observing a peak with a given number of reads. 
A large number of peaks, P, are sampled with replacement from the length 
distribution of putative peaks, and their positions on the genome randomized. The 
number of reads within each randomized peak is counted, generating the empirical 
distribution, F(R), for the number of peaks having a given read count R. The 
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The p-values are subsequently corrected for multiple-testing using the Benjamini-
Hochberg FDR procedure [172]. 
Most ChIP-Seq experiments produce sparse enrichment regions covering a small 




would be likely to overlap significantly enriched regions. However, this is not always 
the case – histone modifications such as, H3K27me3, mark large regions for silencing 
and could occupy a significantly greater genomic fraction. In the latter case, a higher 
proportion of randomized peaks would potentially overlap ‘true’ enrichment regions – 
but this is a fair reflection of a relatively low SNR data set where the boundaries 
between true signal and background are blurred. 
Thus, it is important to note that in predicting areas of true enrichment in ChIP-Seq 
data, we do not make any assumptions about the read distribution, instead relying on 
Monte Carlo sampling techniques – first, to construct the empirical distribution of 
wavelet coefficients and second, to assign significance scores to predicted enriched 
regions using a randomized algorithm constrained by the peak length distribution. In 
addition, the association of statistical significance of a peak with its read count 
provides a natural and interpretable criterion for thresholding genome-wide analyses 
where the number of reads mapping to a region is often indicative of the presence of a 
true biological signal. 
Two-sample experiment 
If a ChIP-Seq experiment has matched controls, WaveSeq uses the binomial 
distribution to compare read counts between normalized test and control samples. For 
each putative peak, reads in the corresponding region of the control data (C) are 
counted and compared to the test sample (T) using a two-sided exact binomial test. A 
putative peak can be considered to be a Bernoulli experiment with t = (C + T) trials 
wherein the number of reads in the test sample T is the number of successes. The 




probability of observing at least T successes in t trials under the null hypothesis, H0: p 
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The p-values for the list of putative peaks are subsequently corrected for multiple 
testing as above [172]. 
Choice of parameters 
Systematic tuning of the WaveSeq peak-calling algorithm was carried out. We 
applied several different wavelet mother functions to ChIP-Seq data e.g. Morlet, 
Coiflets 1 and 2 and Mexican hat, to find the wavelets most suited to the data sets. All 
wavelets performed comparably when applied to punctate ChIP-Seq data sets but the 
morlet wavelet outperformed the others in detecting enrichment regions upto ~10kb 
while the Mexican hat wavelet was the most effective in calling very broad peaks 
(e.g. H3K27me3). A comparison of the energies at the various scales of the wavelet 
transform showed a higher density in a smaller band for the morlet wavelet and a 
more uniform distribution for the Mexican hat wavelet (Figure 2.3). The energy 
compression characteristic of the morlet wavelet represents a higher discriminative 
power over a smaller subset of scales and explains its performance for relatively 
strong enrichment patterns. The diffuse distribution of Mexican hat, however, is a 
better fit for the dispersed H3K27me3 marks as evidenced by its greater sensitivity 
for this dataset. Therefore, we used the morlet wavelet for GABP, NRSF, H3K4me3 





Figure 2.3. Comparison of wavelet energies for different wavelets.  
A comparison of wavelet energies shows a higher density in a smaller band of scales 
for the Morlet wavelet as shown by the arrow-head. Other wavelets have more 
broadly distributed energy densities. Bursa H3K4me3 data from chromosome 2 of the 
S.inf group was used to obtain the above. 
We assessed the effect of the number of samples (N) in the Monte Carlo threshold 
estimation step. The wavelet coefficient thresholds quickly reached saturation for all 
scales (Figure 2.4). Therefore, we chose N = 5000 for optimal accuracy and speed. 
The sampling was performed chromosome-by-chromosome. There was marked 
variation in wavelet coefficient thresholds for different chromosomes at a specified p-
value (Figure 2.5). There are two possible reasons for this: the number of enrichments 
on a specific chromosome and the chromosome size. The first arises out of the natural 
variation of different data sets and the latter out of the particular choice of the length 
and number of samples. In either case, this variation represents important information 
about the data and we account for it in our algorithm as follows: The mean and 
standard deviation of wavelet coefficient thresholds for each scale across the 





























the data were considered significant at the specified p-value if it was greater than the 
mean + standard deviation. The p-value for a significant wavelet power at a window 
was chosen to be pthres = 0.2 for punctate data sets (transcription factors and 
H3K4me3) and pthres = 0.4 for broad marks (H3K36me3 and H3K27me3).  
 
Figure 2.4. Wavelet coefficient thresholds reach saturation quickly. Morlet 
wavelet thresholds at p < 0.001 of H3K4me3 data from chromosome 1 in the chicken 














































Figure 2.5. Comparison of wavelet coefficient thresholds for different 
chromosomes (p = 0.2). A variation is observed in the wavelet coefficient thresholds 
for different chromosomes of the chicken genome. Various factors may be 
responsible for this observation ranging from different chromosome lengths, the 
number of enrichment regions and the choices of size and number of samples. Bursa 
H3K4me3 data from the S.inf group was used for the above plot. 
 
Wavelet coefficient thresholds were larger for greater sample sizes but the effect was 
more pronounced for smaller chromosomes (Figure 2.6). This was possibly due to 
oversampling effects as the increase in wavelet coefficients was inversely correlated 
with chromosome size. We found a strong negative power law correlation between 














0.1198). Greater sample lengths, therefore, are biased by chromosome size that could 
lead to large variations in coefficient thresholds. A smaller sample, on the other hand, 
could lead to lower thresholds and possibly more false positives. These two effects 
appeared to be reduced at a sample size of 2
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experiments. To further minimize the effect of chromosome size, we only considered 
chromosomes that have at least twice the length of the sample. 
 
Figure 2.6. Effect of sample length on wavelet coefficient thresholds (p = 0.2).  
At higher sample sizes, wavelet coefficient thresholds are larger but the effect is only 
noticeable for the smaller chromosomes (13-20) of the chicken genome and is 










 and 7 scales (4-10) for sample length 2
10
. The data corresponds to 
bursa H3K4me3 from the S.inf group. 
 
The minimum scale considered for peak calling was s = 4, since lower scales are 
representative of broader patterns that are more likely to be background noise. We 
also noticed that a significant ChIP-Seq peak was significant at several scales 
simultaneously (See Figures 2.1 B, C) while localized peaks had fewer significant 
scales. Therefore, to further eliminate spurious peak calls due to local fluctuations, a 
window was considered significant only if there were at least 2 significant scales for 
the window. For estimating FDR in one-sample analyses, we used number of 









































Figure 2.7. Correlation of chromosome size and wavelet coefficient thresholds. 
Large sample lengths have a strong negative correlation with chromosome size which 
follows a power law distribution. This correlation is absent for smaller samples. The 
dotted lines represent power law regression lines for different sample lengths. The 
data corresponds to bursa H3K4me3 from the S.inf group. 
 
Figure 2.8. The effect of increasing gap sizes on read coverage of top peaks.  
The fraction of reads covered by the top N peaks saturates at larger gap sizes. This 
saturation is almost immediate for H3K4me3, intermediate for H3K36me3 and more 
gradual for H3K27me3. In the case of H3K4me3, N = 20000, while for H3K36me3 







































The choice of a suitable gap size is dependent upon multiple factors including histone 
mark characteristics and sequencing depth. The read coverage fractions for different 
histone marks appear to saturate with increasing gap sizes (Figure 2.8). However, the 
saturation rate is highly variable between marks - H3K4me3 shows little change with 
increasing gap sizes, H3K27me3 exhibits a gradual increase while the pattern for 
H3K36me3 is intermediate between the two, in keeping with the intermediate 
characteristics of the mark. The above comparison shows that a gap size of 0 to 400 
bp (0-2 200 bp windows) would be suitable for the H3K4me3 data set while larger 
gap sizes may be more appropriate for the broader histone marks e.g. g = 5 for 
H3K36me3 and g = 10 for H3K27me3. A similar comparison of read coverage 
saturation rates can, therefore, help the user choose a gap size appropriate for a 
particular data set. 
Comparison with other methods using published data 
Recent studies have compared the performance of several published ChIP-Seq peak 
calling algorithms [104, 105]. From the list of methods tested in the above studies, we 
chose five commonly used tools: FindPeaks, MACS and SiSSRs [64], which were 
developed primarily for detecting transcription factor binding sites (TF-methods) 
along with SICER and RSEG [100] which were specifically aimed at chromatin 
enrichment data (CH-methods). A variety of ChIP-Seq data sets were selected to 
compare the performance of WaveSeq with the above methods including GABP, 






Figure 2.9. WaveSeq has high sensitivity and precision for punctate data sets. 
(a & b) Plots of peak ranks against the fraction of validated sites detected by 
WaveSeq, FindPeaks, MACS and SiSSRs for the (a) GABP and (b) NRSF data sets. 
(c) A plot of the fraction of true positives (precision) against the fraction of recovered 
peaks (recall) for the synthetic spike-in data set. (d & e) Sensitivity plots for the (d) 
GABP and (e) NRSF data sets shows that WaveSeq has high sensitivity for these data 
sets even in the absence of control.  
 
WaveSeq has high sensitivity 
Several GABP and NRSF binding sites have been validated with qPCR [105] 
allowing us to compare the sensitivities of the TF-methods with that of WaveSeq 
using the corresponding ChIP-Seq data. The peaks called by each TF-method were 
ranked by significance scores output by the method and tested for overlap with the 
validated sites. Subsequently, we plotted the peak rank against the fraction of 
validated sites detected by each algorithm (Figures 2.9 A, B). 
WaveSeq had the highest sensitivity among tested methods for both data sets. In the 




had slightly lower recall. SiSSRs came in third but still significantly outperformed 
FindPeaks which had low sensitivity for this data set. On the other hand, all the 
methods had similar performance on the NRSF data. WaveSeq showed marginally 
higher sensitivity with MACS, FindPeaks and SiSSRs performing comparably. A 
further comparison of peak lengths showed that MACS, FindPeaks and WaveSeq had 
similar peak length distributions while a majority of SiSSRs peaks were very small 
(Figure 2.10).  
 
Figure 2.10. WaveSeq has comparable peak lengths to MACS and FindPeaks in 
punctate data sets.  
A comparison of peak length densities of the top 20000 peaks for the (a) GABP and 
(b) NRSF data sets for WaveSeq, MACS, FindPeaks and SiSSRs. 
WaveSeq has good precision 
It is difficult to evaluate the specificity of ChIP-Seq peak-calling algorithms due to 
the unavailability of adequate ‘true-negative’ binding sites for systematic analysis. 
However, one can estimate the false positive rates using synthetic data sets which 
contain simulated binding events. For this analysis we utilized a published synthetic 




reads at fixed locations [107]. We applied WaveSeq and the TF-methods to this data 
set and plotted the proportion of recovered peaks (recall) against the fraction of true 
positives (precision) (Figure 2.9 C). 
MACS had the best combination of precision (0.724) and recall (0.799), closely 
followed by WaveSeq which had slightly better precision (0.728) but lower recall 
(0.716). However, FindPeaks had a very high number of false positives (precision = 
0.06) in this test while SiSSRs failed to detect any peaks.  
WaveSeq performs well even without a control data set 
The data from a matched input control sample is considered to improve the power of 
a ChIP-Seq experiment by reducing systematic biases [77]. However, matching input 
controls are often not available and negative controls such as IgG that bind in a non-
specific manner, can give rise to additional sources of error. Moreover, it is not clear 
if the use of input alone can offset the effect of various confounding factors such as 
mappability and G/C content. Therefore, it is important to assess the performance of 
ChIP-Seq peak callers in the absence of a matched control. 
We compared the sensitivity of TF-methods and WaveSeq using the GABP and 
NRSF data sets as above, but without the use of control data (Figures 2.9 D, E). 
WaveSeq again had high sensitivity for both data sets, almost identical to FindPeaks 
which performed much better on these data sets without control. SiSSRs and MACS 
had mixed results; the former had similar performance to FindPeaks and WaveSeq for 




reversed for MACS. Thus, WaveSeq has high accuracy for punctate peaks and was 
the only method that performed consistently well for the tested data sets. 
WaveSeq improves detection of broad histone modification peaks 
A lack of adequate validated sites for histone modification data makes it difficult to 
assess the performance of analysis methods on these data sets. However, we can 
argue that if multiple methods of analysis based on different detection algorithms 
predicted significant enrichment in a particular region, it was more likely that a true 
region of enrichment existed in that region. Indeed, studies have shown that a smaller 
number of peaks generated by certain methods were largely contained within larger 
peak lists called by other methods, indicating a common set of peaks detected by 
most algorithms [105]. With the above intuition we ran the CH-methods on the MEF 
histone modification data sets. We included MACS in the latter as it has been used for 
broad peak calling [166], even though it was originally developed for the analysis of 
transcription factor ChIP-Seq data. The top peaks (15000 for H3K4me3 and 20000 
for H3K36me3 and H3K27me3) called by each of the above programs were 
compared and regions detected by at least two peak-callers were defined as putative 
‘true positives’. When calculating putative true positive peaks, we did not enforce any 
restrictions on the overlap, i.e. if there was even a single bp overlap between two peak 
calls, these regions were merged together (union) into a putative positive peak. This is 
because peak-calling algorithms will sometimes call only part of a putative histone 
modification enrichment as a peak, and merging adjacent peak-calls is likely to 





Figure 2.11. WaveSeq improves detection of histone modification peaks.  
(a, b & c) Plots of peak ranks against the fraction of putative ‘true positive’ sites 
detected by WaveSeq, SICER, RSEG and MACS for the (a) H3K4me3, (b) 
H3K36me3 and (c) H3K27me3 data sets. (d) A plot of the fraction of true positives 
(precision) from the top 10000 peaks detected by the above four methods in the MEF 
histone modification data sets.  
 
The above procedure yielded 8592, 7522 and 5463 peaks for the H3K4me3, 
H3K36me3 and H3K27me3 data sets, respectively. These peaks were compared with 
the peak lists from all methods (SICER, RSEG, MACS and WaveSeq) and relative 
performance was assessed by comparing the fraction of recovered peaks against peak 
ranks (Figures 2.310 A-C). For punctate H3K4me3 data, all methods apart from 
RSEG performed well, with near-identical recall rates. WaveSeq had the best 
sensitivity on the H3K36me3 and H3K27me3 data sets with SICER coming in 




detected the top peaks with good accuracy but was unable to detect any peaks in 
chromosomes 10-19. A fFurther, WaveSeq had the highest precision in all three data 
sets analysis of precision (Figure 2.310 D) showed that WaveSeq had the highest 
performance in all three data sets. 
Pair-wise comparisons between peaks detected by WaveSeq and those called by 
SICER and MACS showed a high degree of overlap (98-100%) across all the data 
sets. In the case of RSEG the overlap was lower (20-68%) but closer examination 
revealed that a majority of regions not called by WaveSeq, particularly in the 
H3K4me3 and H3K36me3 data sets, had low average read counts and were possibly 
false positives (Appendix II). WaveSeq also called larger peaks on average compared 
to SICER, particularly in the H3K27me3 and H3K4me3 data sets (Figure 2.2). 
However, RSEG detected very broad regions in both H3K27me3 and H3K4me3 data. 
Since this algorithm was developed with the express purpose of detecting dispersed 
chromatin domains, the above behavior is expected, although very long peaks in 
punctate ChIP-Seq data may not be desirable. Also, somewhat surprisingly, WaveSeq 
and SICER had greater average peak lengths compared to RSEG for the H3K36me3 
data. MACS, on the other hand, detected very small peaks in all the data sets, proving 
its general unsuitability for broad histone marks. 
Thus, WaveSeq once again showed the highest sensitivity of all tested methods across 
a variety of histone modification data sets. While there was little to choose between 
the different algorithms for the punctate high SNR H3K4me3 data, WaveSeq 
outperformed the other tested methods in the analysis of broad enrichment regions 




second while MACS has low sensitivity for diffuse data. RSEG has good sensitivity 
for the strongest peaks but has low recall, failing to detect any peaks in chromosomes 
10-19. 
Analysis of complex histone modification data 
The bursa of Fabricius is a specialized immune organ that is the site of 
haematopoiesis and B cell development in chickens. This tissue is one of the first 
targets of Marek’s disease virus (MDV), a herpesvirus that induces T-cell lymphomas 
in susceptible birds. Genetically similar lines of chickens that show differential 
resistance to Marek’s disease (MD) have been developed and studied for decades, but 
the exact causes of the divergent response have not been found, although it is 
believed that epigenetic factors play an important role in determining the level of 
resistance of an individual. This is an interesting epigenetic model for human cancers 
as individuals having high genetic similarity exhibit natural resistance to a cancer-
causing agent. Moreover, this is a complex ChIP-Seq experiment representing studies 
in non-traditional systems that are becoming more prevalent with the plummeting 
costs of sequencing. To demonstrate the utility of WaveSeq in such an experimental 
scenario we used it to analyze H3K4me3 profiles in matched infected and control 
birds from inbred chicken lines having diverse responses to MD. 
WaveSeq detects differential H3K4me3 marks induced by virus infection 
We generated H3K4me3 ChIP-Seq data from inbred chicken lines – line 63 is highly 
resistant while line 72 is highly susceptible to MD – in matched infected and control 




line 72 as R and S groups, respectively. We first analyzed the infected group with the 
non-infected group as control. The samples were then swapped to account for 
significant peaks in the control that were absent in the infected group. This is in 
contrast to traditional ChIP-Seq experiments where peaks detected in an input control 
represent false positives and are removed from subsequent analyses. Statistical 
significance for differentially marked regions (DMRs) was defined at a false 
discovery rate of 5% (FDR < 0.05). DMRs were compared across the control-
swapped comparisons and merged into a single non-redundant list. 
WaveSeq detected a comparable number of peaks in the two groups, with 25050 and 
27169 peaks in the R and S groups, respectively. The resistant line did not show any 
differential H3K4me3 marks at the predefined significance level. In contrast, there 
were 310 H3K4me3 DMRs in the susceptible line, all but five of which were more 
enriched in infected individuals. This confirmed the presence of dramatic differences 
in the epigenetic effects of MDV on the two lines, with a predominantly activating 
effect of the virus infection. 
Table 2.1. Functional annotation of genes having H3K4me3 DMRs 
Gene Ontology Term Count p-value FDR (%) 










GO:0048534: Hemopoietic or lymphoid organ 
development 





GO:0045580: Regulation of T cell differentiation 7 8.60 x 10
-7 
0.001359 
GO:0002521: Leukocyte differentiation 10 1.11 x 10
-6
 0.001747 
GO:0045582: Positive regulation of T cell differentiation 6 1.23 x 10
-6
 0.001951 
GO:0045321: Leukocyte activation 11 1.70 x 10
-6
 0.002693 
GO:0045619: Regulation of lymphocyte differentiation 7 2.39 x 10
-6
 0.003781 
GO:0002684: Positive regulation of immune system 
process 
10 2.73 x 10
-6
 0.004309 
GO:0045621: Positive regulation of lymphocyte 
differentiation 






GO:0046649: Lymphocyte activation 10 4.70 x 10
-6
 0.007428 
GO:0050870: Positive regulation of T cell activation 8 5.53 x 10
-6
 0.008734 
GO:0001775: Cell activation 11 6.17 x 10
-6
 0.009752 
GO:0051251: Positive regulation of lymphocyte activation 8 8.08 x 10
-6
 0.012774 
GO:0002696: Positive regulation of leukocyte activation 8 1.16 x 10
-5
 0.018257 
GO:0050867: Positive regulation of cell activation 8 1.62 x 10
-5
 0.025558 
GO:0050863: Regulation of T cell activation 8 1.62 x 10
-5
 0.025558 
GO:0030098: Lymphocyte differentiation 8 1.90 x 10
-5
 0.030027 
GO:0051249: Regulation of lymphocyte activation 8 2.59 x 10
-5
 0.040908 
GO:0030217: T cell differentiation 7 2.76 x 10
-5
 0.04356 
GO:0002694: Regulation of leukocyte activation 8 4.00 x 10
-5
 0.063158 
GO:0045058: T cell selection 5 6.65 x 10
-5
 0.105094 
GO:0050865: Regulation of cell activation 8 6.80 x 10
-5
 0.107401 
GO:0002252: Immune effector process 6 1.38 x 10
-4
 0.218176 
GO:0033077: T cell differentiation in the thymus 5 2.30 x 10
-4
 0.362727 
GO:0042110: T cell activation 7 2.43 x 10
-4
 0.38295 
GO:0042981: Regulation of apoptosis 14 2.47 x 10
-4
 0.389793 
GO:0043067: Regulation of programmed cell death 14 2.98 x 10
-4
 0.469488 
GO:0010941: Regulation of cell death 14 3.12 x 10
-4
 0.491456 
GO:0033554: Cellular response to stress 12 4.00 x 10
-4
 0.629557 
GO:0045061: Thymic T cell selection 4 4.06 x 10
-4
 0.639966 
The top functional categories (FDR < 1%) enriched among genes having H3K4me3 
DMRs from DAVID shows a large number of immune-related functions. Count refers 
to the number of genes in the gene list annotated with the given GO ID. P-values 
were obtained from a modified Fisher exact test performed by DAVID which tests the 
enrichment of the corresponding functional category in the given gene list against the 
population (chicken genome). FDR correction was performed using the Benjamini-





Figure 2.12. Differentially marked regions detected by WaveSeq suggest 
increased B cell activation in susceptible chickens. 
Several genes involved in the B cell activation such as LYN (a), SYK (b), RAC2 (c), 
PTPRC (d), BLNK (e) and GRB2 (f) show increased levels of H3K4me3 in infected 
birds from the S group as shown by the arrowheads. In contrast, there are no 
significant changes in the R group. *** p < 0.001; **  p < 0.01; *  p < 0.05. S.inf = 
infected S group, S.ctl = control S group, R.inf = infected R group, R.ctl = control R 
group. 
 
Increased B cell activation in susceptible birds as a result of MD 
To investigate the functional implications of observed epigenetic differences, we 
searched for overlaps between H3K4me3 DMRs and gene promoters and were able to 
map 241 regions to 310 Ensembl genes (Appendix III). Functional annotation of these 
genes with DAVID [170] revealed significant enrichment of various immune-related 
functions, such as, hemopoeisis, positive regulation of lymphocyte activation, 




there appeared to be a significant activation of the immune system in infected birds of 
the S group, consistent with the observed response at the early cytolytic stage of the 
disease in susceptible birds.  
Several genes having H3K4me3 DMRs were involved in the PANTHER [173] B-cell 
signalling pathway (p = 1.3 x 10
-3
) such as LYN, SYK, GRB2, PTPRC, RAC2 and 
BLNK, indicative of increased B cell activation in the infected S group. The signalling 
molecules CD45, Lyn and Syk, gene products of PTPRC, LYN and SYK, respectively, 
are major players in the early stages of B cell antigen receptor signalling. These genes 
work together with BLNK and GRB2 to activate B cells via the NF-κB mediated 
pathway while BLNK and RAC2 may also activate B cells via the ERK, p38 or jun 
signalling cascades. H3K4me3 levels on all these genes were unchanged in the R 
group but were significantly higher in the infected S group after MDV infection 
(Figure 2.12). Three of these genes – LYN, SYK and RAC2 – had reported expression 
in bursal cells [174] which suggests that the tissue-specific activation of these genes 
in the bursa might lead to increased B cell activation in susceptible birds. 
MDV primarily targets B cells during early stages of the disease as these cells provide 
the first line of defence via the host humoral immune response. B cells surround the 
invading virus particles and have increased rates of infection and atrophy. The 
infection of B cells, in turn, induces the activation of CD4+ T cells which 
consequently become more vulnerable to virus infection [130]. The increase in B cell 
activation indicated by elevated levels of H3K4me3 on key genes involved in the 
pathway suggests the presence of an increased number of activated B cells in 




lymphocytes. The larger population of cells vulnerable to infection by MDV at the 
early cytolytic stage of the disease in susceptible birds, could, therefore, result in 
increased levels of infection and higher mortality in the latter stages of the disease. 
Discussion  
The analysis of ChIP-Seq data poses several challenges including a diverse array of 
enrichment patterns, the lack of true biological controls and confounding factors such 
as sequencing depth, mappability and G/C content. In the presence of these sources of 
bias, it is important to have methods of analysis robust to various data characteristics 
that also preserve prediction accuracy. In response to these issues, we have developed 
a novel data-driven ChIP-Seq analysis algorithm named WaveSeq which is capable of 
detecting both punctate and diffuse enrichment regions and is free of distributional 
assumptions. WaveSeq utilizes non-parametric modeling of ChIP-Seq data using 
Monte Carlo sampling and a randomized algorithm to accurately estimate the 
empirical distribution of reads in the absence of a control. 
With the aid of a variety of public data sets we were able to demonstrate that 
WaveSeq has high accuracy and performs favourably in comparison with several 
published methods of analysis in detecting punctate and diffuse enrichment regions 
(Figure 2.13). WaveSeq also performed with comparable accuracy in the absence of 
control data. Previous studies have observed that the background signal of ChIP-Seq 
data is non-random [77] and the ability to distinguish regions of true signal from 
background could be potentially improved if this non-randomness is accounted for. 




data set suggests that the non-parametric modeling approach is successful in 
capturing the data characteristics leading to higher prediction accuracy. 
 
Figure 2.13 WaveSeq detects a broad variety of enrichment regions with high 
accuracy. Examples of WaveSeq peak calls on MEF histone modification data. (a) 
WaveSeq detects H3K4me3 and H3K36me3 marks on the housekeeping gene Polm 
located on chromosome 11 and (b) a broad peak of H3K27me3 on the developmental 
transcription factor Cdx4 which is silenced in differentiated cell populations. 
The rapid advance of epigenetics and the advent of cost-effective next-generation 
sequencing technologies have led to complex experimental designs being employed 
to investigate various topics such as the epigenetics of disease response. WaveSeq is 
capable of being used in such an experimental setting and helps make relevant 
biological discoveries. We illustrate this by using our algorithm to analyze a complex 
H3K4me3 data set to investigate the differences in the epigenetic effects of MDV 
infection in inbred chicken lines having divergent responses to MD. WaveSeq detects 




pathway suggesting the presence of increased numbers of activated B cells in infected 
individuals of the susceptible line. B cells are the primary targets of MDV at the early 
cytolytic stage of the disease and infection of these cells by the virus leads to 
activation of CD4+ T cells which are more vulnerable to infection than naive T cells. 
Consequently, an increase in the number of MDV-infected cells at this stage of the 
disease could translate to an increased viral load and a worse prognosis in susceptible 
birds at the latter stages of infection. Thus, epigenetic differences between the two 
lines could have a major impact on disease progression indicating that epigenetic 
marks play an important role in regulating disease response. 
The absence of distributional assumptions in WaveSeq makes it potentially applicable 
to other forms of next-generation sequencing data. The detection of the genomic 
locations of nucleosomes is one such area of current interest. A nucleosome 
positioning experiment typically consists of the sequencing of DNA fragments 
associated with mono-nucleosomes across the whole genome. The data consists of 
broad diffuse regions with peaks that repeat approximately every 147 bp, the length 
of DNA associated with single nucleosomes. Regions of active transcription have 
lower nucleosome enrichment while high nucleosome density is associated with silent 
heterochromatin. Thus, differences in nucleosome density between samples could be 
predictive of transcriptional differences. Sequencing data having such underlying 
patterns could be highly suited to the wavelet transform framework employed by 
WaveSeq. 
One of the primary drawbacks of WaveSeq is the relatively high number of peak calls 




sensitivity of the algorithm. However, since peak calls are ranked by FDR, a more 
stringent criterion can be used to circumvent this issue. Moreover, increased 
sequencing depth significantly improves discriminative power and is highly 
recommended particularly for data having diffuse enrichments. 
Conclusions  
ChIP-Seq experiments having a wide variety of enrichment patterns and a lack of true 
biological controls pose significant challenges for analysis and interpretation. 
WaveSeq is a highly sensitive, data-driven method capable of detecting significantly 
enriched regions in data having diverse characteristics. WaveSeq can detect both 
punctate and diffuse regions with a high degree of accuracy even in low SNR data 
sets. Moreover, it performs with comparable accuracy in the absence of control data. 
WaveSeq is suited for application in complex experimental scenarios, helping make 
biologically relevant functional discoveries and compares favourably with existing 




3. Marek’s Disease Virus Infection Induces Widespread 
Differential Chromatin Marks in Inbred Chicken Lines 
Abstract 
Marek’s disease (MD) is a neoplastic disease in chickens caused by the MD virus 
(MDV). Successful vaccine development against MD has resulted in increased 
virulence of MDV and the understanding of genetic resistance to the disease is, 
therefore, crucial to long-term control strategies. Also, epigenetic factors are believed 
to be one of the major determinants of disease response.  
Here, we carried out comprehensive analyses of the epigenetic landscape induced by 
MDV, utilizing genome-wide histone H3 lysine 4 and lysine 27 trimethylation maps 
from chicken lines with varying resistance to MD. Differential chromatin marks were 
observed on genes previously implicated in the disease such as MX1 and CTLA-4 and 
also on genes reported in other cancers including IGF2BP1 and GAL. We detected 
bivalent domains on immune-related transcriptional regulators BCL6, CITED2 and 
EGR1, which underwent dynamic changes in both lines as a result of MDV infection. 
In addition, putative roles for GAL in the mechanism of MD progression were 
revealed.  
Our results confirm the presence of widespread epigenetic differences induced by 
MD in chicken lines with different levels of genetic resistance. A majority of 
observed epigenetic changes were indicative of increased levels of viral infection in 




caused by early cytolytic infection. The GAL system that has known anti-proliferative 
effects in other cancers is also revealed to be potentially involved in MD progression. 
Our study provides further insight into the mechanisms of MD progression while 
revealing a complex landscape of epigenetic regulatory mechanisms that varies 
depending on host factors. 
Introduction 
Rapid advances in epigenetics have led to the discovery of complex mechanisms of 
gene regulation involving phenomena such as DNA methylation and chromatin 
modifications. Methylation of particular histone residues has been found to correlate 
with specific and often opposing cellular functions, e.g. trimethylation of histone H3 
lysine 4 (H3K4me3) is associated with transcriptional start sites (TSSs) of active 
genes while trimethylation of histone H3 lysine 27 (H3K27me3) is found to mark 
broad genomic regions for repression. Recent studies have also suggested that 
characteristic combinations of histone modifications or ‘chromatin states’ define 
functional elements of the genome and determine their contribution to transcriptional 
regulation [175-177]. Moreover, the epigenetic state of host genes can be affected by 
viral infection leading to tumors in humans [178-180]. Thus, epigenetics constitute a 
dynamic regulatory framework linking genotypes with environmental factors that 
could play a major role in differential disease responses among individuals having 
high genetic similarity. 
Marek’s disease (MD) is a highly contagious disease caused by an oncogenic α-
herpesvirus MD virus (MDV) and characterized by T-cell lymphomas in chickens 




averted due to the success of various vaccination strategies which, remarkably, is also 
the first instance of the successful control of a natural cancer-causing agent using 
vaccines [121, 181, 182]. However, the virulence of the virus may have progressively 
increased as a consequence of vaccine development [183-185]. Several reported 
instances of vaccine breaks or reduced efficacy of vaccination, therefore, underlines 
the importance of investigating resistance to the disease as a long-term strategy to 
control MDV.  
Natural resistance to MDV can be divided into two categories: major 
histocompatibility complex (MHC)-associated resistance, wherein different MHC 
haplotypes at the B blood group locus confer varying levels of resistance and non-
MHC associated resistance in which birds having the same MHC haplotype exhibit 
vastly different responses to MDV infection. Inbred lines 63 and 72 developed at the 
Avian Disease and Oncology Laboratory (ADOL, East Lansing, MI) that we used in 
this study, fall into the latter category. These lines share a high degree of genetic 
similarity but have divergent responses to MDV infection completely independent of 
the MHC. Several studies have attempted to pinpoint factors responsible for 
conferring resistance [186-188], but confounding factors, such as, tissue types, virus 
strains and ages of birds have made it difficult to find a consensus. Multiple risk 
elements are possibly at play in this complex disease, and increased resistance or 
susceptibility is likely to be produced by a combination of such factors. In this study, 
we take a closer look at epigenetic factors behind different responses to MD with a 




We utilized the above population of inbred chickens – line 63 is highly resistant to 
MD, while line 72 is highly susceptible – and compared the epigenetic effects of MD. 
Genome-wide maps of H3K4me3 and H3K27me3 in thymus tissues of birds from 
these chicken lines at the latent stage of MDV infection were generated. We carried 
out systematic analyses to find differential chromatin marks induced by MDV 
infection. We also investigated co-localization patterns of the two chromatin 
modifications to detect putative bivalent domains and the effect of MDV on such 
domains. The results of our study confirm that Marek’s disease has far-reaching 
effects on the epigenetic landscape of chicken lines with diverse responses to the 
virus and, thus, furthers our understanding of this complex disease. 
Methods 
Animals and Viruses 
Two specific-pathogen-free inbred lines of White Leghorn either resistant (63) or 
susceptible (72) to MD were hatched, reared and maintained in Avian Disease and 
Oncology Laboratory (ADOL, Michigan, USDA). Four chickens from each line were 
injected intra-abdominally with a partially attenuated very virulent plus strain of 
MDV (648A passage 40) at 5 days after hatch with a viral dosage of 500 plaque-
forming units (PFU). Infected and control chickens from both lines (n = 4) were 
terminated at 10dpi to collect thymus tissues. All procedures followed the standard 




Quantification of MDV loads in Thymus 
The MDV gene ICP4 was used for quantification of viral genomic DNA in thymus as 
previously described [189]. Quantitative PCR was performed by using 100 ng/μl of 
genomic DNA on the iCycler iQ PCR system (Bio-Rad, USA) and QuantiTect SYBR 
Green PCR Kit (Qiagen, USA) (Figure 3.1). The relative MDV loads were 
determined by normalizing to a single-copy gene Vim (vimentin) [190]. The primers 
for Vim are as follows: Forward: 5’-CAGCCACAGAGTAGGGTAGTC-3’; Reverse: 
5’-GAATAGGGAAGAACAGGAAAT-3’. 
 
Figure 3.1. Quantification of viral loads in the MDV-challenge experiment using 
quantitative RT-PCR. The relative virus load is calculated by quantifying viral ICP4 
normalized to the single-copy Vim gene (mean ± SEM, n = 4). (a) Only infected birds 
from the two lines exhibit measurable virus loads, with (b) the susceptible line 72 
having a significantly higher number of virus particles (p < 0.001). 
Chromatin Immunoprecipitation and Illumina Sequencing 
Chromatin immunoprecipitation (ChIP) was carried out using thymus samples from 
MDV infected and controls birds [191]. About 30 mg thymus samples from three 
individuals were cut into small pieces (1 mm
3
) and digested with MNase to obtain 
mononucleosomes. PNK and Klenow enzymes (NBE, Ipswich, MA, USA) were used 
to repair the ChIP DNA ends pulled down by the specific antibody. A 3′ adenine was 






ligated to the repaired ends. Seventeen cycles of PCR was performed on ChIP DNA 
using the adaptor primers and fragments with a length of about 190 bp 
(mononucleosome + adaptors) were isolated from agarose gel. Subsequently, cluster 
generation and ChIP-sequencing (ChIP-Seq) using the purified DNA was performed 
on the Solexa 1G Genome Analyzer (Illumina, USA) following manufacturer 
protocols. The antibodies used and the total number of reads obtained for each sample 
is listed in Appendix IV. 
Read Mapping and Summary Counts 
Sequence reads obtained from the Illumina 1G Genome Analyzer were aligned to the 
May 2006 version of the chicken genome (galGal3) using Maq version 0.7.1 [78]. 
Default alignment policies of Maq were enforced: a valid alignment could have a 
maximum of two mismatches and if a read aligned equally well to multiple places in 
the genome, one was chosen at random. If multiple reads mapped to the same 
genomic location only one was kept to avoid amplification bias. Summary read 
counts were calculated using non-overlapping windows of 200 bp for visualization 
and normalized to per million mapped reads in each sample for the purpose of 
comparisons. 
Identification of Significantly Enriched Regions (SERs) 
Summarized read counts were subjected to peak calling with SICER [101]. The 
source code was modified to include support for the chicken genome. Fragment 
length was specified to be 190. A window size of 200 bp and gap size of 400 bp was 




the purposes of comparing different samples, SERs found in similar genomic regions 
of different samples were merged to obtain a consolidated list as follows: SERs from 
one sample were used to initialize the list. For each such region M, we searched for 
overlapping SERs in the next sample. In the case of an overlap between M and a 
significant region, S, the merged region was updated to include both M and S. This 
procedure was iterated over all samples to obtain a consolidated list of merged SERs. 
Gene Annotation and Genomic Distribution of SERs 
RefSeq and Ensembl gene annotations were downloaded from UCSC genome 
browser [167]. As there were only 4306 RefSeq genes in the database, we included 
Ensembl genes in our analysis to improve genome-wide coverage. There were 17858 
annotated genes in the Ensembl database, which include validated and predicted 
genes. Redundancies between the databases were listed and accounted for, yielding a 
non-redundant list of 18198 genes with 4306 RefSeq genes and 13892 Ensembl 
genes. We then searched for overlaps between merged SERs and the non-redundant 
list of annotated genes. For H3K4me3, an SER was annotated with a gene if it 
overlapped the TSS region of the gene whereas in the case of H3K27me3, a valid 
overlap constituted an SER overlapping the gene body. To calculate the genomic 
distribution we counted all SERs having an overlap with one of the following regions: 
promoter (TSS ± 1 kb), exons, introns, 5’ UTR and 3’ UTR. 
Histone Modification Profiles and Differential Chromatin Marks 
Genes were divided into 10 sets based on their absolute expression and representative 




visualization. We defined the gene body as the region between the transcription start 
site (TSS) and the transcription termination site (TTS). Histone modification profiles 
surrounding the gene body were calculated in 3 distinct regions: 5000 bp upstream of 
the 5’ end, gene body and 5000 bp downstream of the 3’ end of the gene. For reads 
falling within the gene body, read counts were obtained in bins 5% of the gene length 
while 1000 bp windows were used for the 5’ and 3’ flanking regions. The read counts 
in all cases were normalized to the total number of genes in the categories and total 
number of reads in the sample. We also compared gene expression to histone 
modification levels by plotting normalized microarray data (Zhang, H. unpublished 
data) against reads mapping to (i) TSS ± 500 bp and (ii) the gene body for each gene. 
Reads mapping to merged SERs were tested for epigenetic changes induced by MDV 
infection in lines 63 and 72 using DESeq [119]. We used the method ‘blind’ for 
variance estimation and p-values were corrected for multiple testing using the 
Benjamini-Hochberg FDR procedure [172]. Statistical significance was defined using 
a false discovery rate (FDR) threshold of 0.4. 
Validation of ChIP, ChIP-Seq and Gene Transcription by Q-PCR 
Quantitative real-time RT-PCR was used to validate the quality of the ChIP and gene 
transcript levels on the iCycler iQ PCR system (Bio-Rad, Hercules, CA, USA). The 
real-time RT-PCR reactions were performed with a QuantiTect SYBR Green PCR 
Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. An 




primers and four biological and four technical replicates were performed. The primer 
sequences are shown in Appendix V. 
Data Access 
Raw and processed ChIP-Seq data discussed in this manuscript were deposited in the 
NCBI Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under 
Series accession number GSE33541. 
Results 
Genome-wide Distribution of H3K4me3 and H3K27me3 
We performed ChIP-Seq experiments on infected and uninfected birds from lines 63 
and 72 to investigate the epigenetic effects of MDV infection. More than 76 million 
reads from eight samples were mapped to the chicken genome yielding 14418 and 
24950 significantly enriched regions (SERs) for H3K4me3 and H3K27me3, 
respectively (Table 3.1). We further classified these regions as follows: Ubiquitous 
SERs were found in all samples and were likely due to similarities in the genetic 
background of the chickens. Line-specific SERs were present in only one line either 
before or after MDV infection, while condition-specific SERs appeared in both lines 
but only in individuals with the same infection status. 
Ubiquitous SERs formed the largest percentage of all enriched regions, accounting 
for 74.2% and 23.3% in H3K4me3 and H3K27me3 samples, respectively. In the case 
of H3K4me3, there were large differences in the number of specific SERs - more than 




Similarly, we found 50% more line-specific SERs of H3K27me3 in line 63 (6568) 
compared to line 72 (4494). However, upon closer examination, most of the line-
specific and condition-specific SERs were revealed to have low read counts 
(Appendix V1) corresponding to regions of low enrichment. 
Table 3.1. Significantly enriched regions (SERs) and associated genes in each sample. 
  H3K4me3  H3K27me3  
 Samples SERs (%) Genes SERs (%) Genes 
Line-Specific 63I 647 (4.5) 78 3477 (13.9) 615 
 63N 594 (4.1) 71 2514 (10.1) 896 
 63I,63N 924 (6.4) 190 577 (2.3) 150 
 72I 105 (0.7) 16 1658 (6.6) 451 
 72N 126 (0.9) 11 2506 (10) 346 
 72I,72N 73 (0.5) 17 330 (1.3) 89 
Condition-specific 63I,72I 97 (0.7) 35 2061 (8.3) 579 
 63N,72N 47 (0.3) 9 66 (0.3) 22 
Ubiquitous 63I,63N,72I,72N 10691 (74.2) 9475 5831 (23.4) 2942 
 Total 14418 10206 24950 7904 





Figure 3.2. Genomic distribution of SERs and relationship between histone 
marks and gene expression.  
(a) Distribution of SERs over different genomic elements. (b-e) Relationship between 
gene expression and histone marks in infected line 63 birds. Plots of histone 
modifications around the gene body (b, c) in genes having high (blue), medium (red), 
low (green) and no activity (brown). (d,e) A comparison of epigenetic marks and 
transcriptional levels. Similar trends were observed in other experimental groups 
(Appendices VIII-X). 
 
Genes were divided into five regions – promoter, 5’ untranslated region (UTR), 
exons, introns and 3’ UTR – and the distribution of SERs across these elements was 
probed (Figure 3.2 A). We found a large number of intergenic regions marked by 
H3K27me3, consistent with high levels of this mark associated with areas of silent 
heterochromatin. In the case of H3K4me3, a larger proportion of SERs were found 
around the promoter, exons and the 5’ UTR, while similar proportions of H3K4me3 
and H3K27me3 SERs were present in introns and 3’ UTRs. A comparison of the 




similar number of H3K4me3 SERs across the promoter, exons and the 5’ and 3’ 
UTRs of genes. Line 63 contained a higher number of intronic and intergenic SERs as 
compared to line 72 although this did not appear to change as a result of MDV 
infection. On the other hand, a greater number of H3K27me3 SERs were found in the 
infected samples although these levels were similar in the two different lines. 
 
Figure 3.3. Distribution of SERs over different genomic elements.  
(a) H3K4me3 and (b) H3K27me3 SERs separated by samples. 63_inf: line 63 
infected, 63_non: line 63 control, 72_inf: line 72 infected, 72_non: line 72 control. 
 
To analyze the relationship between histone modifications and gene expression, 
histone modification profiles surrounding the TSS and gene body were plotted for 
genes ranked by their expression level (Figures 3.2 B-E and appendices VII-X). As 
expected, a strong positive correlation was observed between gene expression and 
H3K4me3 marks with a distinct peak around the TSS and little to no enrichment 
within the gene body. On the other hand, H3K27me3 showed negative correlation 
with gene expression with a peak near the TSS followed by a broad plateau across the 
gene body. However, the latter relationship was non-linear – genes with lower 
expression had similar levels of H3K27me3 marks and levels were markedly distinct 




Table 3.2 Differential SERs identified in thymus 






63I vs 63N 9 4 42 1 
72I vs 72N 30 13 5 0 
63N vs 72N 148 46 1094 65 
Total 179 59† 1116 66 
*FDR < 0.4. † Some genes are shared between different comparisons. 63I: line 63 
infected, 63N: line 63 control, 72I: line 72 infected, 72N: line 72 control. 
Differential H3K4me3 Marks on Genes Related to MD 
We conducted a comprehensive analysis of genome-wide chromatin marks to find 
significant differences in MDV-induced responses in line 63 and 72. We used two sets 
of comparisons: First, to assess the influence of MDV infection within each line, we 
compared the infected and the non-infected samples from the same line. Secondly, the 
non-infected samples from the two lines were compared to detect line-specific effects. 
As a result of this analysis we found 179 differential H3K4me3 SERs and 1116 
differential H3K27me3 SERs that mapped to 59 and 66 genes, respectively (Table 
3.2). A majority of differential SERs were found in the comparison between non-
infected samples of the two lines (Appendix X, XI) with several observed on genes 
that have been associated with MDV infection. 
MX1 is a zinc-finger transcription factor that has antiviral properties against a large 
number of viruses. MX1 was upregulated after MDV infection [192] although its 
contribution to MD progression is unknown. MDV infection induced a highly 
significant increase in H3K4me3 enrichment in the promoter region of MX1 in both 
lines (line 63: p = 1.28x10
-7
, line 72: p = 4.26x10
-9
; Figure 3.4 A).  We observed a 




Figure 3.4 B); MX1 expression in line 63 showed a similar trend (fold change = 38.22, 
p=0.085) although mRNA levels were much lower. 
 
Figure 3.4. Genes related to MD show differential H3K4me3 marks.  
MX1 (a, b) and CTLA-4 (c, d) show increased H3K4me3 marks and higher expression 
in infected individuals from both lines; MMP2 (e, f) exhibits higher levels of 
H3K4me3 in susceptible line 72. n = 4; * = significant at p < 0.05; ** = significant at 
p < 0.01; *** = significant at p < 0.001. 
CTLA-4 is a cell surface glycoprotein expressed on CD4+ and CD8+ T lymphocytes 
that is a powerful negative regulator of T-cell activation [193]. The CTLA4 protein is 
expressed on T lymphocytes soon after activation and regulates T-cell proliferation, 
production of IL-2 and also supports the function of Treg cells that suppress immune 
response [194]. Previous studies have reported an increase in CTLA-4 expression after 
MDV infection [195]. We found an increase in H3K4me3 enrichment in line 72 as a 
result of MDV infection (p = 0.0003) and there was a similar trend in line 63 (Figure 
3.4 C). Consistent with the above, there was a significant increase in transcript levels 





MMP2 plays a key role in the degradation of the extra-cellular matrix, and an increase 
in expression has been associated with increasing tumor cell migration and tumor 
angiogenesis [196, 197]. MMP2 was upregulated during the neoplastic stage of MD 
infection in susceptible birds [198] but downregulated in response to MDV infection 
during early lytic infection in susceptible and resistant chickens [192]. We observed a 
slight increase in H3K4me3 enrichment after MDV infection in both lines, while line 
72 exhibited significantly lower levels than line 63 (p = 0.0016; Figure 3.4 E). This 
was coupled with increased MMP2 expression in line 63 after infection (p = 0.0068) 
while there was no such change in line 72 (Figure 3.4 F).  
Genes Related to Cancers Show Epigenetic Changes in Response to 
MD 
We observed differential histone marks on several genes that have been associated 
with other cancers but not in the context of MDV infection. Insulin-like growth factor 
2 binding protein 1 (IGF2BP1) is an RNA-binding factor that regulates the translation 
of mRNAs produced by certain genes like IGF2 and ACTB. Increased expression of 
IGF2BP1 has been implicated in the development and progression of cancers of 
various organs, e.g. lung, brain, breast and colon [199-202]. There was no change in 
the H3K4me3 enrichment levels induced by MDV infection although a significantly 
higher level of enrichment was present in line 72 (p = 4.21x10
-13
; Figure 3.5A). 
Transcript levels in line 72 were much higher than in line 63, but reduced in response 





Figure 3.5. MD induces epigenetic changes in genes related to various cancers. 
IGF2BP1 (a, b) shows differential H3K4me3 marks and increased expression in 
susceptible birds while EAF2 (c, d) and GAL (e, f) have differential H3K27me3 levels 
on the gene body. n = 4; * = significant at p < 0.05; ** = significant at p < 0.01; *** = 
significant at p < 0.001. 
 
ELL associated factor 2 (EAF2) is a testosterone regulated apoptosis inducer and 
tumor suppressor. Inactivation of EAF2 has been shown to lead to tumors in multiple 
organs [167]. There was a significant increase in H3K27me3 levels after MDV 
infection in line 63 (p = 0.0414) while among uninfected chickens these levels were 
markedly higher in line 72 (p = 0.0138; Figure 3.5 C). However, EAF2 expression was 
drastically reduced after MDV infection in line 72 (p=0.0016) but showed only a 





Figure 3.6. Significant H3K4me3 and H3K27me3 enrichment around GALR1 
and GALR2. 
(a) The anti-proliferative GAL receptor GALR1 exhibited both active and repressive 
marks. There is no change in H3K4me3 levels but a definite increase in H3K27me3 
levels after infection in line 72. (b) No significant histone marks observed on GALR2. 
 
Galanin (GAL) is a neuropeptide that modulates various physiological functions, such 
as, inhibition of insulin secretion and stimulation of growth hormone secretion. Three 
galanin receptors are known (GALR1, 2 and 3): the expression of GALR1 has anti-
proliferative effects while GALR2 can be both anti- or pro-proliferative in function. 
Therefore, the GAL system is considered to be a promising candidate for detection 
and treatment of various cancers [203, 204]. We observed an increase in H3K27me3 
levels on GAL after infection in both lines (Figure 3.5 E). Also, expression levels 
were significantly lowered after MDV infection in line 72 (p = 0.00087) while there 
was a similar trend in line 63 (p = 0.051; Figure 3.5 F). Interestingly, GALR1 had both 
H3K4me3 and H3K27me3 enrichments (Figure 3.6 A) although GALR2 showed no 




Chromatin Co-localization Patterns Reveal Putative Bivalent Genes 
Regions of chromatin having both active and repressive marks are said to be bivalent 
and have been shown to play important roles in development and genetic imprinting 
[20, 205]. For example, bivalent domains have been shown to mark promoters of 
genes that are subsequently silenced in tumors by DNA hypermethylation indicating 
their importance in cancer [206]. A mono-allelic bivalent chromatin domain that 
controls tissue-specific genomic imprinting at a specific locus was recently found in 
mice [205]. To investigate the presence of such bivalent chromatin states and the 
possible effect of MDV infection, we defined bivalent genes as those having 
H3K4me3 reads (TSS ± 500 bp) greater than 30 reads per million mapped reads 
(RPM) and H3K27me3 reads (gene body) greater than 2 RPM, respectively (~85
th
 
percentile). This filtering process yielded a list of 99 putative bivalent genes 
(Appendix XII). 
Functional annotation clustering of the above genes using DAVID [170, 207] 
revealed significant enrichment of several immune-related functions. These included 
transcription factor EGR1 which is reported to have tumor suppressor properties, 
genes involved in lymphocyte activation and differentiation such as BCL6, CD4 and 
SMAD3 and genes TLR3 and TIRAP that are part of the toll-like receptor signaling 
pathway. Bivalent domains were also present on a variety of transcription factors with 
immune-related functions such as CITED2, a transactivator that regulates NF-κB, 
MYC a transcription factor associated with hematopoetic tumors and RHOB a Ras 




all genes involved in the top five functional annotation clusters showed higher 
chromatin levels in line 72 primarily after MDV infection (Appendix XIII). 
Bivalent Domains are Altered in Response to MD  
We further investigated the effect of MD on bivalent chromatin domains observed on 
BCL6, CITED2, EGR1, CD4 and TLR3 (Figures 3.7 and 3.8). Interestingly, three of 
these genes, CITED2, BCL6 and EGR1, showed identical epigenetic and 
transcriptional signatures. 
 
Figure 3.7. Bivalent domains on transcriptional regulators are altered by MD. 
H3K4me3 (orange) and H3K27me3 (green) profiles and associated transcript levels 
of BCL6 (a, b), EGR1 (c, d) and CITED2 (e, f). In all three cases we observe a slight 
increase in H3K27me3 induced by MDV infection in line 72 and a concurrent 
significant decrease in transcript levels while increase in active and repressive marks 





CITED2 is a member of the p300/CBP co-activator family that has intrinsic histone 
acetyltransferase activity and plays a major role in regulating and coordinating 
multiple complex cellular signals to determine the expression level of a gene [208]. 
B-cell CLL/lymphoma 6 (BCL6) is a zinc finger protein that functions as a 
transcriptional repressor which was downregulated at 15 dpi in spleen tissues from F1 
progeny (15I5 X 71) of MD-susceptible chickens [195]. EGR1 belongs to a group of 
early response genes induced by a variety of signaling molecules such as growth 
factors, hormones and neurotransmitters that is believed to play a major role in cell 
proliferation and apoptosis [209]. Overexpression of EGR1 promotes tumor growth in 
kidney cells [210] but suppresses growth and transformation in other cell types, e.g. 
fibroblasts and glioblastoma cells [211]. 
In each of the above genes, both active and repressive chromatin marks were 
increased in response to infection in line 63 chickens. However, in line 72, there was a 
definite increase in H3K27me3 marks but no change in H3K4me3 (Figures 3.7 A, C, 
E). Transcript levels were in agreement with this observation: infected line 72 
chickens showed a significant downregulation (CITED2: p=0.0004; BCL6: p=0.0048; 
EGR1: p=0.0005; Figures 3.7 B, D, F), while there were no such changes in line 63.  
On the other hand, TLR3 and CD4 showed a slight increase in H3K4me3 marks after 
MDV infection while there were no appreciable changes in H3K27me3 levels. In 
keeping with the epigenetic changes, there was a small increase in gene expression in 





Figure 3.8. Bivalent domains on some genes are unaffected by virus infection. 
MDV infection has no effect on the bivalent domains or transcription levels of CD4 
and TLR3. 
Discussion 
Immune parameters that are known to play a major role in genetic resistance to MDV 
are correlated with innate immune responses, such as NK cell activity, production of 
nitric oxide and cytokines, such as, interferons. Recent studies have identified host 
cytokines such as IL-18 and IFN-γ that contribute to the initiation and continuation of 
latency [212]. However, cytokine levels can undergo rapid flux in response to 
infection, and consistent with this, we did not observe any epigenetic changes 
associated with these genes in the MHC-congenic lines used in our study (Figure 3.9). 
This suggests the existence of other extrinsic factors responsible for transcriptional 





Figure 3.9. Epigenetic profiles of host cytokines (a) IL-18 and (b) IFN-γ.  
IL-18 does not show any notable changes in response to MDV infection while IFN-γ 
does not show any SER.  
 
A global comparison of histone modification levels in the two inbred chicken lines 
yielded some interesting results. As expected, a majority of SERs were found in all 
the experimental groups, indicating a high level of epigenetic similarity between the 
lines in addition to inherent genetic similarity. In the case of H3K27me3, the 
percentage of ubiquitous SERs was relatively low (23.4%), although this was likely 
due to lower precision of the peak caller for broad chromatin marks. Besides, most of 
the SERs detected in a subset of samples corresponded to regions of low enrichment, 
which may also be the reason behind the relatively low number of differential SERs 
detected in our study.  
Genes that have been previously associated with MD and various other cancers 
showed differential marks that are either MD-induced (MX1, CTLA-4, EAF2 and 




around the TSS of MX1, a gene with known antiviral properties, appeared to be 
correlated with upregulated expression in both lines in response to MDV infection. 
However, lowered overall mRNA levels in the resistant line suggest additional factors 
could be involved in the regulation of this gene. Similarly, increased mRNA levels of 
the lymphocyte surface marker CTLA4 is possibly due to the presence of larger 
numbers of T cells in MDV infected birds as a result of higher levels of infection. 
EAF2 functions as an apoptosis inducer in addition to being a tumor suppressor, and 
therefore, its downregulation could contribute to higher tumor incidence rates in line 
72. However, it is not clear why a significant increase in H3K27me3 levels did not 
have any effect on transcript levels in the resistant line. 
IGF2BP1 is believed to act by stabilizing the mRNA of the c-myc oncogene and 
therefore, the higher expression of this gene and a more stable c-myc gene product 
might play a role in increasing MD susceptibility in line 72 birds via increased cell 
proliferation and transformation. The matrix metalloprotease MMP2 is upregulated 
after infection in the resistant line 63, similar to the previously observed increase at 
the neoplastic stage of MD. However, mRNA levels were similar in the two lines 
before infection contrary to the difference in H3K4me3 levels suggesting that 
additional factors are responsible for regulating this gene. 
The correlation between observed differential histone marks and transcript levels was 
moderate at best. Indeed, differential H3K4me3 marks were strongly predictive of 
gene expression levels but the correlation between H3K27me3 and mRNA levels was 
relatively poor. There could be various reasons for this – indeed, H3K27me3 levels 




difference in the effect on expression. Therefore, in this tissue, the levels of 
H3K27me3 may not be a very good indicator of gene expression levels. Also, the 
transcription of these genes might be controlled by other factors with the change in 
H3K27me3 levels only incidental. 
Bivalent domains were detected on transcriptional regulators BCL6, CITED2 and 
EGR1 and the galanin receptor GALR1. The epigenetic and transcriptional signatures 
observed on these genes indicated that they were poised at the latent stage of the 
disease, but with crucial differences in the two lines. Increased repressive marks in 
the susceptible line correlated with significant downregulation of the genes, while in 
line 63, the increase in both marks appeared to compensate for each other with no 
eventual effect on gene transcription. This suggests that some ‘poised’ bivalent genes 
can become highly repressed even with a relatively small increase in H3K27me3 
marks. The change in the chromatin levels could also be correlated with an increase 
in cell populations having the repressive mark. Taken together, the above findings 
point towards the existence of finely balanced epigenetic control of transcription, 
which may be necessary to mount a rapid response by the immune system. However, 
this machinery could potentially be hijacked by a pathogen and result in an aberrant 
phenotype. The effect of MDV infection on the bivalent domain on GALR1, in 
particular, suggests the repression and potential loss of its anti-proliferative effects. 
Thus, the galanin system possibly plays an important and hitherto unknown role in 
MD progression and could be a novel target for long-term control of the disease. 
One of the major players in MDV-induced malignant transformation is Meq, a virus-




remodeling and regulation of transcription. Meq interacts with and sequesters the 
tumor suppressor protein p53, resulting in the dysregulation of cell-cycle control 
[123] and inhibition of the transcriptional and apoptotic activities of the protein [213]. 
Several genes that show epigenetic changes in response to MDV infection have been 
associated with p53. Downregulation of CITED2 stabilizes the p53 protein leading to 
its accumulation [214]. The BCL6 gene product is believed to contribute to 
lymphomagenesis by inactivation of p53 [215]. Besides, EAF2 has also been shown 
to interact with and suppress the function of p53 [167]. The downregulation of all of 
the above genes in susceptible birds after MDV infection points towards the increased 
production of p53 and a robust anti-tumor response. That we still observe higher 
tumor incidence rates in this line, suggests the presence of large amounts of 
inactivating viral Meq protein which, in turn, indicates that increased numbers of 
MD-infected cells are present in the susceptible line at this stage of the disease. A 
majority of tumors are believed to result from the viral transformation of CD4+ T 
cells some of which are infected at the latent stage of MD [216]. The larger number 
of virus-infected cells produced in the susceptible line is possibly due to lowered 
immunocompetence as a result of the early stages of infection. Thus, a more detailed 
investigation of the early cytolytic stage of MD is necessary to shed further light on 
the causes behind the divergent response to MD observed in these birds. 
Whole tissues represent a mixture of various cell populations, and observed 
epigenetic changes might be due to a change in chromatin marks in a particular cell 
type or a variation in the relative number of cells carrying active or repressive histone 




systems level wherein different cell types might interact in a cooperative manner to 
fight infection. Thus, while the study of pure cell populations is likely to yield greater 
discriminative power, the investigation of tissue macroenvironments is, perhaps, 
closer to reality. 
This study focused on the thymus tissue as it is a major immune organ and contains a 
significant population of T lymphocytes in various stages of differentiation. Our 
earlier study of the MDV-induced transcriptome in these birds indicated the presence 
of line-specific differences at the latent stage of MD [217]. In addition, birds 
susceptible to MD suffer thymic atrophy during the early stages of infection [218], 
indicating the importance of understanding changes in this organ to elucidate the 
mechanisms involved in disease progression. Ongoing studies in our lab include other 
tissues, e.g. spleen [219], and a time-course through the various stages of infection, to 
further investigate the systemic effects of MD and the epigenetic basis of MD 
resistance. 
Conclusions 
We studied the effect of latent MDV infection on two chromatin modifications in 
inbred chicken lines exhibiting different degrees of resistance to MD. Several genes 
showed changes in histone enrichment and this response was often significantly 
different between the two chicken lines. A detailed analysis of co-localization 
patterns of the chromatin marks revealed the presence of bivalent domains on a 
number of immune-related transcriptional regulators. More importantly, these 
domains showed marked changes in response to MDV infection and provide further 




roles for the GAL system in MD progression. A majority of the differential chromatin 
marks are also suggestive of increased levels of viral infection in the susceptible line 
symptomatic of lowered immunocompetence in these birds at early stages of the 
disease. In summary, our study provides further insight into the mechanisms of MD 
progression while revealing a complex landscape of epigenetic regulatory 
mechanisms. Further work is necessary to fully elucidate the underlying mechanisms 
of MD, but our results suggest that this is a promising step towards a deeper 





4. Temporal Chromatin Signatures Induced by Marek’s 
Disease Virus Infection in Bursa of Fabricius 
Abstract 
Marek’s disease (MD) is a highly contagious, lymphomatous disease of chickens 
induced by a herpesvirus, Marek’s disease virus (MDV) that causes major annual 
losses to the poultry industry. Similar to other herpesviral infections, MD 
pathogenesis involves multiple stages including early cytolytic and latency, and 
transitions between these stages are governed by several host and environmental 
factors. The success of vaccination strategies has led to increased virulence of MDV 
and selective breeding of naturally resistant chickens is seen as a viable alternative. 
While multiple gene expression studies have been performed in resistant and 
susceptible populations little is known about the epigenetic effects of infection. Thus, 
in this study, we investigated temporal chromatin signatures induced by MDV by 
analyzing early cytolytic and latent phases of infection in the bursa of Fabricius of 
MD-resistant and –susceptible birds. Several pathways that have been previously 
reported in connection with MD, including apoptosis, p53 signaling and cytokine 
cytokine receptor-interaction, displayed changes in histone modification marks. In 
addition, several novel pathways were enriched. The neuroactive ligand receptor-
interaction pathway showed marked reductions in H3K4me3 marks, particularly in 
MD-resistant chickens and several genes belonging to the spliceosome pathway 




Variations in chromatin marks suggest greater inflammation in susceptible chickens 
at the early cytolytic stage of infection, while the resistant line exhibited recuperative 
symptoms. During latent MD, the resistant line showed widespread reduction in 
H3K4me3 marks suggesting epigenetic silencing. Our observations regarding 
chromatin profiles were also largely in agreement with previous reports.  The 
temporal analysis of chromatin signatures, therefore, revealed further clues about the 
epigenetic effects of MDV infection. Further studies are necessary to understand the 
functional implications of the observed variations in histone modifications. 
Introduction 
Marek’s disease (MD) is a highly infectious disease caused by an α-herpesvirus, 
Marek’s disease virus (MDV), that affects chickens worldwide. MD pathogenesis can 
be divided into three major stages: an early cytolytic phase, which occurs between 3 
and 6 days post infection (dpi), is characterized by the infection of B lymphocytes, 
the first major targets of MDV. The infected B cells enter circulation and induce the 
activation of CD4+ T cells which in turn become infected. In subsequent stages of the 
disease, CD4+ T cells form the primary vehicle for MDV multiplication and 
dissemination, along with a smaller percentage of other cells including B and CD8+ T 
lymphocytes. Around 7 dpi, the infection enters a latent phase defined by the absence 
of expressed viral antigens and virus production. This switch to latency is believed to 
be governed by many viral and host factors, such as, viral interleukin (vIL)-8, which 
acts as a chemoattractant for T lymphocytes [220], and upregulated chicken major 
histocompatibility complex (MHC) class II molecules on infected cells promoting the 




persists at a low level in lymphoid tissues and CD4+ T lymphocytes. However, in 
MD-susceptible genotypes, a second cytolytic phase occurs 2-3 weeks after the 
primary infection, wherein latently infected lymphocytes are transformed and 
proliferate rapidly to form tumors in various tissues. 
The primary lymphoid organs of spleen, thymus and the bursa of Fabricius, are 
important focal points of MD progression. Cytolytic infection initiates in the spleen 
before spreading to other lymphoid organs, which lag behind by a day. This is 
accompanied by significant cytolysis of B and T lymphocytes in addition to varying 
levels of inflammatory response. Bursal follicles and the thymic cortex undergo 
regressive changes in this stage of MD leading to organ weight loss, while there is 
massive apoptosis of thymocytes. In the spleen, however, inflammation results in an 
increase in organ weight. The above changes are reduced within two weeks of 
infection, with the organs almost returning to their normal form and structure. 
However, in MD-susceptible chickens, a second wave of cytolytic infection around 
14-21 dpi results in marked inflammation, severe atrophy of bursa and thymus and 
permanent immunosuppression.  
There have been several studies of the effect of MD, particularly in the spleen, but 
relatively few concerning the bursa of Fabricius [222, 223]. The latter is a primary 
lymphoid organ evolutionarily unique to birds and critical to the development of the 
B cell lineage [224]. B lymphocytes in all the major lymphoid organs, as mentioned 
above, are the primary targets of the virus in the early stages of the disease [129]. 
Embryonal bursectomy resulted in the abolition of early lytic infection along with 




Bursal atrophy was observed in MD-susceptible line L72 chickens with the effect 
reduced in the MD-resistant line L63 individuals [129], while the bursa-dependent 
immune system was impaired in infected chickens [225]. It is, therefore, evident that 
the bursa of Fabricius plays an important role in MD pathogenesis, and it is vitally 
important to understand the effect of MDV on this organ. 
In this study, we used chromatin immunoprecipitation followed by sequencing (ChIP-
Seq) to analyze temporal chromatin marks induced by MDV infection. For this work, 
we utilized a population of inbred chicken lines having contrasting responses to the 
disease and focused on the bursa of Fabricius. In doing so, we extended our previous 
studies [219, 226] to include both the cytolytic and latent phases of MD. Our primary 
goal was to investigate the dynamic changes of chromatin induced by MDV infection 
to uncover the biological pathways that could be affected by variations in histone 
modification enrichments. The biological consequences of chromatin profiles are 
context-specific and similar patterns can lead to a variety of outcomes [227]. 
Therefore, we focused on changes of chromatin enrichments as evidence of possible 
epigenetic regulation. 
Materials and Methods 
Animals and viruses 
Two specific-pathogen-free inbred lines of White Leghorn, either resistant (L63) or 
susceptible (L72) to MD, were hatched, reared and maintained in Avian Disease and 
Oncology Laboratory (ADOL, Michigan, USDA). Eight chickens from each line 




MDV (648A passage 40) at 14 days after hatch with a viral dosage of 500 plaque-
forming units (PFU). Another eight chickens were not infected as age-matched 
controls. Infected and control chickens (n=4) from both lines were terminated at 5 or 
10dpi to collect bursa tissues. All procedures followed the standard animal ethics and 
use guidelines of ADOL. 
Analysis of ChIP-Seq data 
Chromatin immunoprecipitation (ChIP) was carried out using bursa samples from 
MDV infected and controls birds as described elsewhere [8]. Briefly, about 30 mg 
bursa samples were digested with micrococcal nuclease followed by end-repair with 
PNK and Klenow enzymes (NBE, Ipswich, MA, USA) and ChIP with the specific 
antibody. This was followed by addition of 3’ adenine, Illumina adaptor ligation, 
PCR amplification (17 cycles) and size-selection (~ 150 bp). This was followed by 
cluster generation and sequencing on the Illumina Hi-Seq 2000. The antibodies used 
and the total number of reads obtained for each sample is listed in Appendix XIV. 
Sequence reads were aligned to the May 2006 version of the chicken genome 
(galGal3) using bowtie version 0.12.7 [80]. Default alignment policies of bowtie were 
enforced: a valid alignment could have a maximum of two mismatches and if a read 
aligned equally well to multiple places in the genome, one was chosen at random. If 






Promoters were defined as a 2 kb region surrounding the transcription start site (TSS) 
of a gene, e.g. TSS ± 1000 bp. Reads mapping to promoter regions of Ensembl genes 
[228] were tabulated into a matrix and analyzed using edgeR [118]. Separate analyses 
were performed for H3K4me3 and H3K27me3. Diffscores for each gene g were 
calculated as: 
       (      )           
where, sgn(*) is the signum function, logFCg and pg are the log-fold change and p-
values calculated by edgeR. Hierarchical clustering was performed in R [229] with 
the hclust() function using the Ward’s minimum variance method to calculate 
distances. Clustering heatmaps were generated using the package ggplot [230]. For 
visualization purposes, DS values greater than 2 were replaced by 2 and those less 
than -2 by -2. 
RNA-Seq Data Analysis 
RNA-Seq reads obtained from Illumina Hi-Seq 2000 were analyzed as above. 
Detailed analysis of this data set can be found elsewhere (Fei, Z. et al. unpublished). 
Transcript abundances were approximated by the numbers of reads mapping to exons. 
As we did not intend to perform transcriptome assembly as part of this work, we did 
not perform splice-junction mapping. Read counts for Ensembl genes were extracted 
and tabulated for analysis with edgeR as above. Note that several transcripts had no 
mapped reads, indicating undetectable levels of expression. The DS scores were 




Ward’s minimum distance criterion and the clustering dendrogram was cut at height 
150 to produce 19 clusters. 
Co-clustering Analysis 
We compared the RNA-Seq and ChIP-Seq clustering results by adopting the 
technique used in [38]. Briefly, overlaps between each pair of RNA-Seq and ChIP-
Seq clusters were tabulated and tested for independence using a 

-test with simulated 
p-values (10000 iterations). Simulated p-values were used as the table of counts was 
likely to contain several zero counts in which case the test may be rendered 
inappropriate. 
Results 
Promoter clustering by dynamic chromatin changes 
We sampled two critical time-points of MD progression, 5 and 10 dpi, representing 
early cytolytic and latent stages of MD, respectively. ChIP-Seq was performed on 
bursal tissues obtained from MD-resistant line L63 and MD-susceptible line L72 
chickens. Two histone H3 trimethylation marks having opposing effects on gene 
regulation were profiled – H3 lysine 4 trimethylation (H3K4me3), which is associated 
with the 5’ end of active genes, and H3 lysine 27 trimethylation (H3K27me3) which 
marks broad regions for silencing. To uncover gene promoters with similar dynamic 
patterns of chromatin we examined the 2 kb region centered around the transcription 
start sites (TSSs) of 16426 annotated genes in the chicken genome from the Ensembl 




genes and miRNAs. The promoter read counts were compared between infected and 
control groups within each line using edgeR [118]. We quantified the differences 
between MD-infected and control individuals by using log-fold changes (logFC) and 
p-values output by edgeR to score each promoter (diffscore). Thus, a p-value of 0.001 
with a negative fold-change was scored as -2, while the same p-value with a positive 
fold-change was scored as +2. Subsequently, hierarchical clustering of diffscores was 
performed using the Ward’s minimum distance criterion. A traditional threshold-
based approach attempts to discover the largest variations. In contrast, our measure 
was aimed at being more inclusive as we were interested in finding enriched 
pathways. We believe this approach increases the sensitivity of our analysis towards 
detecting subtle variations in chromatin marks, which might still have an important 
role in determining transcriptional regulation.  
We manually curated the clustering dendrogram and chose a cut height of 400 to 
obtain a list of 14 clusters (A-N; Figure 4.1). Two of the clusters (F, H) showed finer 
patterns that were revealed using a cut height of 150 on each clustering sub-tree and 
resulted in 3 (F1, F2, F3) and 2 (H1, H2) clusters, respectively. In addition, cluster C 
contained only 2 genes and was subsequently dropped from the analysis. Thus, the 
hierarchical clustering of diffscores resulted in a set of 16 clusters of promoters 





Figure 4.1. Hierarchical clustering of diffscores reveals dynamic chromatin 
changes. Unsupervised clustering of diffscores reveals striking patterns of chromatin 
as distinct clusters of promoters exhibit strong trends at each time-point. Line L63 
shows a dramatic decrease in H3K4me3 marks at 10 dpi (clusters L, M, N), while 
both lines display corresponding changes at 5 dpi. 
 
Several interesting trends were apparent from the above analysis. Distinct clusters of 
promoters exhibited changes in chromatin enrichment at the cytolytic and latent 
phases of infection. Moreover, disjoint sets of genes shared similar chromatin 
signatures in the two inbred chicken lines. For instance, cluster B consisted of genes 
showing a significant increase in H3K4me3 enrichment in L63 at 5 dpi, while cluster 
H1 demonstrated the opposite trend in the same line. In contrast, cluster F1 genes 
displayed increased H3K4me3 enrichment in L72 at the same time-point, while 
cluster A showed a decrease in promoter H3K4me3. Thus, the chromatin landscape 
revealed the dynamic nature of the epigenetic response in the two chicken lines at 




We conducted functional analysis of the clustered genes to uncover biological 
pathways and other functional terms associated with differences in chromatin 
enrichment induced by MDV infection. Clusters displaying similar trends were 
grouped together (Table 4.1) before gene set enrichment analysis with DAVID [170, 
207].  
Table 4.1. Cluster grouping based on similar chromatin trends. 
DPI Line Trend* Clusters 
5 63 H3K4me3 ↑ B 
  H3K4me3 ↓ H1 
  H3K27me3 ↑ E 
  H3K27me3 ↓ F2 
 72 H3K4me3 ↑ F1, J 
  H3K4me3 ↓ A 
  H3K27me3 ↑ D 
10 63 H3K4me3 ↑ F3, K 
  H3K4me3 ↓ L, M, N 
 72 H3K4me3 ↑ H2 
*The trends summarized above are based on strong observed patterns in the 
corresponding clusters. 
Apoptosis and p53 pathways show early H3K4me3 changes 
particularly in MD-susceptible chickens 
At the early cytolytic stage, genes involved in the p53 signaling pathway (KEGG: 
gga04115) in both the resistant and susceptible lines displayed changes in H3K4me3 
enrichment (Figure 4.2). However, there were several key differences. In line L72, 
genes associated with stress signals such as DNA damage, e.g. ATM, CHEK2 and 
STT3A, exhibited increased H3K4me3 marks, while downstream p53 targets which 
induce the apoptosis pathway, e.g. ZMAT3 and CYCS, showed similar chromatin 
patterns.  In the resistant line, increased H3K4me3 enrichment was present on genes 




while upstream genes (CHEK2, STT3A) mirrored the changes observed in the 
susceptible line only at the later time-point. Moreover, in line L63, we saw increased 
H3K4me3 on genes associated with inhibition of angiogenesis and metastasis 
(CD82), and those that can promote DNA repair and damage prevention (RRM2 and 
SESN1), which were absent in the susceptible line.  
 
 
Several genes associated with the apoptosis pathway (KEGG: gga04210), displayed 
perturbed chromatin marks in response to cytolytic infection in line L72 (Figure 4.3). 
A B
A 
Figure 4.2. The p53 pathway displays 
significant changes in H3K4me3 
marks at 5 dpi in both lines. 
(a) MD-susceptible line L72 shows 
evidence of greater DNA damage, while 
line L63 exhibits downstream 
recuperative effects. (b) Clustering of 










The pro-inflammatory cytokine IL1B and downstream gene MYD88, which can 
induce the NF-B signaling pathway, along with genes involved in PI3K-Akt 
signaling, such as, the nerve growth factor NGFB, showed increased H3K4me3 on 
their promoters. However, other genes exhibited contrasting signals. For instance, 
there was increased promoter H3K4me3 on PI3KR2, but a reduction on PI3KCG, an 
increase on cAMP-dependent protein kinase PRKAR1B, but a corresponding 
reduction on PRKACB. Other important genes associated with the apoptosis pathway, 
FADD and CFLAR, exhibited reduced H3K4me3 marks in the susceptible line while 
apoptosis-inhibitor BIRC2 exhibited the same trend in both lines at 5 dpi. 
 
Figure 4.3. Apoptosis pathway shows H3K4me3 changes in line L72 at 5 dpi. (a) 
KEGG pathway and (b) clustering heatmap. Members of the NF-B signaling 
pathway display increased H3K4me3 enrichment at 5 dpi, while apoptosis-related 
genes FADD, CFLAR and BIRC2, have reduced promoter H3K4me3. 
Interestingly, the ubiquitin-mediated proteolysis pathway (KEGG: gga04120), which 
has been linked to the regulation of p53, also displayed significant changes in 
H3K4me3 marks in the susceptible line (Appendix XV). All three classes of enzymes 









enzymes (E2s) and ubiquitin-protein ligases (E3s) showed increased H3K4me3 
enrichment in infected individuals including UBA3, 7 (E1), UBE2A, 2R2 (E2) and 
multiple classes of E3 enzymes and associated complex subunits, e.g. ITCH (HECT-
type), CBL (U-box type), PIAS4 (single RING-finger type), SKP1, FBXO2 and 
SOCS3 (multiple subunit RING-finger type).  
Highly perturbed chromatin on the neuroactive ligand-receptor 
interaction pathway in MD-resistant chickens 
Several genes involved in the neuroactive ligand-receptor interaction pathway 
(KEGG: gga04080), which is a collection of neural stimulatory molecules and their 
receptors, displayed striking changes in chromatin marks in the resistant line L63, at 
both stages of the disease (Figure 4.4). 
Certain components of the pathway showed reduced H3K4me3 enrichment in the 
resistant line at 5 dpi. This included various G-protein coupled receptors (GPCRs), 
such as, the dopamine receptors (DRD4, DRD5), histamine receptor HRH4, 5-
hydroxytryptamine (5-HT) receptor HTR2A, etc. However, a larger proportion of 
associated molecules demonstrated H3K4me3 reductions at the latent stage of MD 
including virtually all classes of GPCRs, (e.g. DRD2, HTR1D, 1E and 1F), among a 
variety of others, e.g. GABA receptors (GABRA2, B2, D and G1) and the growth 
hormone receptor GHR. In addition, several genes belonging to this pathway also 





Thus, various members of the NLR interaction pathway displayed H3K4me3 
reductions at either time-point or increased promoter H3K27me3 at 10 dpi, each 
suggesting possible repression. Some genes belonging to this pathway were also 
previously reported to be associated with MD. For instance, the proinflammatory 
Figure 4.4. Neuroactive ligand-
receptor interaction pathway 
displays marked reduction of 
H3K4me3 in line L63 at 10 dpi. 
(a) KEGG pathway map and (b) 
diffscore clustering heatmap. Several 
classes of genes involved in the 
neuroactive ligand-receptor pathway 
display striking reductions in promoter 
H3K4me3 and increases in H3K27me3 
indicating large-scale repression during 







protease granzyme A (GZMA) has been shown to be upregulated during early 
cytolytic MD in susceptible chickens [162]. We found a significant reduction of 
H3K4me3 on the promoter of GZMA in line L63 at 5 dpi, while an increase was 
evident in susceptible chickens. Also, the growth hormone gene GH1 has been 
associated with MD resistance [187], and shown to be upregulated in susceptible 
chickens [186]. Interestingly, the growth hormone receptor GHR displayed reduced 
promoter H3K4me3 in infected L63 chickens at 10 dpi while a slight increase was 
evident at 5 dpi in susceptible birds. 
Signature cytokines and cytokine receptors show H3K4me3 
alterations at the latent stage 
Several cytokines and cytokine receptors (CCR interaction pathway, KEGG: 
gga04060) showed changes in H3K4me3 marks at 10 dpi (Figure 4.5). This included 
notable chemokine IL8, fractalkine receptor CX3CR1 and interferons IFNA 
(LOC768614) and IFNB, all of which had reduced H3K4me3 in response to infection 
in the resistant line L63. Certain subfamilies were especially well-represented in this 
group, such as, hematopoietic interleukins (IL7, 12B, 15, PRL and TPO), and 
receptors LEPR, OSMR and PRLR; platelet-derived growth factors (PDGFs) FIGF 
and HGF, and PDGF receptors (FLT1, KDR, KIT and MET); IL-1 family receptors 
(IL1R1, 2 and IL18RAP) and TGFβ family receptors ACVR2B and BMPR2. In 
contrast, some components of this pathway displayed increased promoter H3K4me3 
in line L72 at this time-point, which included the inflammatory cytokine IL6, 
interleukin receptors IL7R and 21R, TNF superfamily receptors TNFRSF1B, 11B and 





The expression profiles of host cytokines in response to MDV infection has been 
studied previously [131, 160, 161]. The interleukin IL6 is upregulated in MD-
susceptible chickens [160] while inducible nitric oxide synthetase (iNOS) is higher in 
MD-resistant than susceptible chickens after 5 dpi [141]. Our observations of 
increased H3K4me3 on IL6 in the MD-susceptible line suggesting activation, and an 
Figure 4.5. Cytokine-cytokine 
receptor-interaction pathway exhibits 
marked changes in H3K4me3 marks 
in both lines at 10 dpi. 
(a) KEGG pathway map and (b) 
diffscore clustering heatmap. Several 
notable cytokines, e.g. IL8, had reduced 
promoter H3K4me3 in line L63, while 
others, such as, IL6, displayed the 








evident reduction on iNOS at 5 dpi indicating repression, thus, appear to be consistent 
with the above. Moreover, there were several novel genes showing marked 
differences between the two lines. The chemokine receptor CX3CR1, displayed 
significantly increased promoter H3K4me3 in the susceptible line at 10 dpi, while the 
reverse was true of L63. The interleukin receptor IL11RA showed a marked increase 
in H3K4me3 enrichment in infected L72 chickens similar to IL6 and IL7R, while the 
resistant line showed no change. On the other hand, IL6ST receptors LEPR, OSMR, 
TGF family receptors ACVR2B, BMPR2, and interleukin IL12B demonstrated 
reduced H3K4me3 in line L63 at both time-points. Notable similarities were also 
apparent between the two lines, e.g. LOC424261 and FASLG, showed increased 
H3K4me3 in both lines at 10 dpi, while EGF displayed corresponding reductions. 
MAPK signaling pathway displays H3K27me3 changes in both lines 
Among the relatively few promoters with striking changes in H3K27me3 marks, 
several were associated with the MAPK signaling pathway (KEGG: gga04010) in 
both lines (Figure 4.6). In line L72 at the early cytolytic stage, this included elements 
of the classical MAPK pathway, such as, PDGFA, a growth factor involved in cell 
proliferation and migration, various Ras-related genes e.g. RASA1 and MRAS, 
tyrosine kinase receptor NTRK2 and transmembrane calcium channel CACNG4. In 
addition, multiple components of the JNK and p38 MAPK pathways also appeared to 
have perturbed levels of H3K27me3, such as, the proliferation-regulatory cytokine 
TGFB2, the p38 MAP kinase MAPK12, Ras-related small GTPase RAC2, and the 





In the resistant line, increased H3K27me3 marks were observed at 10 dpi on several 
components of this pathway. This included several fibroblast growth factors (FGFs; 
FGF1, 3, 16, 19 and 20), PDGFB and transmembrane calcium channels (CACNA1D, 
1E, 1G and 2D1), which were part of the classical pathway. However, a significant 
proportion of associated genes also belonged to p38 and JNK MAPK signaling, such 
Figure 4.6. MAPK signaling pathway 
demonstrates increased promoter 
H3K27me3. 
(a) KEGG pathway map and (b) diffscore 
clustering heatmap. Several genes 
involved in the MAPK signaling 
pathway displayed increased promoter 








as, TGFβ family receptor ACVR1C, p38 MAP kinase MAPK13, dual-specificity 
phosphatase DUSP6, MAPK-activated protein kinases (MAPKAPK2, 3) and 
NFATC2. 
Multiple genes showed similar signatures at different time-points in the two lines. For 
instance, the TGF family receptor ACVR1C had increased promoter H3K27me3 in 
line L72 at 5 dpi and line L63 at 10 dpi. This was also true of several other genes, such 
as, growth factors FGF1, 3, 16 and 19, calcium channels CACN1G and E, TGFB2 
and MAP kinase MAPK12. Interestingly, RASA1 and MEF2C, which showed 
increased H3K27me3 in line L72 at both time-points, also exhibited H3K4me3 
increases at 5 dpi, but not at 10 dpi. Similarly, TGFB2, PDGFB, DUSP6 and 
NFATC2, which displayed higher promoter H3K27me3, particularly at 10 dpi in line 
L63, demonstrated increased H3K4me3 in the susceptible line at the same time-point. 
Taken together, our results suggest overall silencing of this pathway in the susceptible 
line during cytolytic infection, which is abrogated by the latent stage. In contrast, the 
silencing occurs in the resistant line at a later stage of infection. 
Novel pathways display chromatin variations 
At the latent stage of the disease, the focal adhesion pathway (KEGG: gga04510), 
which consists of several sub-pathways, such as, extra-cellular matrix (ECM) 
interaction, CCR interaction and MAPK signaling, was highly represented in the 
resistant line L63 (Appendix XVI). The genes displaying reduced H3K4me3 marks 
included several collagens (COL4A1, 4A2, 5A2 and 11A1), laminins (LAMA1, 2), 
thrombospondins (THBS1, 4) and integrins (ITGA1, A4, B1, B6 and B8). In addition, 




ARHGAP5 and RHOA, cytoskeletal protein VCL, protein kinases ROCK1 and 
ROCK2, and other elements of the focal adhesion pathway such as AKT kinases 
(AKT1, 2) and adherens junction component CTNNB1 (catenin-), displayed reduced 
H3K4me3 enrichment. Decreased H3K4me3 marks were also present on growth 
factor IGF1, IGF-1 receptor (IGF1R), oncogene FYN and SHC signaling adaptors 
SHC3 and SHC4. Integrin signaling is believed to play an important role in MDV 
transformation [231], while some collagens are downregulated during lytic MD in 
MD-susceptible chickens [162]. Our results suggest that this pathway might undergo 
epigenetic regulation in response to MDV infection. Moreover, reduced H3K4me3 
and possible downregulation of pro-neoplastic IGF1 and its receptor, along with 
oncogene FYN, in the resistant line is also an interesting finding. 
Another interesting pathway that contained a large number of genes with increased 
H3K4me3 marks, particularly in line L63 at 10 dpi, was the spliceosome pathway 
(KEGG: gga03040; Figure 4.7), which consists of molecules that regulate pre-mRNA 
splicing, such as, small nuclear ribonucleoproteins (snRNPs) U1-U6 and 
spliceosome-associated proteins (SAPs). Genes belonging to each of the above 
components of this pathway displayed increased H3K4me3 marks in response to 
MDV infection, e.g. SNRPD1 and D3 (U1), SF3A1 and PHF5A (U2), PRPF4 and 
PPIH (U4/6), EFTUD2 (U3) and BCAS2 (Prp19 complex). Some of these genes, such 
as, ZMAT2, EFTUD2 and PRPF8, also demonstrated increased promoter H3K4me3 
in the susceptible line at 5 dpi, further evidence of a possible ‘phase-difference’ in 




Moreover, this is a novel pathway, which, to the best of our knowledge, has not been 
previously reported in the context of MD progression.  
     
Figure 4.7. The spliceosome pathway shows increased H3K4me3 marks 
particularly in L63 at 10 dpi. 
(a) KEGG pathway map and (b) diffscore clustering heatmap. Several genes 
belonging to this pathway had increased promoter H3K4me3 in resistant birds during 
latent infection, while some showed the same trend at the earlier time-point in 
susceptible L72 chickens. 
Immune-related microRNAs demonstrate characteristic signatures 
MicroRNAs (miRNAs) are short, non-coding RNAs that play a major role in post-
transcriptional regulation via translational repression or mRNA destabilization. 
Several miRNAs have been shown to play major roles in immune response, e.g. miR-
146 is a possible tumor suppressor [232] and along with miR-155 is believed to 
contribute to innate immunity [233]. The miR-17~92 cluster is thought to function as 
an oncogene, promoting cell proliferation and suppressing apoptosis [234]. We 
extracted a list of 449 chicken miRNAs and clustered their promoters using 
diffscores. The miRNAs formed characteristic clusters as observed in the case of 






we compiled a list of candidate miRNAs from various reports [235-238] and 
examined their temporal chromatin profiles (Figure 4.8). 
 
Figure 4.8. Selected immune-related miRNAs display repressive changes in 
chromatin marks. 
Several members of the let-7 family had reduced promoter H3K4me3 marks in line 
L63 birds either at 5 or 10 dpi, while other important miRNAs, e.g. gga-mir-21 and 
gga-mir-155 displayed reductions in H3K4me3 in line L72 at 5 dpi. 
 
Several miRNAs displayed predominantly repressive changes in chromatin in both 
lines. Multiple immune-related miRNAs gga-mir-155 [239], gga-mir-21 [240] and 
gga-let-7i [241] had reduced promoter H3K4me3 in the susceptible line at 5 dpi, but 
in the case of gga-mir-21 and gga-let-7i, this trend was reversed at 10 dpi. Several 
other members of the let-7 family displayed reduced H3K4me3 in the resistant line 
L63 at the two time-points: gga-let-7a-2, j and k at 5 dpi and gga-let-7a-1, a-3, b, c, d 




showed reduced H3K4me3 in line L63 at both time-points. At 10 dpi, gga-mir-101, 
which can play a role in curbing autoimmune reactions [244], had reduced 
H3K27me3 marks in line L63, while other immune-related miRNAs, gga-mir-10b, 
124a-2 and 146b displayed the reverse trend. The inhibition of miR-10b has been 
associated with reduced metastasis [245], while loss of miR-124a functions as a 
tumor suppressor [246]. Interestingly, both these miRNAs displayed increased 
H3K27me3 only in the resistant line, suggesting line-specific silencing. 
Chromatin signatures distinguish genes with similar expression 
patterns 
We compared the chromatin marks with RNA-Seq data from the same tissue to look 
for possible correlations. The expression data was analyzed with edgeR, as above, 
and diffscores obtained from the comparison of infected and control samples were 
clustered to obtain a set of 19 groups (Appendix XVII). The two clustering results 
showed definite correlation (

-test, p < 10-6). The 

-residuals were subsequently 





Figure 4.9. Hierarchical clustering of diffscores for RNA-Seq data and co-
clustering with ChIP clusters. 
Co-clustering analysis reveals that genes with the same expression profiles can have 
diverse chromatin signatures. 
 
We found that genes with similar temporal expression patterns displayed remarkable 
diversity in chromatin marks and vice-versa. There were a few clusters that showed a 
certain level of correlation between the chromatin marks and expression. For 
example, chromatin clusters F1 and J which displayed increased H3K4me3 marks in 
the susceptible line at 5 dpi overlapped expression clusters 7 and 9 which consisted of 
genes upregulated at that time-point in the same line. However, such correlations 
were largely low. This is consistent with several prior reports [247] that emphasize 
the diversity of the epigenetic regulatory landscape as evidenced by the expanding 





The histone code is a universal, multi-layered guide to the transcriptional regulatory 
machinery that allows tremendous diversity to be encoded into the genome, while 
providing an essential link between the genetic material and environmental cues. 
Interpreting the biological consequences of variations in chromatin marks is 
exceedingly complex and can be likened to an attempt to discern the outcome of a 
voluminous treatise from the preface. The task of understanding the broader genomic 
effects of a complex disease, such as MD, from epigenetic profiling is a similarly 
daunting undertaking. Our prior studies of the epigenetic effects of latent MD on 
resistant and susceptible chicken lines [219, 226] have provided us with some 
perspective. However, the chromatin landscape is dynamic and temporal analyses of 
histone modification profiles are necessary to obtain a more complete picture. Thus, 
in contrast to the candidate gene approach of the earlier studies, we conducted a more 
comprehensive functional analysis of chromatin variations induced by MD. 
Major functional differences in response to MDV infection 
There were broad similarities, together with striking differences, between the resistant 
and susceptible lines in response to MD. The most striking difference was the NLR 
interaction pathway, with variations in chromatin marks on a wide variety of genes. 
We have previously reported the possible association of this pathway to MD response 
via miRNAs [219], but the sheer number of differentially-marked genes suggests a 
significantly greater level of  involvement and warrants further investigation. Several 




resistant chickens, while others displayed the reverse trend in the susceptible line. The 
MAPK signaling pathway, which had significant representation in the proteome of an 
MDV-transformed cell line [231], displayed H3K27me3 increases predominantly in 
the resistant line at 10 dpi.  Also, several genes in the spliceosome pathway showed 
increased promoter H3K4me3 in line L63.  
Interestingly, in the latter two cases, certain genes shared similar chromatin profiles in 
both lines, but at different time-points. This suggests a possible ‘phase-difference’ in 
the epigenetic response to MD depending on the level of susceptibility of the 
chickens. Also, a large proportion of chromatin changes were repressive in nature 
(H3K4me3 ↓, H3K27me3 ↑), and appeared at a later stage of the disease in the 
resistant line. Epigenetic reprogramming of host genes by viruses and other 
pathogenic microbes has been associated with gene silencing [248] and it is possible 
that this is another example of such a phenomenon. 
Apoptosis in both lines during lytic MD 
Virus-induced apoptosis or programmed cell death can occur either as a result of host 
defense mechanisms eliminating infected cells or as a mode of increased replication 
and spread of virus particles [249]. We observed an enrichment of the apoptosis 
pathway among differentially marked promoters in line L72 during lytic infection, 
with possible involvement of NF-B signaling (IL1B and MYD88). However, certain 
other genes, which are also critical for inducing apoptosis, e.g. caspases CASP3, 
CASP8, Bcl-2 family death regulator BID, and SHISA5, which can induce apoptosis 
in a p53-dependent manner, displayed increased H3K4me3 marks in the resistant line 




response to infection, and is frequently associated with inflammatory diseases and 
tumors [250]. NF-B also plays a major role in MDV-induced transformation of 
CD30+ lymphocytes [163]. Early stages of MD have been associated with 
inflammatory changes in susceptible chickens [251], and the activation of NF-B 
signaling could be part of an inflammatory response in line L72 chickens. Therefore, 
while higher levels of apoptosis are possibly clearing greater numbers of infected 
cells and thus, lowering viral load in line L63 chickens, the activation of a different 
subset of genes could be causing inflammatory response in line L72. 
At the early cytolytic stage, the p53 pathway demonstrated significant changes in 
H3K4me3 in both lines, but the genes differentially marked in each line suggested 
contrasting outcomes – the susceptible line displayed signs of greater DNA damage, 
while the resistant line showed evidence of increased DNA repair and recuperative 
effects. The p53 protein functions as a tumor suppressor and is known to be targeted 
and inhibited by the viral oncoprotein Meq [123, 213]. We have previously observed 
variations in chromatin profiles of genes associated with p53 [226], but this is the first 
direct evidence of multiple components of this pathway undergoing epigenetic 
variations at early stages of MD. The E3 ubiquitin ligase, Mdm2 [252], responsible 
for p53 degradation did not exhibit epigenetic changes suggesting activation (cluster 
F2), but several other components of the ubiquitin-mediated proteolysis pathway 
displayed increased H3K4me3 in the susceptible line, suggesting possible activation 




Novel candidates for epigenetic regulation 
The variations in chromatin profiles of some MD-associated genes, such as, IL6 and 
GZMA (increased H3K4me3 in line L72), which were upregulated in susceptible 
chickens [160, 162], suggested epigenetic regulation in response to virus infection. 
We also observed increased H3K4me3 around the pro-inflammatory cytokine IL1B 
(line L72 at 5 dpi), which was upregulated in brain tissue of chickens infected with 
MDV [251]. In addition, several novel candidates were also revealed. For instance, 
CX3CR1, which is important for efficient chemotaxis of macrophages to apoptotic 
lymphocytes [253], displayed contrasting trends in the two lines. Various cytokines 
sharing the IL6ST subunit have been found to induce proliferation in cases of 
multiple myeloma [254]. Receptors belonging to the above class showed changes in 
chromatin marks, e.g. IL11RA in line L72 and LEPR, OSMR in line L63. Previous 
reports have also indicated the involvement of the pro-inflammatory cytokine induced 
gene IRG1 in MD susceptibility. This gene is preferentially upregulated in susceptible 
chickens [162] and involved in inflammatory response via the action of MYD88 
which displayed increased promoter H3K4me3 (and mRNA levels) in the susceptible 
line at 5 dpi. MYD88 is an essential regulator of immunity to invading microbes, 
particularly the activation of T cell responses [255] and, thus, could be an interesting 
candidate for further study. Moreover, the increase of both H3K4me3 and H3K27me3 
in line L72 on RASA1 and MEF2C suggest their involvement in MD-susceptibility. 
The let-7 family of miRNAs have diverse physiological roles and its deregulation has 
been associated with many human cancers [241]. Several members of this family 




(except gga-let-7i), which suggested possible epigenetic silencing in response to 
MDV infection. Oncomir gga-mir-21, which has also been associated with several 
cancers [240, 256, 257], displayed H3K4me3 variations in the susceptible line 
(decrease at 5 dpi and increase at 10 dpi). Also, H3K27me3 appeared to target certain 
immune-related miRNAs, e.g. gga-mir-10b and gga-mir-124a-2, only in the resistant 
line suggesting their involvement in MD-resistance. Previous studies of miRNA 
expression profiles conducted in our lab [238] suggested large scale down-regulation 
of host miRNAs during late cytolytic MD (spleen, 21 dpi) in susceptible chickens. 
Our results indicate a different scenario at the early stages of MD which further 
underlines the importance of temporal analyses to uncover a truer picture of 
transcriptional regulation. 
Conclusions 
In summary, we conducted a comprehensive analysis of the temporal chromatin 
landscape induced by MDV in two inbred chicken lines with contrasting responses to 
the disease. We investigated the variations in chromatin marks in response to virus 
infection to uncover biological pathways possibly under epigenetic control. In doing 
so, we eschewed a traditional threshold-based analysis, instead utilizing the entire 
gene set and unsupervised clustering to find groups of promoters that displayed 
similar patterns of chromatin. Our approach revealed several interesting pathways 
with large proportions of genes displaying variations in chromatin, such as 
neuroactive ligand-receptor interaction and apoptosis. Epigenetic variations suggested 
a heightened inflammatory response during lytic MD in the susceptible line while 




line. At the latent stage of infection, the resistant line demonstrated widespread 
reduction in promoter H3K4me3 suggesting epigenetic silencing. Our observations 
with regard to certain MD-related genes were largely in agreement with previous 
reports. In addition, we uncovered several novel genes and miRNAs that undergo 











5. Conclusions and Future Directions 
The long-term objective of our laboratory is to understand the epigenetics of MD, the 
complex disease of poultry, and the mechanisms of MD-resistance and susceptibility. 
Our chosen model to achieve this goal is a population of inbred chicken lines 63 and 
72 from ADOL, MI that are naturally either highly MD-resistant or highly MD-
susceptible. In keeping with this, the focus of my graduate research has been two-
fold: the development of novel methods for analyzing genome-wide epigenetic data, 
e.g. histone modifications, and the application of these and other methods to the data 
generated from the above chicken population. The works presented here constitute 
novel contributions in both these areas. 
We developed WaveSeq, a novel algorithm for peak-detection in ChIP-Seq data that 
is accurate, sensitive and robust to diverse enrichment patterns. Our approach is 
unique as we do not make any restrictive (and erroneous) assumptions about the data 
distribution, which is a feature of virtually all existing tools primarily for the purposes 
of computational efficiency. The accuracy of our method relies on the discriminative 
power of wavelets for pattern recognition. We employed Monte Carlo sampling 
techniques to estimate the distribution of wavelet coefficients, effectively 
constraining the wavelet space for pattern detection. Finally, we assign significance 
scores to predicted peaks by utilizing a novel permutation procedure. WaveSeq 
performed favorably in comparison with existing methods, particularly for diffuse 




of the scientific community and we are working towards a full release on the R 
platform free for public use. 
In conjunction with the development of WaveSeq, we embarked on our study of the 
histone modification landscape in our chosen animal model. Our work in spleen and 
thymus tissues of MD-resistant and susceptible chickens resulted in the first 
publications related to chromatin marks in poultry [219, 226]. Due to the novelty of 
our approach, these studies have a strong exploratory element. In our investigations of 
latent MD in thymus, we employed ChIP-Seq to profile H3K4me3 and H3K27me3 in 
matched infected and control birds from lines 63 and 72. Several genes previously 
implicated in MD progression, e.g. MX1 and CTLA-4, and others associated with 
various cancers, such as, IGF2BP1 and GAL, exhibited line-specific or condition-
specific enrichments. Moreover, bivalent chromatin domains, thought to be 
predominantly associated with developmental genes, were observed on several genes. 
Three of these genes were p53-associated transcription factors, EGR1, BCL6 and 
CITED2, and associated chromatin signatures showed identical responses to MDV 
infection. Thus, we demonstrated that MDV induces large-scale variations in 
chromatin marks, with differential effects in resistant and susceptible chickens. 
The next step in our journey was the extension of our efforts to the temporal 
evolution of chromatin marks in response to MDV infection. We conducted this 
experiment only 12 months after our initial studies and even within this short interval, 
Illumina sequencers had improved by several orders of magnitude making it possible 
to include multiplexing in our protocol. As a result, we were able to generate a much 




biological replicates in our experimental design. As histone modifications are 
context-specific, we reasoned that changes in chromatin enrichment are evidence of 
epigenetic regulation. Following this intuition, we analyzed promoter regions of 
annotated genes and miRNAs for differential H3K4me3 and H3K27me3 enrichments. 
The results of this analysis were quantified using a measure we termed ‘diffscore’, 
which we subjected to hierarchical clustering for evidence of coregulation. Functional 
analysis of clustered promoters revealed several interesting features: during early 
cytolytic MD, the susceptible line showed evidence of greater DNA damage and 
inflammation (possibly via NK-B signaling), while resistant chickens appeared to 
have higher apoptosis rates and recuperative symptoms (downstream p53 targets). At 
the latent stage, line L63 displayed marked repressive changes on the neuroactive 
ligand-receptor interaction pathway. Several immune-related miRNAs, e.g. multiple 
members of the let-7 miRNA family, showed reduced H3K4me3 at 10 dpi in line 63, 
while others, such as, gga-mir-21 and gga-mir-155 displayed similar trends in the 
susceptible line at the earlier time-point. In addition, various MD-associated genes, 
e.g. IL6, GZMA and IL1B, displayed repressive changes in the susceptible line after 
infection, consistent with reported trends. Thus, this extensive study gave us further 
insights into the epigenetic effects of MD, although further work is necessary to 
confirm some of these findings. 
In many of our studies, we adopted the commonly-used approach of assigning 
functional significance to chromatin marks by annotating putative enrichments with 
adjacent genes. Whilst analysis of such gene lists for functional enrichment can well 




there are additional factors that determine the biological outcome. For instance, 
assaying a representative set of histone modifications is a valid approach to 
investigate the chromatin landscape. However, the transience of a majority of histone 
marks suggests that such a view is nothing more than a snapshot of a dynamic system 
under a specific set of conditions and definitive predictions based on such a fleeting 
picture is fraught with the possibility of error. Therefore, extensive temporal analyses 
are necessary as the maturation of NGS technology makes such experimental designs 
more accessible. However, the validation of ChIP-Seq findings remains difficult and 
time-consuming, with causal relationships nearly impossible to prove.  
The discovery of numerous histone modifications led to the ‘histone code’ 
hypothesis, which proposed the existence of a system of epigenetic marks that can 
define the functional elements of the genome in a combinatorial and deterministic 
manner. However, over the years this simplistic view has been replaced by the 
understanding that chromatin signatures comprise a nuanced and subtle network, 
which only forms part of the transcriptional regulation machinery. Instead of studying 
each such component in isolation, integrative approaches are necessary, wherein 
multiple sources of information, such as, transcription factor binding, DNA 
methylation, copy number variations and gene expression, are studied together with 
histone modifications. The recent tool, ZINBA [102], attempts to provide a general 
solution to the problem by using a mixture regression approach. However, the 
extensive computational requirements are major limiting factors for such analyses and 




profusion of peak callers there is an urgent need for large-scale benchmarking efforts 






Appendix I. Sequencing results showing the antibody used and read 
numbers for each sample from bursa of Fabricius at 5 days post 
infection. 




H3K4me3 R.ctl 9623392 6284246 65.30178 5483970 56.98583 
(Millipore,  R.inf 5589297 4641859 83.04907 3763076 67.32646 
Cat. #17- 614) S.ctl 8333094 4790077 57.48257 4432040 53.18601 
 S.inf 7298525 5189925 71.10923 4479908 61.38101 
        
                 
           
;               
                         
             
  






Appendix II. RSEG peaks not detected by WaveSeq have low 
average read counts and are possibly false positives. 
Average read counts within RSEG peaks (a, b & c) and peak length distributions (d, e 
& f) in the H3K4me3 (a & d), H3K36me3 (b & e) and H3K27me3 (c & f) data. The 
solid lines correspond to all peaks called by RSEG (All Peaks) and the dashed lines 
represent those peaks that are not detected by WaveSeq (No overlaps). These plots 
show that WaveSeq detects a majority of large RSEG peaks in the H3K27me3 and 
H3K36me3 data. However, most of the H3K4me3 peaks detected by RSEG are very 






Appendix III. List of H3K4me3 DMRs and overlapping genes 
The chromosome, start and end columns refer to the significant DMRs detected by 
WaveSeq. The columns S.inf and S.ctl contain the normalized reads (per million) 
mapped to the DMRs in the infected and control samples of the S group, respectively. 
P-values are calculated by WaveSeq using an exact binomial test and fold change = 
(S.inf+1)/(S.ctl+1). The columns RefSeq_ID and Ensembl_ID contain RefSeq and 
Ensembl genes that overlap the corresponding DMRs. 
Chr Start End RefSeq_ID Ensembl_ID S.inf S.ctl FC p-value FDR 
chr1 9000 20199 CD69 ENSGALG00000009761 119.86 64.03 1.86 5.82E-05 0.009021 
chr1 5832600 5843199 - ENSGALG00000006713 135.05 82.70 1.63 0.000391 0.029701 
chr1 14735200 14746199 - ENSGALG00000008167 186.45 125.47 1.48 0.000645 0.039621 
chr1 15029200 15038799 - - 66.59 32.37 2.03 0.00077 0.043481 
chr1 15388000 15397999 PIK3CG ENSGALG00000008081 220.33 135.15 1.63 7.52E-06 0.002114 
chr1 28607600 28615199 - ENSGALG00000009443 114.25 51.04 2.21 1.04E-06 0.000451 
chr1 32535200 32546799 - ENSGALG00000009665 167.99 111.05 1.51 0.000938 0.048411 
chr1 35649000 35656599 - - 78.21 131.31 0.60 0.000301 0.043824 
chr1 46275800 46287999 - ENSGALG00000019338 214.26 144.84 1.48 0.000255 0.023634 
chr1 48574800 48582599 - ENSGALG00000011516 
ENSGALG00000011531 
67.06 32.84 2.01 0.000562 0.037928 
chr1 52668000 52674199 - ENSGALG00000023146 101.17 53.16 1.89 0.000136 0.0155 
chr1 53366800 53374799 CYTH4 ENSGALG00000012454 
ENSGALG00000012490 
136.22 84.35 1.61 0.000555 0.037928 
chr1 53379200 53385599 RAC2 ENSGALG00000012456 122.90 73.72 1.66 0.000553 0.037928 
chr1 61677000 61684599 - - 99.53 56.00 1.76 0.00049 0.035743 
chr1 63058000 63067799 ADIPOR2 ENSGALG00000013000 134.12 75.85 1.76 5.42E-05 0.008658 
chr1 64218000 64224999 - ENSGALG00000013057 97.90 26.46 3.60 7.97E-11 1.73E-07 
chr1 69309800 69325199 - ENSGALG00000014011 240.66 136.57 1.76 9.05E-08 6.87E-05 
chr1 70414000 70423799 PPFIBP1 ENSGALG00000014106 117.29 61.67 1.89 3.26E-05 0.006499 
chr1 71352400 71360599 - ENSGALG00000014203 87.15 46.78 1.84 0.000477 0.035335 
chr1 75541600 75547199 CCND2 ENSGALG00000017283 91.59 50.56 1.80 0.000699 0.040987 
chr1 78757000 78769599 FOXM1 ENSGALG00000013424 
ENSGALG00000013420 
132.71 82.46 1.60 0.000771 0.043481 
chr1 79043200 79047599 AICDA ENSGALG00000014280 135.05 82.70 1.63 0.000391 0.029701 
chr1 80183600 80188799 - - 144.86 81.52 1.77 3.20E-05 0.006499 
chr1 80320800 80330199 MLF2 ENSGALG00000014468 145.10 92.62 1.56 0.000698 0.040987 
chr1 80674800 80685199 ZYX ENSGALG00000014688 154.91 90.26 1.71 5.02E-05 0.008282 
chr1 81189400 81201199 - - 227.81 142.48 1.59 1.13E-05 0.002901 
chr1 92041400 92056799 - ENSGALG00000015398 373.84 253.53 1.47 1.84E-06 0.000682 
chr1 94886400 94900399 - - 242.76 153.35 1.58 8.77E-06 0.002377 
chr1 95046800 95056999 - - 182.48 121.69 1.50 0.000545 0.037807 
chr1 95259600 95270999 LOC396098 ENSGALG00000015461 369.40 245.26 1.50 6.36E-07 0.000292 
chr1 101540800 101552599 SAMSN1 ENSGALG00000015679 190.42 121.69 1.56 0.000109 0.013225 




chr1 116747800 116754799 - ENSGALG00000016261 103.51 57.18 1.80 0.000344 0.028366 
chr1 119277200 119286199 - - 82.48 43.95 1.86 0.000618 0.039418 
chr1 125765800 125777399 MOSPD2 
FANCB 
ENSGALG00000016569 146.73 83.17 1.76 3.77E-05 0.007225 
chr1 126826000 126835199 TLR7 ENSGALG00000016590 146.50 86.24 1.69 9.88E-05 0.012633 
chr1 129227600 129244599 - ENSGALG00000021892 135.05 85.53 1.57 0.000912 0.047596 
chr1 140524800 140538599 - - 96.96 52.69 1.82 0.000373 0.029344 
chr1 144368400 144377599 TNFSF13B ENSGALG00000016852 166.83 104.20 1.60 0.000194 0.020125 




194.63 121.69 1.59 4.63E-05 0.007893 
chr1 170074000 170090599 - ENSGALG00000016947 371.04 233.21 1.59 2.17E-08 2.73E-05 
chr1 170225000 170237199 - ENSGALG00000016954 227.57 148.62 1.53 5.31E-05 0.008567 
chr1 170986400 170988799 - ENSGALG00000016964 12.29 38.08 0.34 0.000306 0.044243 
chr1 172334400 172345599 LCP1 ENSGALG00000016986 146.73 85.77 1.70 7.22E-05 0.010434 
chr1 172404000 172418999 - ENSGALG00000016988 179.21 101.60 1.76 3.66E-06 0.001156 
chr1 173527200 173532399 - ENSGALG00000019094 50.00 21.74 2.24 0.000767 0.043481 
chr1 173562400 173571599 - ENSGALG00000017008 85.28 45.37 1.86 0.000572 0.038095 
chr1 173671800 173675199 - - 11.81 36.22 0.34 0.000346 0.046853 
chr1 174685200 174694799 CKAP2 ENSGALG00000017025 
ENSGALG00000017026 
116.59 67.10 1.73 0.00036 0.029344 




169.16 97.82 1.72 1.20E-05 0.003024 
chr1 183458400 183467199 PSPC1 ENSGALG00000017142 107.01 63.80 1.67 0.000919 0.047759 
chr1 183588800 183597199 PARP4 ENSGALG00000017146 
ENSGALG00000017148 
125.24 75.85 1.64 0.000499 0.036272 
chr1 183916600 183922399 - - 82.48 43.48 1.88 0.000618 0.039418 
chr1 185429600 185435999 - ENSGALG00000017174 69.16 32.37 2.10 0.000296 0.026037 
chr1 193389200 193400599 - ENSGALG00000017247 178.74 105.15 1.69 1.69E-05 0.003902 
chr10 1013400 1022399 - - 122.67 70.41 1.73 0.000215 0.021151 
chr10 6554200 6560799 - ENSGALG00000003809 115.42 69.23 1.66 0.00086 0.045898 
chr10 13802400 13821199 - - 319.63 195.17 1.63 5.01E-08 4.01E-05 
chr10 14303800 14313599 - ENSGALG00000006505 109.58 63.80 1.71 0.000561 0.037928 
chr10 16315600 16324799 - - 156.08 91.21 1.70 4.24E-05 0.007537 
chr10 16330400 16340199 - ENSGALG00000006949 63.80 123.37 0.52 1.29E-05 0.005 
chr11 1044000 1050999 - ENSGALG00000021442 64.02 30.48 2.07 0.000588 0.038465 
chr11 3337200 3348599 - - 106.54 59.54 1.78 0.000314 0.026814 
chr11 18750000 18760399 COTL1 ENSGALG00000017644 
ENSGALG00000020995 
ENSGALG00000005651 
178.04 99.71 1.78 2.39E-06 0.000865 
chr12 4733000 4745199 VGLL4 ENSGALG00000004937 199.77 137.28 1.45 0.000849 0.04571 
chr12 6958200 6972799 - ENSGALG00000005237 235.99 134.45 1.75 1.63E-07 0.000103 
chr12 7464200 7474199 - ENSGALG00000005385 88.09 44.18 1.97 0.00016 0.017498 
chr12 9208600 9224399 IP6K2 ENSGALG00000005701 360.76 227.30 1.58 4.48E-08 3.78E-05 
chr12 11063800 11071799 CHCHD4 ENSGALG00000006328 
ENSGALG00000006345 
117.53 69.23 1.69 0.000533 0.03747 




chr13 2220200 2234199 MATR3 ENSGALG00000002478 177.57 105.15 1.68 2.14E-05 0.004852 
chr13 3876800 3889799 - ENSGALG00000002080 167.29 101.60 1.64 6.63E-05 0.009773 
chr13 8409200 8425199 CSNK1A1 ENSGALG00000001364 154.68 99.71 1.55 0.000657 0.040051 
chr13 8509000 8515399 - ENSGALG00000001210 54.21 14.89 3.48 1.11E-06 0.000468 
chr13 10681400 10695999 UBLCP1 ENSGALG00000003672 
ENSGALG00000003691 
108.18 60.49 1.78 0.000264 0.023821 
chr13 11470600 11481399 - ENSGALG00000003818 100.94 57.18 1.75 0.00075 0.043081 




57.89 109.35 0.53 6.65E-05 0.015909 
chr13 13655800 13670199 HNRNPH1 ENSGALG00000005955 183.88 103.49 1.77 2.59E-06 0.000895 
chr13 13690400 13701799 - ENSGALG00000005989 192.99 126.65 1.52 0.000255 0.023634 
chr13 17015400 17030599 - - 201.17 126.88 1.58 3.97E-05 0.007269 
chr13 17456800 17463199 IRF1 ENSGALG00000006785 40.66 14.18 2.74 0.000535 0.03747 
chr14 34400 41999 - ENSGALG00000002796 88.79 41.82 2.10 4.27E-05 0.007537 
chr14 820400 829999 PARN ENSGALG00000003091 
ENSGALG00000003111 
104.21 58.36 1.77 0.000375 0.029344 
chr14 2322400 2336999 - - 174.30 113.89 1.53 0.00038 0.029563 
chr14 3478000 3486799 CARD11 ENSGALG00000004398 143.46 82.46 1.73 5.75E-05 0.009018 
chr14 3538000 3546599 SDK1 ENSGALG00000004420 124.54 71.36 1.73 0.000181 0.019029 




122.20 70.18 1.73 0.000215 0.021151 
chr14 6639200 6652599 LCMT1 ENSGALG00000005962 
ENSGALG00000005973 
173.37 116.25 1.49 0.000955 0.048948 
chr14 9155000 9169599 SOCS1 ENSGALG00000007158 148.60 84.83 1.74 3.17E-05 0.006499 
chr15 4994400 5009799 DDX55 ENSGALG00000003298 
ENSGALG00000003314 
104.68 57.65 1.80 0.000263 0.023821 
chr15 5463000 5469199 - ENSGALG00000003863 58.41 26.70 2.14 0.000628 0.039475 
chr15 5752200 5765599 - ENSGALG00000004379 125.00 76.08 1.63 0.000672 0.040492 
chr15 5954600 5963399 - ENSGALG00000004493 
ENSGALG00000004515 
103.04 58.13 1.76 0.000487 0.035682 




101.40 55.76 1.80 0.000287 0.025728 
chr15 6479000 6489399 PTPN11 ENSGALG00000023491 85.52 46.78 1.81 0.000832 0.045331 
chr15 8923800 8933199 - ENSGALG00000006695 169.86 109.64 1.54 0.000384 0.029701 




70.56 35.21 1.98 0.000821 0.045177 
chr17 5462600 5470999 FAM102A ENSGALG00000005074 107.95 61.67 1.74 0.000481 0.035409 
chr18 6990600 7001199 KPNA2 ENSGALG00000003584 108.18 60.72 1.77 0.000264 0.023821 
chr18 10739400 10756399 GRB2 ENSGALG00000008016 175.47 110.82 1.58 0.000141 0.015755 
chr19 1228400 1234199 - - 88.55 45.84 1.91 0.000242 0.022787 
chr19 3094400 3108999 - ENSGALG00000001410 179.44 114.83 1.56 0.000175 0.018648 
chr19 7315200 7323999 MIR21 ENSGALG00000021733 180.61 112.23 1.60 8.24E-05 0.011372 
chr19 8979800 9002399 EVI2A ENSGALG00000005588 320.33 200.13 1.60 1.60E-07 0.000103 
chr19 9776000 9787599 - ENSGALG00000006005 
ENSGALG00000006011 
135.28 84.35 1.60 0.000693 0.040987 




chr2 10329200 10337599 - ENSGALG00000006723 105.84 60.25 1.74 0.000572 0.038095 
chr2 19928000 19939599 RSU1 ENSGALG00000008720 144.86 87.19 1.65 0.000214 0.021151 
chr2 22863400 22871199 - ENSGALG00000009479 60.52 10.87 5.18 8.00E-10 1.22E-06 
chr2 25992400 25999999 - - 75.24 38.75 1.92 0.000641 0.039537 
chr2 26788000 26797199 - ENSGALG00000010777 105.84 58.83 1.79 0.000288 0.025728 
chr2 39805400 39818399 TGFBR2 ENSGALG00000011442 222.67 143.19 1.55 4.18E-05 0.007537 
chr2 41617800 41627999 - ENSGALG00000011574 127.57 77.74 1.63 0.000569 0.038095 
chr2 46427200 46435599 ELMO1 ENSGALG00000012093 149.30 87.90 1.69 6.55E-05 0.009773 
chr2 51290400 51298199 PSMA2 ENSGALG00000019598 
ENSGALG00000012337 
116.36 61.67 1.87 4.32E-05 0.007542 
chr2 51745000 51759599 - - 200.94 138.93 1.44 0.00088 0.046554 
chr2 60674600 60679999 - - 55.14 22.92 2.35 0.000217 0.021151 
chr2 63051600 63064399 RBM24 ENSGALG00000012712 155.14 101.84 1.52 0.000889 0.046703 
chr2 82940600 82957199 IKZF1 ENSGALG00000013086 426.64 264.16 1.61 7.42E-10 1.22E-06 
chr2 91573200 91582599 INVS ENSGALG00000013441 
ENSGALG00000013452 
111.68 62.38 1.78 0.000241 0.022787 
chr2 92042400 92047799 ISG12-2 ENSGALG00000013575 45.56 13.47 3.22 3.01E-05 0.006349 
chr2 92549400 92568199 - ENSGALG00000013628 130.66 213.79 0.61 8.67E-06 0.003529 
chr2 92807000 92817599 - - 83.88 42.06 1.97 0.00031 0.026638 
chr2 98936800 98945399 C2H18orf1 ENSGALG00000013886 118.46 65.21 1.80 0.000109 0.013225 
chr2 109884800 109893599 - - 138.55 86.72 1.59 0.000623 0.039475 
chr2 114789000 114816799 LYN ENSGALG00000018967 401.41 254.71 1.57 1.02E-08 1.40E-05 
chr2 129130000 129140599 NBN ENSGALG00000015912 
ENSGALG00000015913 
84.11 40.40 2.06 9.65E-05 0.012633 
chr2 154012200 154019999 LY6E ENSGALG00000016152 77.34 33.79 2.25 3.30E-05 0.006499 
chr20 6692000 6696799 - ENSGALG00000004859 59.58 15.36 3.70 2.55E-07 0.000155 
chr20 8313200 8319399 - ENSGALG00000005609 52.57 21.50 2.38 0.000371 0.029344 
chr20 8425800 8435999 SLC17A9 ENSGALG00000005711 131.78 81.05 1.62 0.000727 0.042269 
chr20 9705200 9712599 - - 40.89 14.18 2.76 0.000535 0.03747 




253.28 150.04 1.68 3.26E-07 0.000171 
chr20 10800000 10810199 - - 97.20 55.76 1.73 0.000825 0.045191 
chr20 11580000 11588199 - ENSGALG00000007640 133.18 76.79 1.72 9.79E-05 0.012633 
chr20 11977600 11988599 - ENSGALG00000007757 
ENSGALG00000007768 
109.11 63.80 1.70 0.000561 0.037928 
chr20 12030000 12042999 - ENSGALG00000020895 229.91 139.41 1.64 3.14E-06 0.001059 
chr20 12509600 12520999 - - 178.98 111.05 1.61 9.68E-05 0.012633 
chr21 1741400 1750199 SKI ENSGALG00000001229 90.19 45.60 1.96 0.000134 0.015386 
chr21 1906400 1913999 GNB1 ENSGALG00000001334 82.01 43.95 1.85 0.000618 0.039418 
chr21 2677400 2691199 LOC419429 ENSGALG00000002005 252.34 150.04 1.68 4.12E-07 0.000208 
chr21 4799200 4810199 NBL1 ENSGALG00000004043 98.60 47.97 2.03 2.76E-05 0.00589 
chr22 307600 318799 ARHGAP25 ENSGALG00000000132 74.53 36.86 2.00 0.000371 0.029344 





142.76 82.94 1.71 7.37E-05 0.010555 




chr23 99600 108599 - - 130.61 73.01 1.78 7.67E-05 0.010684 
chr23 176000 188999 - ENSGALG00000000519 141.83 84.12 1.68 0.000176 0.018648 
chr23 248400 257799 - ENSGALG00000000562 151.87 80.57 1.87 3.48E-06 0.001147 
chr23 4078800 4085399 - ENSGALG00000002021 236.22 145.55 1.62 3.63E-06 0.001156 
chr23 5896400 5903799 SRSF10 ENSGALG00000004133 74.53 38.75 1.90 0.000861 0.045898 
chr24 4347800 4358599 POU2AF1 ENSGALG00000006809 207.01 124.05 1.66 5.91E-06 0.001759 




235.29 133.03 1.76 1.17E-07 8.09E-05 
chr26 2975200 2983799 - ENSGALG00000001373 93.46 52.22 1.77 0.000833 0.045331 
chr26 3369000 3371199 MOV10 ENSGALG00000023899 6.38 27.10 0.26 0.000324 0.044602 
chr3 2365000 2372799 XPO1 ENSGALG00000004377 128.74 77.97 1.64 0.000451 0.033709 
chr3 7631800 7645199 EHD3 ENSGALG00000009086 141.12 89.79 1.57 0.000736 0.042668 




120.10 72.54 1.65 0.000655 0.040051 
chr3 23135000 23144799 - ENSGALG00000009828 71.03 36.86 1.90 0.000923 0.047825 
chr3 23424800 23439399 TRAF5 ENSGALG00000009864 197.67 129.96 1.52 0.000197 0.020321 
chr3 24231000 24236399 - - 98.83 55.05 1.78 0.000637 0.039537 
chr3 28942600 28952199 - - 150.47 85.77 1.75 2.67E-05 0.00579 
chr3 31412600 31420399 - ENSGALG00000010149 86.92 27.88 3.04 2.34E-08 2.73E-05 
chr3 32338800 32348799 RASGRP3 ENSGALG00000010435 179.44 117.91 1.52 0.000375 0.029344 
chr3 33238000 33247199 EIF2AK2 ENSGALG00000023188 
ENSGALG00000010560 
150.47 54.58 2.73 1.21E-11 3.06E-08 
chr3 34825000 34834799 - ENSGALG00000010612 110.28 63.56 1.72 0.000437 0.03283 
chr3 39374400 39383199 GPR137B ENSGALG00000010843 161.45 102.31 1.57 0.000331 0.027882 
chr3 40011800 40016799 - - 56.08 25.75 2.13 0.000752 0.043081 
chr3 44712200 44724199 - ENSGALG00000020005 133.18 82.70 1.60 0.000616 0.039418 
chr3 47834000 47842799 - - 110.28 49.38 2.21 1.47E-06 0.000558 
chr3 49995400 50006399 - ENSGALG00000012359 91.12 48.67 1.85 0.000333 0.027921 
chr3 58815600 58824999 STX7 ENSGALG00000002930 122.43 71.12 1.71 0.000297 0.026037 
chr3 62261000 62271399 NCOA7 ENSGALG00000014834 136.45 82.94 1.64 0.000311 0.026638 
chr3 62284400 62292599 - - 128.04 73.25 1.74 0.000128 0.014869 
chr3 66395400 66404799 - ENSGALG00000014937 
ENSGALG00000014940 
99.30 57.42 1.72 0.000966 0.049211 
chr3 66447400 66454199 - - 44.16 13.94 3.02 4.71E-05 0.007944 
chr3 66455000 66465999 FAM26E ENSGALG00000014961 190.42 106.56 1.78 1.20E-06 0.000493 
chr3 77930400 77938399 - - 77.57 40.64 1.89 0.0008 0.044674 
chr3 85865600 85873199 LMBRD1 ENSGALG00000016174 107.01 62.38 1.70 0.000668 0.040379 
chr3 97873800 97877799 - ENSGALG00000016398 33.41 10.87 2.90 0.000606 0.039317 
chr3 97880800 97884199 - ENSGALG00000016400 21.26 4.25 4.24 0.000911 0.047596 
chr3 100739400 100749599 TRIB2 ENSGALG00000016457 146.26 84.59 1.72 5.23E-05 0.008543 
chr3 110034800 110045999 - - 153.98 91.68 1.67 8.69E-05 0.011881 
chr4 1435200 1443199 GPR174 ENSGALG00000004111 87.85 47.02 1.85 0.000695 0.040987 




chr4 11303800 11313399 - ENSGALG00000007482 61.92 29.30 2.08 0.000973 0.049383 




159.82 101.37 1.57 0.000388 0.029701 
chr4 18848000 18856399 - ENSGALG00000009177 87.39 47.73 1.81 0.000695 0.040987 
chr4 21107600 21114799 TLR2-2 ENSGALG00000009239 148.83 82.46 1.80 1.61E-05 0.003902 
chr4 33107000 33118799 - ENSGALG00000010022 
ENSGALG00000010031 
102.10 56.00 1.81 0.000219 0.021151 
chr4 36092800 36102799 - ENSGALG00000010324 99.53 54.82 1.80 0.000343 0.028366 
chr4 36171000 36181399 - ENSGALG00000020220 72.67 21.50 3.27 1.04E-07 7.51E-05 
chr4 47665200 47674599 - - 205.14 133.03 1.54 0.000106 0.013225 





100.70 57.89 1.73 0.00075 0.043081 
chr4 56545800 56554399 METTL14 ENSGALG00000012000 153.74 98.53 1.55 0.000625 0.039475 
chr4 58662600 58671799 - ENSGALG00000012048 
ENSGALG00000012063 
110.52 60.25 1.82 0.000155 0.017164 
chr4 61723000 61732799 DAPP1 ENSGALG00000000056 88.32 48.44 1.81 0.000763 0.043481 
chr4 64244000 64254399 - - 160.98 100.66 1.59 0.000239 0.022787 
chr4 70911800 70930799 - - 299.31 187.61 1.59 4.27E-07 0.000209 
chr4 71445000 71450999 - - 167.53 96.40 1.73 1.42E-05 0.003527 
chr4 85898200 85907199 - ENSGALG00000015690 208.18 133.50 1.56 5.76E-05 0.009018 
chr4 86948600 86959599 SLBP ENSGALG00000015712 105.14 39.22 2.64 3.53E-08 3.15E-05 
chr4 86991000 87006399 FAM53A ENSGALG00000015713 283.88 181.70 1.56 2.52E-06 0.000888 
chr4 88807800 88817199 KDM3A ENSGALG00000015803 123.83 71.59 1.72 0.000232 0.022266 




98.13 55.05 1.77 0.000637 0.039537 
chr5 11410200 11415799 - - 114.25 68.76 1.65 0.000804 0.044699 
chr5 14740200 14749599 CD81 ENSGALG00000006546 162.15 107.27 1.51 0.000958 0.048954 
chr5 15723400 15732999 BRSK2 ENSGALG00000006681 125.24 69.23 1.80 7.06E-05 0.010304 
chr5 16703800 16711799 - ENSGALG00000006841 91.12 45.37 1.99 9.90E-05 0.012633 
chr5 20523600 20535799 CD44 ENSGALG00000007849 256.55 164.93 1.55 8.31E-06 0.002293 
chr5 25090200 25099999 SPI1 ENSGALG00000008127 205.61 141.53 1.45 0.000685 0.040931 
chr5 27791600 27798999 GANC ENSGALG00000009018 
ENSGALG00000009036 
116.36 67.10 1.72 0.00036 0.029344 
chr5 30238600 30247399 - - 169.40 98.29 1.72 1.65E-05 0.003902 
chr5 36498000 36504599 G2E3  99.77 51.75 1.91 0.00011 0.013225 
chr5 45570200 45582199 ZC3H14 ENSGALG00000010616 
ENSGALG00000010622 
117.99 66.16 1.77 0.000201 0.020456 
chr5 47503200 47513199 LOC423422 ENSGALG00000017387 126.87 76.08 1.66 0.000533 0.03747 
chr5 48531200 48542199 GLRX5 ENSGALG00000011079 93.93 51.98 1.79 0.000585 0.038465 
chr5 50600600 50606999 - ENSGALG00000011139 103.74 60.72 1.70 0.000944 0.048588 
chr5 50899400 50908799 EVL ENSGALG00000011209 133.88 83.41 1.60 0.000816 0.045177 
chr5 52993200 53001999 XRCC3 ENSGALG00000011533 
ENSGALG00000011534 
103.51 55.29 1.86 0.000166 0.018016 





chr6 5447400 5459999 - ENSGALG00000002414 
ENSGALG00000024347 
123.37 73.25 1.68 0.000436 0.03283 
chr6 11716200 11725799 DNA2 ENSGALG00000004037 149.30 95.46 1.56 0.000661 0.040118 
chr6 16445600 16453799 - - 109.11 64.74 1.67 0.000774 0.043491 
chr6 17827200 17845399 PIK3AP1 ENSGALG00000005547 361.69 235.57 1.53 2.77E-07 0.000162 
chr6 19510800 19527199 - - 241.36 162.56 1.48 9.74E-05 0.012633 
chr6 19856200 19867999 - ENSGALG00000006254 185.28 106.56 1.73 4.24E-06 0.001314 
chr6 20438400 20448799 - ENSGALG00000006384 96.73 19.38 4.80 1.45E-13 4.39E-10 
chr6 22375200 22386999 BLNK ENSGALG00000006973 250.71 162.80 1.54 1.70E-05 0.003902 
chr6 24225200 24236599 - ENSGALG00000007753 180.84 121.45 1.49 0.000801 0.044674 
chr6 24987600 24994799 - - 49.62 93.46 0.54 0.000278 0.041705 
chr6 25713000 25725799 - - 176.41 108.22 1.62 6.51E-05 0.009773 
chr6 28162800 28172799 ACSL5 ENSGALG00000008840 96.26 52.22 1.83 0.000373 0.029344 




143.69 86.24 1.66 0.000201 0.020456 
chr6 29163800 29176399 - ENSGALG00000008971 117.76 68.52 1.71 0.000389 0.029701 
chr7 4553400 4566599 UBE2F ENSGALG00000003812 96.26 53.64 1.78 0.000536 0.03747 
chr7 7149800 7156399 ITGB2 ENSGALG00000007511 125.00 71.59 1.74 0.00014 0.015755 
chr7 8893600 8903599 STAT1 ENSGALG00000007651 107.95 40.88 2.60 3.04E-08 2.88E-05 
chr7 12449200 12466199 CFLAR ENSGALG00000008239 
ENSGALG00000008240 
197.90 126.18 1.56 9.25E-05 0.012429 
chr7 12500800 12511999 CASP8 ENSGALG00000008355 184.12 116.72 1.57 0.000103 0.012915 
chr7 15658000 15667999 UBE2E3 ENSGALG00000020793 211.92 145.31 1.46 0.000553 0.037928 
chr7 18007200 18018999 - - 78.74 41.59 1.87 0.000888 0.046703 
chr7 22601800 22610999 IFIH1 ENSGALG00000011089 96.26 19.38 4.77 1.45E-13 4.39E-10 
chr7 29843600 29847599 - ENSGALG00000012072 38.55 9.69 3.70 2.49E-05 0.005479 
chr7 32372600 32382799 - - 125.24 74.67 1.67 0.000368 0.029344 
chr7 34326800 34344399 ARHGAP15 ENSGALG00000012421 245.80 154.53 1.59 6.06E-06 0.00177 
chr8 1933800 1944399 - - 182.01 114.36 1.59 9.22E-05 0.012429 
chr8 2083400 2096399 PTPRC ENSGALG00000002192 214.96 141.06 1.52 0.000126 0.01485 
chr8 3630200 3648599 - - 198.60 123.58 1.60 3.36E-05 0.006531 
chr8 4002200 4014599 - ENSGALG00000021112 117.06 70.88 1.64 0.000726 0.042269 
chr8 6853200 6863599 - - 134.82 81.75 1.64 0.000367 0.029344 
chr8 7374200 7384599 - - 118.69 67.34 1.75 0.000218 0.021151 
chr8 8331000 8338999 FAM129A ENSGALG00000004812 102.81 58.83 1.73 0.000629 0.039475 
chr8 10178800 10187799 C8H1orf27 ENSGALG00000005080 
ENSGALG00000005105 
88.32 47.73 1.83 0.000527 0.03747 
chr8 15813800 15822599 - - 145.56 89.31 1.62 0.000305 0.026604 
chr8 25134000 25143599 ORC1 ENSGALG00000010623 
ENSGALG00000010627 
169.86 103.49 1.64 7.52E-05 0.010671 
chr8 25179000 25195199 GPX7 ENSGALG00000010629 
ENSGALG00000010633 
119.63 52.22 2.27 3.21E-07 0.000171 
chr9 3527800 3547399 KLHL6 ENSGALG00000002263 316.36 216.67 1.46 1.68E-05 0.003902 




chr9 11264000 11273399 - - 209.35 137.75 1.52 0.000128 0.014869 
chr9 25418800 25425399 - - 64.25 30.48 2.07 0.000588 0.038465 
chrZ 861200 868399 ACAA2 ENSGALG00000002793 
ENSGALG00000002777 
60.98 27.88 2.15 0.000524 0.03747 






96.03 46.55 2.04 3.29E-05 0.006499 
chrZ 1553800 1565799 PIAS2 ENSGALG00000001851 
ENSGALG00000001843 
84.58 39.93 2.09 6.10E-05 0.009352 
chrZ 8422800 8427599 CD72 ENSGALG00000021353 94.63 41.59 2.25 5.87E-06 0.001759 
chrZ 8786200 8794999 - - 172.43 74.67 2.29 3.67E-10 6.97E-07 
chrZ 9086200 9092599 - - 111.68 61.91 1.79 0.00017 0.018263 
chrZ 9915000 9927399 BRIX1 ENSGALG00000003365 
ENSGALG00000003373 
ENSGALG00000003387 
110.98 49.38 2.22 1.47E-06 0.000558 




68.93 30.01 2.26 0.000156 0.017176 
chrZ 10932400 10940199 WDR70 ENSGALG00000003688 
ENSGALG00000003708 
54.67 23.63 2.26 0.000539 0.037514 
chrZ 13075800 13081399 HMGCS1 ENSGALG00000014862 78.27 34.02 2.26 3.91E-05 0.007239 
chrZ 17652400 17658399 - ENSGALG00000014727 52.57 20.56 2.49 0.000208 0.02088 
chrZ 19978000 19985599 CENPK ENSGALG00000014753 
ENSGALG00000014756 
73.13 34.73 2.07 0.000206 0.02088 
chrZ 20015000 20023799 CZH5orf44 ENSGALG00000014765 
ENSGALG00000014767 
ENSGALG00000020567 
75.47 38.99 1.91 0.000641 0.039537 
chrZ 21011200 21014199 - - 99.53 49.86 1.98 4.83E-05 0.008055 
chrZ 22870600 22882999 F2RL1 ENSGALG00000014984 137.85 66.16 2.07 6.98E-07 0.000312 
chrZ 23296000 23302799 - - 71.50 35.92 1.96 0.000606 0.039317 
chrZ 25974000 25977999 - - 60.75 28.35 2.10 0.000846 0.04571 
chrZ 26494000 26500999 CBWD1 ENSGALG00000010147 60.98 28.35 2.11 0.000846 0.04571 
chrZ 26522600 26529799 - ENSGALG00000010156 104.68 52.93 1.96 3.81E-05 0.007225 
chrZ 27926200 27956199 - ENSGALG00000023324 18.22 106.56 0.18 2.31E-16 1.17E-12 
chrZ 27952200 27956199 - - 10.05 89.08 0.12 5.52E-17 4.19E-13 
chrZ 27962800 27966999 - ENSGALG00000018479 21.03 3.74 4.65 0.000277 0.041705 
chrZ 27968600 27973199 - ENSGALG00000018479 38.75 5.61 6.02 2.50E-07 0.000252 
chrZ 33393000 33402199 PLIN2 ENSGALG00000015090 80.38 38.51 2.06 0.000138 0.015659 
chrZ 37218800 37226199 - - 101.87 47.73 2.11 1.07E-05 0.002796 
chrZ 37696800 37702599 - - 42.99 16.30 2.54 0.000862 0.045898 
chrZ 40796200 40807199 DAPK1 ENSGALG00000012608 173.84 84.35 2.05 2.97E-08 2.88E-05 
chrZ 41465800 41473399 - ENSGALG00000012621 75.00 34.73 2.13 0.000107 0.013225 
chrZ 41665200 41674599 - - 65.89 29.06 2.22 0.000262 0.023821 
chrZ 42824600 42836199 - ENSGALG00000010693 
ENSGALG00000010694 
171.03 92.15 1.85 1.27E-06 0.000507 




chrZ 44067800 44077599 - ENSGALG00000017686 125.47 56.94 2.18 3.14E-07 0.000171 
chrZ 44165800 44173999 HINT1 ENSGALG00000000428 93.46 47.73 1.94 0.000126 0.01485 
chrZ 45132000 45138399 - - 69.39 31.90 2.14 0.000183 0.019172 
chrZ 45245400 45250399 - - 60.75 26.94 2.21 0.000317 0.026881 
chrZ 55077800 55084199 LMNB1 ENSGALG00000014692 48.60 19.38 2.43 0.000522 0.03747 
chrZ 56311400 56320199 ARSK ENSGALG00000014672 
ENSGALG00000014670 
78.27 34.50 2.23 3.91E-05 0.007239 
chrZ 58562000 58569599 - ENSGALG00000014648 55.38 21.74 2.48 0.000121 0.014418 
chrZ 59123800 59137999 - ENSGALG00000014645 419.40 204.86 2.04 4.69E-18 7.12E-14 
chrZ 61615400 61623199 TMEM167A ENSGALG00000015619 57.95 26.70 2.13 0.000878 0.046554 
chrZ 62751200 62760399 - ENSGALG00000015576 64.49 30.48 2.08 0.000588 0.038465 




69.86 29.06 2.36 6.57E-05 0.009773 
chrZ 65032800 65037799 SMC2 
PTGR1 
ENSGALG00000015691 118.93 61.20 1.93 2.45E-05 0.005477 
chrZ 66784000 66792199 - ENSGALG00000001765 69.86 33.55 2.05 0.000469 0.034867 
chrZ 67021800 67029999 - ENSGALG00000001864 68.23 31.43 2.13 0.000255 0.023634 
chrZ 69690600 69699599 - - 83.18 42.53 1.93 0.00031 0.026638 
chrZ 69701800 69704199 - - 6.38 32.24 0.22 2.43E-05 0.00824 
chrZ 72281400 72288199 - ENSGALG00000008204 114.02 55.05 2.05 6.64E-06 0.001901 
chrZ 73532600 73536399 - ENSGALG00000005316 70.56 35.21 1.98 0.000821 0.045177 





Appendix IV. Sequencing results showing raw and mapped reads for 
from thymus samples. 
Chicken 
Line 






63 Infected 13188253 10008826 75.892 4559032 0.455501175 
 Control 11901057 10019594 84.1908 5615896 0.560491373 
72 Infected  10716016 7417387 69.2178 2850746 0.384332919 
 Control 6046819 4520471 74.7578 2365956 0.523387054 
63 Infected  12496897 10152490 81.2401 7523315 0.74103151 
 Control 9010579 7471261 82.9165 6836444 0.915032148 
72 Infected  8754256 7082681 80.9056 5933170 0.837701147 
 Control 7838478 5921978 75.5501 3603345 0.608469839 
        
                 
           
;               
                         






Appendix V. Primers used for quantitative PCR validation. 
Genes Purpose Primers Sequence 
CTLA-4 Gene expression F 5’- TCAAACAGACAGGCGACAAG-3’ 
  R 5’- GGGCTAACATGGCACTGAAT-3’ 
BCL6 Gene expression F 5’- ATCCAGTTCACCCGCCACGC-3’ 
  R 5’- AGAGGCCACTGCAGGCCATCA-3’ 
CITED2 Gene expression F 5’- CACGTCAGCCCGGGAGAGGA-3’ 
  R 5’- TTCCGCCATCTCCCACCTCCC-3’ 
EGR1 Gene expression F 5’- AGCACCTTGCGGCAGACACTT-3’ 
  R 5’- GGAGAAGCGCCCCGTGTAGG-3’ 
TLR3 Gene expression F 5’- CCATGGTGCAGGAAGTTTAAGGTGC-3’ 
  R 5’- CTGGCCAGTTCAAGATGCAGCA-3’ 
MX1 Gene expression F 5’- TGGAGGAGCCAGCTGTTGCG-3’ 
  R 5’- ATTCTGGCCTGAGCAGCGTTGT-3’ 
MMP2 Gene expression F 5’- GCTTTCTGCTTAGGCATTGG-3’ 
  R 5’- GCATTGGCATTTCATGTTTG-3’ 
IGF2BP1 Gene expression F 5’- GCGTGACTCCGGCCGACTTG-3’ 
  R 5’- TGCAGCTCCACTTTCCCCGAA-3’ 
TNFSF1A Gene expression F 5’- CTGCGTCGCTGGCTTCTCTCC-3’ 
  R 5’- GTTAGGATAACCGTCCCCAGCGA-3’ 
GAL Gene expression F 5’- GCTCCCTGCGAGACACCGTT-3’ 
  R 5’- GGTTATCTACTGCATGTGGCCCAAG-3’ 
EAF2 Gene expression F 5’- GCGGGCCATGGTGTGAGGTG-3’ 
  R 5’- AGTCATAGCGCACGGTGTGGAA-3’ 
HAPLN1 Gene expression F 5’- GCGCATCTCGACTTGGGAGCT-3’ 
  R 5’- GGCGGGGTCCATTTTCTTCTTGGA-3’ 
CD4 Gene expression F 5’- TGTCAACGCCGGATGTATAA -3’ 
  R 5’- CTTGTCCATTGGCTCCTCTC -3’ 
GAPDH Gene expression F 5’-GAGGGTAGTGAAGGCTGCTG-3’ 
  R 5’-ACCAGGAAACAAGCTTGACG-3’ 
GAPDH-
ChIP 
ChIP validation F 5’-GTCACGTCCCAGGAGCAG-3’ 
  R 5’-AGGACCGTGCTAATGAGGAA-3’ 
MyoD-ChIP ChIP validation F 5’-TTGGTGGAGATCATGCCATA-3’ 




  R 5’-GGACCTGTACTCGCAAGCTC-3’ 





Appendix VI. Probability densities of peak length distributions in 
different classes of SERs.  
Line-specific and condition-specific SERs predominantly correspond to low 
enrichment regions for both H3K4me3 (a-d) and H3K27me3 (e-h).  







Appendix VII. Relationship between gene expression and histone 
marks in line 63 control samples.  
Plots of histone modifications around the gene body (a & b) in genes having high 
(blue), medium (red), low (green) and no activity (brown). We also compared 
epigenetic marks with transcriptional levels: H3K4me3 shows positive correlation 






Appendix VIII. Relationship between gene expression and histone 
marks in line 72 control samples.  
Plots of histone modifications around the gene body (a & b) in genes having high 
(blue), medium (red), low (green) and no activity (brown). We also compared 
epigenetic marks with transcriptional levels: H3K4me3 shows positive correlation 






Appendix IX. Relationship between gene expression and histone 
marks in line 72 infected samples.  
Plots of histone modifications around the gene body (a & b) in genes having high 
(blue), medium (red), low (green) and no activity (brown). We also compared 
epigenetic marks with transcriptional levels: H3K4me3 shows positive correlation 






Appendix X. Differential H3K4me3 marks.  
Genome-wide differential H3K4me3 marks produced by DESeq (FDR < 0.4) and 
associated genes. P-values from three contrasts are displayed as follows: 63: 63I vs 
63N, 72: 72I vs 72N, 63v72N: 63N vs 72N.  
 
SER Samples 63 63v72N 72 Genes 
chr1:51052800-51055599 72 0.716728 0.667995 3.82E-06 ENSGALG00000019325 
chr1:170985000-170989599 72 0.002904 0.306603 4.55E-06 ENSGALG00000016964 
chr1:53428200-53431799 72 0.052888 0.30538 0.000259 ENSGALG00000012472 
chr5:25094000-25097799 72 0.449986 0.005768 0.000298 SPI1 
chr7:14495200-14497999 72 0.170978 0.209627 0.000303 CTLA4 
chr2:37739800-37741599 72 0.570832 0.021549 0.000589 ENSGALG00000011298 
chr1:133186800-133192199 72 0.180816 0.034588 0.000633 P2RY8 
chr20:6692200-6696799 72 0.012873 0.337854 0.000765 ENSGALG00000004859 
chr6:20438000-20445599 72 0.000887 0.407654 0.000803 ENSGALG00000006384 
chr1:112367400-112371799 63,72 1.28E-07 0.415314 4.26E-09 MX1 
chrZ:27968600-27972599 63,72 3.41E-06 0.220991 1.41E-05 ENSGALG00000018479 
chrZ:27964800-27967199 63,72 7.99E-05 0.982308 1.99E-06 ENSGALG00000018479 
chr2:92042800-92046599 63,72 0.000149 0.469067 5.88E-05 ISG12-2 
chr2:22865400-22868199 63,72 0.000232 0.015605 6.48E-09 ENSGALG00000009479 
chr8:17511400-17515199 63v72N 0.479617 1.59E-15 0.664428 ENSGALG00000008854 
chr27:3433400-3435399 63v72N 0.770916 4.21E-13 0.854824 IGF2BP1 
chr19:8963800-8966399 63v72N 1 3.22E-12 0.757603 ENSGALG00000005578 
chr20:8475000-8478399 63v72N 0.609497 5.00E-08 0.551674 BHLHB4 
chr2:42132800-42135999 63v72N 0.885306 5.45E-08 0.11767 ENSGALG00000011613 
chr2:125007000-125012399 63v72N 0.606371 1.12E-06 0.653623 ENSGALG00000015732 
chr17:2454000-2459199 63v72N 0.257894 2.32E-06 0.969863 ENSGALG00000008472 
chr15:11138400-11145599 63v72N 0.348842 3.37E-06 0.669509 ENSGALG00000007891 
chr1:34419600-34421399 63v72N 0.326263 7.36E-06 0.0056 NM_205429 
chr5:9146600-9149999 63v72N 0.574535 8.79E-06 1 ENSGALG00000005569 
chr9:24010000-24011399 63v72N 0.691296 1.19E-05 1 ENSGALG00000009651 
chr18:2129800-2131199 63v72N 0.065392 1.84E-05 0.782984 ENSGALG00000001261 
chr1:58694400-58697399 63v72N 0.86674 2.08E-05 1 ENSGALG00000012842 
chr6:20700600-20706799 63v72N 0.98773 3.56E-05 0.542148 ENSGALG00000006478 
chr1:16635600-16638799 63v72N 0.34467 7.53E-05 0.967558 ENSGALG00000007025 
chr4:88993400-88995799 63v72N 0.450676 0.000352 0.616238 RHACD8-4 
chr2:31255200-31257599 63v72N 0.754165 0.00045 0.501096 ENSGALG00000010977 
chr3:78289800-78291599 63v72N 0.400008 0.000464 0.868325 ENSGALG00000015768 
chr4:89068600-89071199 63v72N 0.536311 0.000498 0.198913 ENSGALG00000015900 
chr16:254000-260599 63v72N 0.167746 0.000532 0.727697 ENSGALG00000024350 
chr28:2385800-2387599 63v72N 0.056255 0.000752 0.475928 HMHA1 




chr5:21118200-21127599 63v72N 0.442807 0.000858 0.974084 ENSGALG00000007920 
chr4:35196200-35199399 63v72N 0.668563 0.00089 0.08687 ENSGALG00000010119 
chr1:86640200-86646399 63v72N 0.702909 0.001168 0.47306 ENSGALG00000015152 
chr1:73596000-73597999 63v72N 0.292515 0.001353 0.354935 ENSGALG00000009702 
chr1:493800-497599 63v72N 0.828115 0.001482 0.011776 ENSGALG00000013772 
chr3:91008600-91012999 63v72N 0.914485 0.001541 0.222185 ENSGALG00000016313 
chr28:950600-953199 63v72N 0.065569 0.001577 0.216139 LOC429451 
chr11:3713800-3717199 63v72N 0.937602 0.001624 0.144532 MMP2 
chr9:6356600-6361199 63v72N 0.286756 0.001771 0.380294 ENSGALG00000024277 
chr11:18834600-18838599 63v72N 0.236689 0.001905 0.69083 ENSGALG00000021839 
chr5:9901200-9904599 63v72N 0.285583 0.001913 0.59137 ENSGALG00000005662 
chr24:5576000-5580199 63v72N 0.410471 0.00203 0.210206 ENSGALG00000024072 
chr3:8004400-8011999 63v72N 0.245685 0.002035 0.364679 LBH 
chr7:11293600-11296999 63v72N 0.899936 0.002137 0.02535 ENSGALG00000008118 
chr5:60369200-60372999 63v72N 0.56105 0.002249 0.180948 ENSGALG00000012295 
chr9:18230200-18232799 63v72N 0.203495 0.002359 0.183201 ENSGALG00000008852 
chr16:287400-289799 63v72N 0.101651 0.002374 0.836484 YFV 
chr6:20271600-20273799 63v72N 0.601004 0.002532 0.389374 ENSGALG00000006315 
chr1:80088400-80090199 63v72N 0.036097 0.002575 0.50626 GAPDH 
chr17:2197800-2203399 63v72N 0.203224 0.003068 0.72636 ENSGALG00000008623 
chr11:540400-541799 63v72N 0.446134 0.003207 0.041007 ENSGALG00000001149 
chr6:21718400-21721199 63v72N 0.5093 0.003402 0.723345 CYP26A1 
chr1:80531600-80534199 63v72N 0.112136 0.003602 0.417485 ENSGALG00000014570 
chr27:4011000-4012599 63v72N 0.027087 0.003641 0.880761 RPL19 





Appendix XI. Differential H3K27me3 marks.  
Genome-wide differential H3K27me3 marks produced by DESeq (FDR < 0.4) and 
the associated genes. P-values from three contrasts are displayed as follows: 63: 63I 
vs 63N, 72: 72I vs 72N, 63v72N: 63N vs 72N.  
 
SER Samples 63 63v72N 72 Genes 
chrZ:61242600-61246599 63 0.000433 0.020859 0.950978 HAPLN1 
chr1:200341000-200346199 63v72N 0.005362 8.03E-06 0.004025 PLEKHB1 
chr20:13944200-13946199 63v72N 0.011424 0.000339 0.07724 ENSGALG00000021818 
chr6:3937800-3940599 63v72N 0.086992 0.000453 0.024937 CHAT 
chr1:56375000-56377399 63v72N 0.303852 0.000477 0.000864 SLC41A2 
chr4:68468600-68471999 63v72N 0.316764 0.000736 0.015472 CNGA1 
chr2:105030600-105041199 63v72N 0.005641 0.001004 0.599687 YES1 
chr5:53554000-53556399 63v72N 0.141409 0.001085 0.705233 LOC396507 
chrZ:14565400-14567599 63v72N 0.455076 0.001942 0.127439 ISL1 
chr9:22131400-22134199 63v72N 0.062622 0.001942 0.013793 SERPINI1 
chrZ:53399000-53401399 63v72N 0.453352 0.002075 0.039701 LPL 
chr3:83227600-83228999 63v72N 0.298938 0.002459 0.054133 MYO6 
chr4:61633000-61634799 63v72N 0.136925 0.002736 0.016587 MTTP 
chr15:1026600-1029599 63v72N 0.062622 0.002745 0.173465 TXNRD2 
chr17:10782800-10784999 63v72N 0.015864 0.00291 0.604932 LMX1B 
chr1:34734400-34739999 63v72N 0.170909 0.003188 0.049861 USP15 
chr2:142382800-142388799 63v72N 0.036544 0.003623 0.241009 COL14A1 
chr7:38258000-38260599 63v72N 0.635254 0.003987 0.005603 BAZ2B 
chr12:13025200-13035799 63v72N 0.248088 0.004195 0.359076 PTPRG 
chr1:86479600-86480599 63v72N 0.385484 0.004399 1 CLDND1 
chr2:9614800-9616999 63v72N 0.24546 0.004417 0.132706 VIPR2 
chr20:13529400-13532599 63v72N 0.346345 0.004507 0.048222 PARD6B 
chr8:10056400-10060999 63v72N 0.120295 0.004617 0.611896 PTGS2 
chrZ:73849400-73853199 63v72N 0.725354 0.005114 0.001516 SNX2 
chr8:25401600-25405399 63v72N 0.058472 0.005189 0.34897 LRP8 
chr3:83220400-83222599 63v72N 0.298938 0.005312 0.138533 MYO6 
chr12:20438000-20440399 63v72N 0.302634 0.00538 0.063607 ENSGALG00000008546 
chr8:10061600-10063599 63v72N 0.919869 0.005598 0.091557 PTGS2 
chr20:13611000-13614599 63v72N 0.156188 0.005903 0.04699 PTPN1 
chr3:107835800-107838599 63v72N 0.038119 0.006081 1 SELI 
chr14:3565400-3566399 63v72N 0.661808 0.006367 0.076777 SDK1 
chr19:9934600-9937199 63v72N 0.012778 0.006736 0.684263 ENSGALG00000024472 
chr2:19019200-19020999 63v72N 0.657886 0.006888 0.156392 ARL5B 
chr3:98841000-98849999 63v72N 0.037394 0.006998 0.200231 MBOAT2 
chrZ:31223800-31228399 63v72N 0.539413 0.007079 0.040181 NFIB 




chr5:32322800-32325799 63v72N 0.138907 0.007372 0.157171 LOC423287 
chr1:136063000-136065199 63v72N 1 0.007507 0.122353 CNGA3 
chr1:119394000-119397399 63v72N 0.338779 0.007685 0.84737 NR0B1 
chr1:82674400-82681599 63v72N 0.021767 0.007708 0.839856 TNFRSF1A 
chr13:12341200-12342999 63v72N 0.236329 0.008054 0.184991 MFAP3 
chr1:82682800-82684999 63v72N 0.09838 0.009211 0.557042 TNFRSF1A 
chr4:12203800-12206399 63v72N 0.285549 0.00941 0.072009 CDX4 
chr11:3259800-3261399 63v72N 0.221089 0.00946 0.119613 RBM35B 
chr15:3199600-3202399 63v72N 0.413584 0.009922 0.151783 STX2 
chr5:17802200-17813599 63v72N 0.07643 0.010175 0.161937 GAL,GAL 
chr2:142391600-142393199 63v72N 0.924871 0.01037 0.124309 COL14A1 
chr7:13565400-13567999 63v72N 0.326274 0.01084 0.087589 ADAM23 
chr3:98829000-98834999 63v72N 0.065783 0.01114 0.067188 MBOAT2 
chr21:2663200-2673399 63v72N 0.819859 0.011482 0.032016 LOC419429 
chr2:32833000-32834599 63v72N 0.426118 0.011758 0.176766 HIBADH 
chr20:13521000-13522799 63v72N 0.657886 0.011758 0.065858 PARD6B 
chr10:464600-471199 63v72N 0.275583 0.011908 0.056682 RBPMS2 
chr9:6139600-6145199 63v72N 0.660708 0.012047 0.012202 BOK 
chr9:25551600-25554399 63v72N 0.086893 0.012453 0.023952 ENSGALG00000023481 
chr9:22134600-22157599 63v72N 0.105332 0.012688 0.351075 PDCD10 
chr10:12022000-12024199 63v72N 0.30003 0.01291 0.54086 GALK2 
chr11:10590400-10593399 63v72N 0.108908 0.013312 0.370375 NUDT19 
chr23:2790000-2791599 63v72N 0.270433 0.013363 0.000515 PTPRU 
chr3:57077400-57080199 63v72N 0.083218 0.013476 0.173465 MAP7 
chr15:2961000-2962399 63v72N 0.183799 0.013643 0.08126 STX2 
chr2:119649400-119658799 63v72N 0.14125 0.013823 0.172635 COPS5 
chr7:27897400-27900599 63v72N 0.041375 0.013832 0.528546 EAF2 
chr1:199701000-199703999 63v72N 0.417345 0.014276 0.024195 MAP6 
chr1:200229400-200232599 63v72N 0.084398 0.015005 0.817811 PLEKHB1 
chr10:9020600-9022599 63v72N 0.773433 0.01506 0.077735 PRTG 
chr2:34385400-34391599 63v72N 0.379072 0.015335 0.053537 DAZL 
chr14:8924600-8928999 63v72N 0.224468 0.015342 0.566168 CDR2 
chr2:32821200-32824599 63v72N 0.136263 0.015538 0.160668 HIBADH 
chr19:9764800-9766799 63v72N 0.837869 0.015928 0.066012 ENSGALG00000005995 
chr24:932800-935599 63v72N 0.189546 0.016521 0.765579 TNIP1 
chr7:12495800-12498999 63v72N 0.369589 0.017077 0.599676 CASP18 
chr1:174433000-174438599 63v72N 0.335686 0.017193 0.755401 WDFY2 
chr3:81190800-81193199 63v72N 0.473563 0.017221 0.28765 LOC421845 
chr15:2944400-2947999 63v72N 0.497322 0.017263 0.033 STX2 
chr3:11203000-11210399 63v72N 0.098602 0.017496 0.181967 PPP3R1 





Appendix XII. Putative bivalent genes from colocalization analysis of 
H3K4me3 and H3K27me3. 
Gene Alternative Name Samples 
CITED2 ENSGALG00000013818 L63_inf,L72_inf 
BCL6 ENSGALG00000007357 L63_inf,L72_inf,L72_non 
EGR1 ENSGALG00000007669 L63_inf,L72_inf,L72_non 
TLR3 ENSGALG00000013468 L63_inf,L72_inf,L72_non 
ST6GAL1 ENSGALG00000005550 L63_non,L72_inf 
TIRAP ENSGALG00000001077 L72_inf 
NECAP2 ENSGALG00000003745 L72_inf 
UBB ENSGALG00000004509 L72_inf 
SMAD3 ENSGALG00000007870 L72_inf 
ANXA5 ENSGALG00000011885 L72_inf 
GCH1 ENSGALG00000012200 L72_inf 
YFV ENSGALG00000024344 L72_inf 
LOC417083 ENSGALG00000024350 L72_inf 
LOC378902 ENSGALG00000006407 L72_inf,L72_non 
ST3GAL6 ENSGALG00000015252 L72_inf,L72_non 
RHOB ENSGALG00000016485 L72_inf,L72_non 
CD4 ENSGALG00000014477 L72_non 
PLS1 ENSGALG00000002647 L63_inf 
ENSGALG00000008952 ENSGALG00000008952 L63_inf 
RAB33B ENSGALG00000009790 L63_inf 
C9orf18 ENSGALG00000001352 L63_inf,L63_non,L72_inf,L72_non 
ENSGALG00000003545 ENSGALG00000003545 L63_inf,L63_non,L72_inf,L72_non 
PFN2 ENSGALG00000010410 L63_inf,L63_non,L72_inf,L72_non 
PLEKHA8 ENSGALG00000011185 L63_inf,L63_non,L72_inf,L72_non 
ENSGALG00000011364 ENSGALG00000011364 L63_inf,L63_non,L72_inf,L72_non 
SIX1 ENSGALG00000022994 L63_inf,L63_non,L72_inf,L72_non 
BTBD14A ENSGALG00000001728 L63_inf,L72_inf 
STK10 ENSGALG00000002816 L63_inf,L72_inf 
LOC768803 ENSGALG00000003048 L63_inf,L72_inf 
CDC25A ENSGALG00000004934 L63_inf,L72_inf 
RAP1GAP2 ENSGALG00000005868 L63_inf,L72_inf 
REEP6 ENSGALG00000015189 L63_inf,L72_inf 
ENSGALG00000020995 ENSGALG00000020995 L63_inf,L72_inf 
ENSGALG00000023324 ENSGALG00000023324 L63_inf,L72_inf 
RAB33A ENSGALG00000024049 L63_inf,L72_inf 
LOC419892 ENSGALG00000002568 L63_inf,L72_inf,L72_non 
AGPHD1 ENSGALG00000003063 L63_inf,L72_inf,L72_non 
ENSGALG00000003598 ENSGALG00000003598 L63_inf,L72_inf,L72_non 




ENSGALG00000004884 ENSGALG00000004884 L63_inf,L72_inf,L72_non 
IL13RA1 ENSGALG00000006032 L63_inf,L72_inf,L72_non 
GLT8D4 ENSGALG00000007804 L63_inf,L72_inf,L72_non 
ENSGALG00000007909 ENSGALG00000007909 L63_inf,L72_inf,L72_non 
C10orf26 ENSGALG00000008119 L63_inf,L72_inf,L72_non 
ENSGALG00000009816 ENSGALG00000009816 L63_inf,L72_inf,L72_non 
SPP1 ENSGALG00000010926 L63_inf,L72_inf,L72_non 
PRRG4 ENSGALG00000012032 L63_inf,L72_inf,L72_non 
C11orf54 ENSGALG00000017219 L63_inf,L72_inf,L72_non 
C1orf190 ENSGALG00000017379 L63_inf,L72_inf,L72_non 
LOC768635 ENSGALG00000019568 L63_inf,L72_inf,L72_non 
ENSGALG00000023347 ENSGALG00000023347 L63_inf,L72_inf,L72_non 
MACROD2 ENSGALG00000023773 L63_inf,L72_inf,L72_non 
ENSGALG00000023864 ENSGALG00000023864 L63_inf,L72_inf,L72_non 
PDE8A ENSGALG00000005992 L63_inf,L72_non 
RAB3B ENSGALG00000010567 L63_inf,L72_non 
MIB1 ENSGALG00000014974 L63_inf,L72_non 
PLEKHF2 ENSGALG00000015988 L63_inf,L72_non 
TAF12 ENSGALG00000000991 L63_non 
RPLP1 ENSGALG00000016172 L63_non 
BATF ENSGALG00000010323 L63_non,L72_inf 
ZDHHC18 ENSGALG00000000869 L72_inf 
ORAI2 ENSGALG00000001837 L72_inf 
TRIM65 ENSGALG00000002209 L72_inf 
GSTT1 ENSGALG00000005204 L72_inf 
GFI1 ENSGALG00000005940 L72_inf 
SLC24A6 ENSGALG00000008337 L72_inf 
KCNMB4 ENSGALG00000010044 L72_inf 
CYP46A1 ENSGALG00000011162 L72_inf 
MYC ENSGALG00000016308 L72_inf 
ENSGALG00000020271 ENSGALG00000020271 L72_inf 
ENSGALG00000022653 ENSGALG00000022653 L72_inf 
TPCN3  L72_inf 
RAB40B ENSGALG00000001545 L72_inf,L72_non 
SPTAN1 ENSGALG00000004719 L72_inf,L72_non 
GSTT1 ENSGALG00000006344 L72_inf,L72_non 
CCDC40 ENSGALG00000007042 L72_inf,L72_non 
NELF ENSGALG00000008681 L72_inf,L72_non 
C14orf174 ENSGALG00000010457 L72_inf,L72_non 
CSTB ENSGALG00000014410 L72_inf,L72_non 
LOC421845 ENSGALG00000015865 L72_inf,L72_non 
CRYL1 ENSGALG00000017135 L72_inf,L72_non 




DYDC1 ENSGALG00000002432 L72_non 
ACSBG1 ENSGALG00000003286 L72_non 
PTGS2 ENSGALG00000005069 L72_non 
DHRS11 ENSGALG00000005403 L72_non 
C16orf45 ENSGALG00000006456 L72_non 
C22orf36 ENSGALG00000006588 L72_non 
CCDC104 ENSGALG00000008064 L72_non 
ENSGALG00000010412 ENSGALG00000010412 L72_non 
TPMT ENSGALG00000012687 L72_non 
ENSGALG00000014777 ENSGALG00000014777 L72_non 
SNX3 ENSGALG00000015304 L72_non 
CCDC125 ENSGALG00000015572 L72_non 
TP53I3 ENSGALG00000016502 L72_non 
N6AMT2 ENSGALG00000017133 L72_non 
ENSGALG00000021811 ENSGALG00000021811 L72_non 
ENSGALG00000024306 ENSGALG00000024306 L72_non 
SLMAP  L72_non 






Appendix XIII. Functional annotation clustering of bivalent genes. 
Top 5 functional annotation clusters from enrichment analysis of putative bivalent 
genes using DAVID. P-values were generated by the program and FDR calculated 
using the Benjamini-Hochberg procedure. 
 
Annotation Cluster 1     Enrichment Score: 2.1845463098819007    
Term Count P-Value FDR 
GO:0006955~immune response 7 1.98E-04 0.110468 
GO:0045087~innate immune response 3 0.012582 0.656019 
GO:0006952~defense response 3 0.111974 0.834128 
    
Annotation Cluster 2     Enrichment Score: 1.6487663600383535    
Term Count P-Value FDR 
GO:0046649~lymphocyte activation 4 0.007963 0.692509 
GO:0045321~leukocyte activation 4 0.011364 0.674961 
GO:0001775~cell activation 4 0.016505 0.706945 
GO:0030097~hemopoiesis 4 0.019778 0.657496 
GO:0048534~hemopoietic or lymphoid organ development 4 0.026651 0.735031 
GO:0010604~positive regulation of macromolecule metabolic 
process 
6 0.028689 0.733148 
GO:0002520~immune system development 4 0.030149 0.700043 
GO:0030098~lymphocyte differentiation 3 0.030369 0.679294 
GO:0042110~T cell activation 3 0.033032 0.688318 
GO:0002521~leukocyte differentiation 3 0.047625 0.729812 
  
Annotation Cluster 3     Enrichment Score: 1.6398579175050156    
Term Count P-Value FDR 
GO:0010033~response to organic substance 5 0.00998 0.693819 
GO:0010604~positive regulation of macromolecule metabolic 
process 
6 0.028689 0.733148 
GO:0044093~positive regulation of molecular function 4 0.042032 0.718255 
    
Annotation Cluster 4     Enrichment Score: 1.1692334713765171    
Term Count P-Value FDR 
GO:0070085~glycosylation 3 0.046075 0.734266 
GO:0006486~protein amino acid glycosylation 3 0.046075 0.734266 
GO:0043413~biopolymer glycosylation 3 0.046075 0.734266 
GO:0009101~glycoprotein biosynthetic process 3 0.055656 0.727326 
GO:0009100~glycoprotein metabolic process 3 0.067634 0.736268 
GO:0031090~organelle membrane 5 0.123709 0.999998 
GO:0012505~endomembrane system 4 0.143513 0.993977 
 
 




Annotation Cluster 5     Enrichment Score: 1.1590029316201944    
Term Count P-Value FDR 
GO:0010604~positive regulation of macromolecule metabolic 
process 
6 0.028689 0.733148 
GO:0009967~positive regulation of signal transduction 3 0.103793 0.825775 






Appendix XIV. Sequencing results showing read numbers for each 
sample from bursa of Fabricius at 5 and 10 days post infection. 
 




H3K4me3 5 L63 inf 1 10146707 9469948 93.33026 5990070 63.25346 
    2 13131449 12144366 92.48306 7392050 60.86814 
   non 1 16445821 15134536 92.02664 9744869 64.38829 
    2 17765727 16502268 92.88822 12311597 74.60548 
  L72 inf 1 13685625 12397340 90.58658 8567829 69.11022 
    2 15693208 14242909 90.75843 9231076 64.81173 
   non 1 22800222 11537587 50.60296 7102076 61.55599 
    2 23472442 12579614 53.59312 8094915 64.34947 
 10 L63 inf 1 11207008 10454772 93.28781 7216101 69.02208 
    2 8743345 8174684 93.49607 5686370 69.56073 
   non 1 16180287 15023018 92.84766 11294506 75.18134 
    2 13562130 12506700 92.21782 9863369 78.86468 
  L72 inf 1 17597960 15956904 90.67474 10980332 68.81242 
    2 15109789 13756612 91.04437 10963779 79.69825 
   non 1 20238612 1872581 9.252517 985452 52.62533 
    2 21964876 11188450 50.93792 8784442 78.51348 
H3K27me3 5 L63 inf 1 13033297 12535093 96.17745 9701319 77.39328 
    2 9233419 8823724 95.56291 7086270 80.30929 
   non 1 14458859 13576043 93.89429 11482089 84.57611 
    2 12628694 11812297 93.53538 10014981 84.78436 
  L72 inf 1 17480503 16641372 95.19962 14810698 88.99926 
    2 15159625 14573824 96.13578 12974760 89.02784 
   non 1 22208836 11979948 53.94226 10340280 86.31323 
    2 24457902 17323581 70.8302 14925120 86.15494 
 10 L63 inf 1 8915797 8521946 95.58255 6299382 73.91952 
    2 10798509 10335407 95.71143 7510955 72.67208 
   non 1 13943995 13132816 94.18259 11627720 88.53943 
    2 11968746 11235976 93.87764 9362469 83.32582 
  L72 inf 1 15202340 14301081 94.07158 12719372 88.93993 
    2 13530768 12757146 94.2825 11426112 89.56637 
   non 1 24191568 9603288 39.69684 5565871 57.95797 
    2 21476908 11605789 54.03845 10150591 87.46145 
        
                 
           
;               
                         





Appendix XV. Ubiquitin-mediated proteolysis pathway displays 
increased H3K4me3 marks in line L72 at 5 dpi.  
(a) KEGG pathway map and (b) diffscore clustering heatmap. All classes of enzymes, 









Appendix XVI. Focal adhesion pathway displays reduced H3K4me3 
marks in line L63 at 10 dpi. 
(a) KEGG pathway map and (b) diffscore clustering heatmap. Several members of the 
focal adhesion pathway demonstrate reductions in promoter H3K4me3 in resistant 









Appendix XVII. Hierarchical clustering of diffscores from 
differential analysis of RNA-Seq data from Bursa. 
Heatmap of clustered diffscores with green denoting upregulation and red 
representing downregulation after MDV infection. Blank rows in cluster 17 
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